{"add": {"doc": {"field": [{"@name": "docid", "#text": "BR-TU.19009"}, {"@name": "filename", "#text": "26108_Lucchesi_Carolina_D.pdf"}, {"@name": "filetype", "#text": "PDF"}, {"@name": "text", "#text": "i \n\n \n\n\n\nii \n\n \n\n \n\n \n\n \n\n \n\n \n\n  \n\n\n\niii \n\n \n\n  \n\n\n\niv \n\n \n\nAGRADECIMENTOS \n\n \n\nAos meus pais por me mostrarem o valor do conhecimento, \u00e0 minha m\u00e3e Julia que \n\nnunca negou um tost\u00e3o para comprar livros, mesmo em momentos de grande dificuldade e ao \n\nmeu pai Dom Lucchesi in memoriam.  \n\nAgrade\u00e7o a minha fam\u00edlia por todo apoio, em especial minha av\u00f3 B\u00e1 que sempre rezou \n\nmuito, meus irm\u00e3os e Natassja. \n\nAos meus sogros Elisa e \u00c1lvaro, os quais sempre me trataram como filha, me dando \n\napoio, carinho e incentivo em todos os momentos. \n\nAo meu marido e amigo Daniel, pela bolsa DNPq por todo suporte e paci\u00eancia mesmo \n\nnos momentos ma\u00eds cr\u00edticos. \n\nAos amigos de bancada Larissa, Silvia Cristina, Andr\u00e9a, Lucas, Alis, Hsi Chin, e em especial \n\nao Am\u00e9m, Andr\u00e9 e Rom\u00e1n por darem de comer, limpar, conversar e cantar para a menina nos \n\nmomentos em que lhes fiz falta e ao Marcelo Jos\u00e9, pela preocupa\u00e7\u00e3o com a cisticercose. \n\nAgrade\u00e7o ao professor Paulo pela orienta\u00e7\u00e3o, apoio, conhecimento e emails divertidos. \n\nN\u00e3o tenho palavras suficientes para agradecer \u00e0 professora Eliana, a qual sempre esteve \n\nao meu lado, n\u00e3o importando a presen\u00e7a f\u00edsica. Nem em uma eternidade pagarei tudo que fez \n\npor mim.  \n\nA equipe de pesquisa do Centro de Tecnologia da Informa\u00e7\u00e3o Renato Archer (CTI), \n\nMarcelo Oliveira, Izaque Maia, Jorge Vicente da Silva por todo apoio, colabora\u00e7\u00e3o e \n\ncompet\u00eancia e a Dra Betina Ferreira, pela amizade, colabora\u00e7\u00e3o e aux\u00edlio. \n\nAo Programa de P\u00f3s-Gradua\u00e7\u00e3o em Biologia Celular e Estrutural, especialmente a \n\nsecret\u00e1ria do programa, L\u00edliam, a qual muito me ajudou, al\u00e9m da extrema compet\u00eancia. \n\nAgrade\u00e7o aos programas de aux\u00edlio e pesquisa, FAPESP, Capes e CNPq por todo aux\u00edlio \u00e0 \n\npesquisa de forma geral. \n\n \n\n\n\nv \n\n \n\nSUM\u00c1RIO \n \n \n\nAGRADECIMENTOS .................................................................................................................................................... IV \nLISTA DE ABREVIA\u00c7\u00d5ES E SIGLAS ............................................................................................................................... VI \nARTIGOS QUE COMP\u00d5EM ESTA TESE ........................................................................................................................ VII \nRESUMO................................................................................................................................................................... VIII \nABSTRACT ................................................................................................................................................................... X \nCAP\u00cdTULO 1 ................................................................................................................................................................ 12 \nI. INTRODU\u00c7\u00c3O .................................................................................................................................................. 13 \n1. BIOLOGIA DO TECIDO \u00d3SSEO ............................................................................................................................ 14 \n1.1 C\u00c9LULAS \u00d3SSEAS ................................................................................................................................................ 15 \n1.1.1 OSTEOBLASTOS E OSTE\u00d3CITOS ......................................................................................................................... 15 \n1.1.2 OSTEOCLASTOS ................................................................................................................................................. 16 \n1.2 OSTEOG\u00caNESE ...................................................................................................................................................... 16 \n1.3 PROTE\u00cdNAS \u00d3SSEAS .............................................................................................................................................. 19 \n1.3.1 COL\u00c1GENO ........................................................................................................................................................ 19 \n2. REGENERA\u00c7\u00c3O \u00d3SSEA ...................................................................................................................................... 20 \n3. ENGENHARIA DE TECIDO \u00d3SSEO ....................................................................................................................... 22 \n3.1 POL\u00cdMEROS ......................................................................................................................................................... 24 \n3.1.1 POL\u00cdMEROS SINT\u00c9TICOS: PHB, PCL E PLGA. ....................................................................................................... 25 \n3.2 TRATAMENTO DE SUPERF\u00cdCIES ............................................................................................................................ 28 \nII. OBJETIVOS ....................................................................................................................................................... 30 \nCAP\u00cdTULO 2 ................................................................................................................................................................ 31 \nCAP\u00cdTULO 3 ................................................................................................................................................................ 39 \nCAP\u00cdTULO 4 ................................................................................................................................................................ 63 \nCAP\u00cdTULO 5 ................................................................................................................................................................ 83 \nCONCLUS\u00d5ES ............................................................................................................................................................. 84 \nCAP\u00cdTULO 6 ................................................................................................................................................................ 85 \nREFER\u00caNCIAS BIBLIOGR\u00c1FICAS .................................................................................................................................. 86 \nAP\u00caNDICE ................................................................................................................................................................... 96 \n\n \n\n \n\n\n\nvi \n\n \n\n \n\nLISTA DE ABREVIA\u00c7\u00d5ES E SIGLAS \n\n \n\nPCL \u2013 Poli (?-caprolactona) \n\nPLGA \u2013 Poli (\u00e1cido l\u00e1tico-co-\u00e1cido glic\u00f3lico) \n\nPHB \u2013 Poli(hidroxibutirato)  \n\nPHBV \u2013 Poli(hidroxubutirato-co-hidroxivalerato) \n\nPHA - Polihidroxialcanoatos \n\n3D \u2013 tri-dimensional  \n\nHA - Hidroxiapatita \n\nMSC \u2013 C\u00e9lulas Tronco Mesenquimais, do ingl\u00eas Mesenchymal Stem Cells. \n\nDNA \u2013 \u00c1cido Desoxirribonucleico \n\nGS \u2013 Sulfato de Gentamicina  \n\nMEC \u2013 Matrix extracelular \n\nSFF \u2013 Forma s\u00f3lida livre, do ingl\u00eas solid free form  \n\nSLS \u2013 Sinteriza\u00e7\u00e3o seletiva a laser, do ingl\u00eas Selective laser sintering \n\nRP \u2013 Prototipagem r\u00e1pida, do ingl\u00eas rapid prototyping \n\nMTT - (3-(4,5-dimetiltiazol-2-il)-2,5-difeniltetrazolium bromide), tetrazolium \n\nDMEM \u2013 Meio Eagle modificado por Dulbecco, do ingl\u00eas Dulbelcco\u2019s modified Eagle\u2019s \n\nm\u00e9dium \n\nUV - ultravioleta \n\nMEV \u2013 Microscopia eletr\u00f4nica de varredura \n\nBMP \u2013 Porte\u00edna morfogen\u00e9tica \u00f3ssea, do ingl\u00eas Bone Morphogenetic Protein  \n\nOP \u2013 Prote\u00edna osteog\u00eanica, do ingl\u00eas osteogenic protein \n\nMMP - metaloproteinase \n\nCOP \u2013 Centro de ossifica\u00e7\u00e3o prim\u00e1ria \n\nPBS \u2013 Tamp\u00e3p fosfato salino, do ingl\u00eas phosphate buffer saline \n\nFBS \u2013 Soro fetal bovino, do ingl\u00eas fetal bovine serum \n\nDMSO \u2013 Dimetil Sulfoxido \n\n \n\nhttp://en.wikipedia.org/wiki/Di-\nhttp://en.wikipedia.org/wiki/Di-\nhttp://en.wikipedia.org/wiki/Thiazole\nhttp://en.wikipedia.org/wiki/Phenyl\n\n\nvii \n\n \n\n \n\n \n \nARTIGOS QUE COMP\u00d5EM ESTA TESE \n\n \n \nLucchesi, C.; Barbanti, S.H.; Joazeiro, P.P.; Duek, E.A.R. Cell Culture on PCL/PLGA Blends. \nJournal Applied Polymer Science, v.115, n.5, p.2609-2615, 2010. DOI 10.1002/app.29919 \n \n \nLucchesi, C.; Lorenzon, R.Z.; Ferreira, B.M.P.; Oliveira, M.F.; Maia, I.A.; Silva, J.V.L.; Duek, \nE.A.R.; Joazeiro, P.P. Rapid prototyping of poly(hydroxybutyrate) scaffolds treated by plasma to \nsupport osteoblastic cells from rabbit calvaria. Ser\u00e1 submetido ao Journal of Material Science \nMaterials in Medicine. \n \n \nLucchesi, C.; Santos, C.C.; Ferreira, B.M.P.; Oliveira, M.F.; Maia, I.A.; Silva, J.V.L.; Duek, \nE.A.R.; Joazeiro, P.P.  Osteoblast cells on 3D PHB obtained by rapid prototyping: in vivo study. \nSer\u00e1 submetido ao Journal of Biomedical Material Reasearch. \n\n \n \n\n\n\nviii \n\n \n\nRESUMO \n\n \n\nOs pol\u00edmeros biorreabsorv\u00edveis, tais como, PHB, PCL e PLGA, t\u00eam sido estudados como \n\ndispositivo para engenharia de tecidos por serem biocompat\u00edveis, suportarem o crescimento e \n\ndiferencia\u00e7\u00e3o celular e os produtos de sua degrada\u00e7\u00e3o serem at\u00f3xicos. No entanto, a escolha do \n\nbiomaterial depende das necessidades exigidas para uma determinada aplica\u00e7\u00e3o.  \n\nOs suportes para engenharia de tecidos devem se basear na constru\u00e7\u00e3o de r\u00e9plicas \n\nbiol\u00f3gicas in vitro, como que o biomaterial se tornasse parte integrada para transplante in vivo \n\npara a recupera\u00e7\u00e3o de perdas ou mau funcionamento de tecidos ou \u00f3rg\u00e3os, devendo \n\nsubseq\u00fcentemente, atuar sem agredir o restante do organismo, isto \u00e9, sem o risco de rejei\u00e7\u00e3o ou \n\ncomplica\u00e7\u00e3o. \n\nMuitas estrat\u00e9gias t\u00eam sido desenvolvidas com o intuito de substituir tecidos ou \u00f3rg\u00e3os \n\ndanificados, incluindo a aplica\u00e7\u00e3o de suportes tridimensionais (3D), os quais devem possuir \n\ncaracter\u00edsticas estruturais e mec\u00e2nicas para guiar a prolifera\u00e7\u00e3o e espalhamento de c\u00e9lulas in vitro \n\ne in vivo.  Os suportes, feitos de materiais sint\u00e9ticos ou naturais, servem como substitutos para a \n\nmatriz extracelular (MEC) nativa. \u00canfase especial \u00e9 dada as t\u00e9cnicas com controle \n\ncomputadorizado, como a fabrica\u00e7\u00e3o s\u00f3lida com forma livre (SFF), conhecida como \n\nprototipagem r\u00e1pida (RP), a qual permite preparar suportes 3D com geometrias complexas, tanto \n\nexternamente como internamente, al\u00e9m de ser uma t\u00e9cnica r\u00e1pida e de baixo custo.  \n\nAl\u00e9m disso, grande parte dos pol\u00edmeros possuem superf\u00edcie hidrof\u00f3bica, caracter\u00edstica \n\ninadequada para a maior parte dos diferentes tipos celulares, o que dificulta aplica\u00e7\u00e3o na engenharia \n\nde tecidos. Uma alternativa a este problema \u00e9 o tratamento da superf\u00edcie por plasma. Este \n\ntratamento induz modifica\u00e7\u00e3o restrita ao topo da superf\u00edcie, conferindo carater hidrof\u00edlico \u00e0 \n\nsuperf\u00edcie, dependendo do g\u00e1s utilizado.  \n\nNeste estudo, arcabou\u00e7os de pol\u00edmeros biorreabsorv\u00edveis PCL, PLGA e PHB foram \n\npreparados por diferentes t\u00e9cnicas, casting e sinteriza\u00e7\u00e3o seletiva a laser, avaliando-se o \n\ncomportamento de c\u00e9lulas osteobl\u00e1sticas diferenciadas sobre os biomateriais polim\u00e9ricos \n\ntridimensionais. Inicialmente o trabalho foi desenvolvido com os pol\u00edmeros PCL e PLGA \n\npreparando-se blendas polim\u00e9ricas, as quais demonstraram melhorar as caracter\u00edsticas gerais dos \n\npol\u00edmeros, quando utilizados como dispositivos para tecido \u00f3sseo, como as propriedades \n\n\n\nix \n\n \n\nmec\u00e2nicas. Com o intuito de aprimorar o design tridimensional do material, optou-se pela \n\nrealiza\u00e7\u00e3o da t\u00e9cnica de sinteriza\u00e7\u00e3o seletiva a laser. No entanto, a t\u00e9cnica exige uma grande \n\nquantidade de material e devido ao alto do custo do PCL e PLGA, este foi substitu\u00eddo pelo \n\npol\u00edmero PHB, o qual \u00e9 produzido pela ind\u00fastria nacional Biocycle possuindo um baixo custo e \n\nainda ser biocompat\u00edvel. Os dados s\u00e3o apresentados em cap\u00edtulos independentes. \n\nArcabou\u00e7os porosos de PCL, PLGA e suas blendas foram preparados pela t\u00e9cnica de \n\nevapora\u00e7\u00e3o do solvente, onde sais de citrato de s\u00f3dio com granulometria de 180-250 \u00b5m, foram \n\nadicionados a solu\u00e7\u00e3o para a promo\u00e7\u00e3o dos poros, sendo posteriormente lavados do arcabou\u00e7o. \n\nC\u00e9lulas osteobl\u00e1sticas provenientes de calota craniana de ratos Wistar foram semeadas sobre os \n\narcabou\u00e7os, sendo avaliado o comportamento de citoxicidade do material e o comportamento de \n\nades\u00e3o e morfologia celular atrav\u00e9s de ensaios bioqu\u00edmicos e MEV.  \n\nOs arcabou\u00e7os de PHB foram obtidos por uma das t\u00e9cnicas de RP, a sinteriza\u00e7\u00e3o seletiva a \n\nlaser (SSL), sendo sua superf\u00edcie modificada por plasma pelos gases oxig\u00eanio e nitrog\u00eanio. C\u00e9lulas \n\nosteobl\u00e1sticas provenientes de calota craniana de coelhos foram semeadas sobre os arcabou\u00e7os \n\nrealizando-se o estudo in vitro, atrav\u00e9s de an\u00e1lises bioqu\u00edmicas pela t\u00e9cnica do MTT, para \n\nviabilidade e ades\u00e3o celular, quantifica\u00e7\u00e3o de col\u00e1geno por S\u00edrius Red e Microscopia Eletr\u00f4nica de \n\nVarredura (MEV). Para o estudo in vivo, ap\u00f3s o cultivo celular sobre os arcabou\u00e7os, defeitos \u00f3sseos \n\nforam provocados em coelhos e os arcabou\u00e7os contendo as c\u00e9lulas foram ent\u00e3o implantados, \n\navaliando-se a intera\u00e7\u00e3o PHB/osteoblasto/tecido, atrav\u00e9s da an\u00e1lise histol\u00f3gica.  \n\nTodos os arcabou\u00e7os estudados, PCL, PLGA e suas blendas, assim como o PHB, n\u00e3o \n\napresentaram \u00edndices de citotoxicidade, permitiram \u00e0s c\u00e9lulas a capacidade de ades\u00e3o, prolifera\u00e7\u00e3o \n\ne s\u00edntese de matriz, mantendo seu fen\u00f3tipo osteobl\u00e1stico. As amostras de PHB tratadas por plasma \n\nde Nitrog\u00eanio mostrou melhorar a capacidade de ades\u00e3o celular. Os arcabou\u00e7os de PHB contendo \n\nc\u00e9lulas mostraram-se os mais adequados para o preenchimento de defeitos \u00f3sseos, melhorando o \n\nprocesso de regenera\u00e7\u00e3o apresentando uma boa osteointegra\u00e7\u00e3o. A sinteriza\u00e7\u00e3o seletiva a laser \n\napresentou-se uma excelente t\u00e9cnica para a obten\u00e7\u00e3o de PHB 3D para a Engenharia de Tecidos. \n\n\n\nx \n\n \n\nABSTRACT  \n\nThe bioresorbable polymers as, PHB, PCL and PLGA have been studied as device for \n\nTissue Engineering for their biocompatibility and to support the cell growth and differentiation \n\nand their degradation products are nontoxics. However, the choice of the biomaterial depends on \n\nthe needs demanded for a certain application.    \n\nThe scaffolds for tissue engineering have to be designed to mimetize the biological \n\nconditions in vitro to became part integrated for transplant for the recovery of tissue or organs \n\nlost or without function, and subsequently, to work in a cordial way with the remaining of the \n\norganism without the rejection risk or complication.   \n\nA lot of strategies have been developed with to substitute damaged tissues or organs, and \n\nit has been used the application of three-dimensional supports (3D), which should possess \n\nstructural and mechanical applications to guide the cells proliferation and spread in vitro and in \n\nvivo. The scaffolds, made from synthetic or natural materials, serve as substitutes for the \n\nextracellular matrix (ECM) native. Special emphasis is given the techniques with computerized \n\ncontrol, as the free solid form (SFF), known as rapid prototyping (RP), which allows to prepare \n\nthree-dimensional supports with complex geometries, so much externally as internally, besides to \n\nbe a fast technique with low cost.    \n\nBesides, great part of the polymers possess hydrophobic surface, inadequate characteristic \n\nfor most of the different cell types, which is not desirable for tissue engineering applications. An \n\nalternative to this problem is the surface treatment by plasma. Plasma treatment induces restricted \n\nmodification to the top of the surface, improving the surface hydrophilicity, depending on the gas \n\nused.  \n\nIn this study, scaffolds of bioresorbable polymer PCL, PLGA e PHB were prepared by \n\ndifferent techniques, casting and selective laser sintering, being evaluated the osteoblast cells \n\nbehavior on the 3D polymer scaffolds.  \n\nPreviously we developed the studies preparing the polymeric blends with PCL and PLGA, \n\nwhich demonstrated improve the general characteristic of the material, as the mechanical \n\nproperties, as devices for bone tissue. With the intention to improve the design of the scaffolds, \n\nwe chose for the selective laser sintering technique. However, the technique demands a great \n\n\n\nxi \n\n \n\namount of material and due to the high cost of PCL and PLGA, those weres substituted by  PHB \n\npolymer, which is produced by Brazilian industry Biocycle with low cost and still to be \n\nbiocompatible. For those reasons the data are presented in independent chapters. \n\n PCL, PLGA porous scaffolds and their blends were prepared those scaffolds by casting \n\nsolvent, and sodium citrate with 180-250 \u00b5m were added to the solution for porous formation \n\nwhen the salt was washed later of the scaffolds. Osteoblast cells from rat Wistar calvaria were \n\nseemed on the scaffolds, being evaluated the behavior of cell adhesion and viability behavior, cell \n\nmorphology through biochemical assays, and scanning electron microscopy.  \n\nThree-dimensional PHB scaffolds were obtained by selective sintering laser (SSL), with \n\nthe surface modified by nitrogen and oxygen plasma. Osteoblast cells obtained from rabbit \n\ncalvaria were seemed on the scaffolds to the in vitro studies, through biochemical analyses by \n\nMTT test for cell viability and cell adhesion, collagen quantification of by Sirius Red \n\ncolorimetric assay and scanning electron microscopy (SEM). For the in vivo studies, bone defects \n\nwere provoked in rabbits and they were filling out with 3D PHB with osteoblast cells culture \n\nprior implant. We evaluated the PHB/osteoblast/tissue, interaction through the histological \n\nanalysis.  \n\nAll the scaffolds studied PCL, PLGA and their blends, as well as the PHB did not showed \n\ncytotoxicity effects, allowed cells adhere, proliferated, and matrix synthesized, maintaining their \n\nosteoblastic phenotype.   \n\nThe PHB samples treated by nitrogen plasma have been showed to improve the cell \n\nadhesion. The PHB scaffolds with cell seeded previously demonstrated to be more suitable for \n\nfilling out bone defects, improving the regeneration process showing a good osteointegration. \n\nThe selective laser sintering was excellent technique to obtain PHB scaffolds for Tissue \n\nEngineering. \n\n  \n\n \n\n \n\n \n\n \n\n\n\n12 \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nCAP\u00cdTULO 1 \n\n\n\n13 \n\n \n\nI. INTRODU\u00c7\u00c3O \n\n \n\nA incid\u00eancia de defeitos \u00f3sseos devido a fraturas, tumores e infec\u00e7\u00f5es tem-se elevado com o \n\naumento da expectativa de vida da popula\u00e7\u00e3o, gerando problemas de grande impacto social (World \n\nHealth Organization, 2003). Aproximadamente 150 doen\u00e7as ou s\u00edndromes relacionadas a osso foram \n\ndiagnosticadas, sendo geralmente progressivas e causadoras de dor. No que diz respeito \u00e0 repara\u00e7\u00e3o das \n\nfraturas entre 5 a 10% dos casos que ocorrem anualmente nos EUA, resultam em reparo \u00f3sseo lento e \n\nineficiente (Li &amp; Wosney, 2001); e entre 5-35% das cirurgias de fus\u00e3o vertebral resultam em insucesso no \n\nprocesso de fus\u00e3o (Ludwig et al, 2000).  \n\nOs custos na \u00e1rea da sa\u00fade t\u00eam se elevado, devido \u00e0 necessidade frequente de se substituir o \n\ntecido \u00f3sseo. A cada ano, milh\u00f5es de cirurgias para implantes s\u00e3o realizadas para o reparo ou cura de um \n\n\u00f3rg\u00e3o. Os implantes se constituem de enxertos aut\u00f3logos e hom\u00f3logos, cimentos \u00f3sseos, materiais \n\npolim\u00e9ricos, metais e cer\u00e2micas (Ishaug et al, 1997). Atualmente as estrat\u00e9gias que utilizam enxertos \n\naut\u00f3logos se mostram favor\u00e1veis, nesse tipo de repara\u00e7\u00e3o, devido \u00e0s caracter\u00edsticas de osteoindu\u00e7\u00e3o, \n\nosteocondu\u00e7\u00e3o e por n\u00e3o causarem resposta imune (Marquis et al, 2009). Por outro lado, possuem \n\nlimita\u00e7\u00e3o na quantidade de tecido que pode ser extra\u00eddo, al\u00e9m de morbidez do doador. Esse fato \n\nincentivou as buscas por m\u00e9todos alternativos para reconstitui\u00e7\u00e3o de grandes defeitos \u00f3sseos.  \n\nA limita\u00e7\u00e3o nas t\u00e9cnicas existentes gera a necessidade de se buscar novos m\u00e9todos para \n\nregenera\u00e7\u00e3o \u00f3ssea, demandando uma variedade de terapias e implantes de materiais dependendo do \n\ntipo e tamanho do defeito. Dessa busca, surge a Engenharia de Tecidos, ci\u00eancia que emerge como uma \n\nalternativa promissora para o tratamento de perda ou mau funcionamento tecidual, combinando \n\nc\u00e9lulas, biomaterial e fatores f\u00edsico-qu\u00edmicos e bioqu\u00edmicos para melhorar ou substituir fun\u00e7\u00f5es \n\nbiol\u00f3gicas (Langer &amp; Vacanti, 1993).  \n\nA intera\u00e7\u00e3o c\u00e9lulas-biomateriais \u00e9 de fundamental import\u00e2ncia, pois influencia os subseq\u00fcentes \n\nprocessos biol\u00f3gicos como diferencia\u00e7\u00e3o e prolifera\u00e7\u00e3o celular (Marquis et al 2009). Al\u00e9m disso, o \n\nprocesso de ades\u00e3o celular \u00e9 um importante requerimento para o sucesso da incorpora\u00e7\u00e3o do implante \n\nou a coloniza\u00e7\u00e3o do arcabou\u00e7o para o reparo do tecido. No presente estudo, o comportamento de \n\nc\u00e9lulas \u00f3sseas foi estudado sobre pol\u00edmeros sint\u00e9ticos, preparados por diferentes t\u00e9cnicas, com o \n\nprop\u00f3sito de preenchimento \u00f3sseo em locais de dif\u00edcil reparo tecidual.  \n\n  \n\n\n\n14 \n\n \n\n1. BIOLOGIA DO TECIDO \u00d3SSEO \n\n \n\n O tecido \u00f3sseo \u00e9 uma forma especializada de tecido conjuntivo, sendo um importante  elemento \n\ndo esqueleto. Este tecido \u00e9 composto pela matriz org\u00e2nica e inorg\u00e2nica. A matriz org\u00e2nica \u00e9 composta \n\npor aproximadamente 95% de fibras col\u00e1genas, tipo I e III, e prote\u00ednas n\u00e3o-col\u00e1genas, como \n\nosteocalcina, osteopontina, prote\u00edna osteoprogenitora (OP-1) ou prote\u00edna morfogen\u00e9tica \u00f3ssea (BMP-7), \n\nosteonectina, atualmente denominada SPARC (do ingl\u00eas Secreted protein acidic rich in cystein), \n\nsialoprote\u00edna \u00f3ssea, glicosaminoglicano, c\u00e9lulas, entre outras. J\u00e1 a matriz inorg\u00e2ncia \u00e9 constitu\u00edda de \n\n\u00e1gua, 65-70% de compostos de fosfato de c\u00e1lcio, principalmente na forma de cristais de hidroxiapatita \n\nCa10(PO4)6(OH)2 (HA), e composta ainda por bicarbonato, magn\u00e9sio, pot\u00e1ssio, s\u00f3dio, citrato em pequenas \n\nquantidades (Junqueira &amp; Carneiro, 2004). Diferencia-se de outros tecidos conjuntivos pelo fato de sua \n\nmatriz tornar-se mineralizada. Este tecido \u00e9 composto por osteoblastos, osteoclastos, c\u00e9lulas \n\nmesenquimais osteoprogenitoras e oste\u00f3citos.  \n\n O tecido \u00f3sseo \u00e9 din\u00e2mico, altamente vascularizado e com a capacidade \u00fanica de regenera\u00e7\u00e3o e \n\nremodela\u00e7\u00e3o sem a ocorr\u00eancia de fibrose (Buckwalter et al 1996; Kneser et al, 2006). \u00c9 respons\u00e1vel pelo \n\nsuporte mec\u00e2nico do esqueleto, suportando carga, promovendo prote\u00e7\u00e3o aos \u00f3rg\u00e3os internos e os \n\nmovimentos, juntamente com o sistema muscular. Serve ainda como reserva mineral e tem a capacidade \n\nde mobilizar seu estoque rapidamente, quando se faz necess\u00e1ria a homeostase do n\u00edvel de \u00edons c\u00e1lcio no \n\nsangue. Esta diversidade funcional requerida ao tecido \u00f3sseo reflete na complexidade de sua arquitetura \n\n(Kneser et al, 2006).  \n\n Em indiv\u00edduos humanos adultos, os ossos t\u00eam arranjo trabecular e compacto, al\u00e9m da cavidade \n\nmedular. Os ossos trabeculares ou esponjosos s\u00e3o organizados em poros assemelhando-se a uma \n\nesponja, que permite o alojamento da medula \u00f3ssea, estando presente na metafise dos ossos longos, \n\ncrista il\u00edaca e corpos vertebrais. J\u00e1 os \u00f3ssos compactos, mostram-se s\u00f3lido, com porosidade menor que \n\n10%, sendo revestido extremamente por uma membrana de tecido conjuntivo, o peri\u00f3steo e \n\ninternamente, pelo end\u00f3steo. Ambos cont\u00eam osteoblastos, osteoclastos e seus progenitores. Este \n\narranjo s\u00f3lido faz parte dos ossos longos, curtos e achatados, sendo de grande import\u00e2ncia para o \n\nsuporte do esqueleto (Ackerman et al, 1976; Datta et al, 2008). \n\nA capacidade regenerativa dos ossos \u00e9 dependente da quantidade de massa \u00f3ssea perdida e/ou \n\ndanificada. Quando o defeito ocorrido n\u00e3o permite que o tecido \u00f3sseo se regenere por ele mesmo, este \n\n\n\n15 \n\n \n\ndefeito \u00e9 denominado como defeito cr\u00edtico (Prado et al, 2006; Jan et al 2006; Schmitz &amp; Hollinger, 1986). \n\nO defeito cr\u00edtico varia de esp\u00e9cie para esp\u00e9cie, sexo, idade, local do defeito e ainda do metabolismo \n\nindividual. Em geral, em calota craniana de coelhos New Zealand, o defeito cr\u00edtico \u00e9 estimado em 15mm \n\nde di\u00e2metro (Hollinger &amp; Kleinschmidt 1990), no entanto, existem v\u00e1rias discuss\u00f5es na literatura  sobre o \n\ntamanho apropriado do defeito cr\u00edtico. Um estudo realizado por Hokugo et al (2007), onde criou-se um \n\ndefeito cr\u00edtico com 5mm de di\u00e2metro, verificou-se que n\u00e3o ocorreu  a completa regenera\u00e7\u00e3o tecidual \n\nap\u00f3s 60 dias. \n\n  \n\n  \n1.1 C\u00c9LULAS \u00d3SSEAS \n\n \n\nAs c\u00e9lulas \u00f3sseas descritas s\u00e3o os osteoblastos, oste\u00f3citos e osteoclastos, os quais possuem \n\ndiferentes origens e fun\u00e7\u00f5es, sendo de crucial import\u00e2ncia na remodela\u00e7\u00e3o \u00f3ssea. No entanto, n\u00e3o \n\npodemos deixar de citar as c\u00e9lulas mesenquimais de medula \u00f3ssea (BMSCs do ingl\u00eas, bone marrow \n\nstromal cells), as quais s\u00e3o capazes de se diferenciar em uma variedade de tipos celulares incluindo \n\nosteoblastos. Durante este processo de osteoblastog\u00eanese, os osteoblastos passam por diversos eventos \n\nmorfol\u00f3gicos e moleculares, a c\u00e9lula adquire a capacidade de sintetizar e depositar matriz extracelular \n\nmineralizada, caracter\u00edstica do tecido \u00f3ssseo (Ducy et al, 2000; Lavery et al, 2009). Esta transforma\u00e7\u00e3o \u00e9 \n\num processo multi-passos altamente dependente de sinais provenientes do ambiente e justamente \n\nregulados.  \n\n \n\n1.1.1 OSTEOBLASTOS E OSTE\u00d3CITOS \n\n \n\nOs osteoblastos derivam de c\u00e9lulas mesenquimais provenientes da medula \u00f3ssea, do peri\u00f3steo \n\nou end\u00f3steo. Quando ativos, possuem proeminente ret\u00edculo endoplasm\u00e1tico rugoso, assim como, \n\ncomplexo de Golgi, devido \u00e0 alta s\u00edntese de prote\u00ednas como, col\u00e1geno, SPARC, osteonectina, \n\nosteocalcina, glicosaminoglicano entre outras. S\u00e3o ricos em fosfatase alcalina, enzima fundamental na \n\ndeposi\u00e7\u00e3o de matriz mineralizada. Encontram-se na matriz da superf\u00edcie \u00f3ssea existente (osteoblastos de \n\nsuperf\u00edcie) ou depositando camadas de tecido \u00f3sseo rec\u00e9m sintetizadas sobre estas (osteoblastos \n\nmesenquimais) ou acabam morrendo por apoptose (Shapiro, 1988; Marie, 2008; Marquis et al, 2009). \n\n\n\n16 \n\n \n\nAlguns osteoblastos permanecem livres na superf\u00edcie, enquanto outros se tornam gradativamente \n\naprisionados pela matriz que a pr\u00f3pria c\u00e9lula secreta. Este material rec\u00e9m produzido \u00e9 conhecido como \n\n\u00f3steon e o osteoblasto aprisionado na matriz mineralizada, passa a ser denominado oste\u00f3cito, \n\ncontinuando a secretar matriz em torno de si, por\u00e9m em quantidade reduzida. Apesar de aprisionado na \n\nmatriz, os oste\u00f3citos n\u00e3o se encontram isolados, ligam-se a oste\u00f3citos vizinhos por proje\u00e7\u00f5es celulares, \n\natrav\u00e9s de canal\u00edculos, formando jun\u00e7\u00f5es comunicantes (Alberts et al, 2005; Datta et al 2008). \n\nQuando avaliados in vitro, a diferencia\u00e7\u00e3o requer a presen\u00e7a de v\u00e1rios fatores os quais incluem \n\nfatores de crescimento, dexametasona, ?-glicerofosfato e L-\u00e1cido asc\u00f3rbico (Bruder &amp; Caplan 2000). \n\nOutros elementos como a prote\u00edna osteoprogenitora, tem sido estudados por Lavery e colaboradores \n\n(2009) descrevendo a bioatividade da OP-1 durante o processo inicial de diferencia\u00e7\u00e3o de c\u00e9lulas \n\nmesenquimais humanas em osteoblastos in vitro, sendo estas informa\u00e7\u00f5es importantes para uma \n\nmelhor compreens\u00e3o das contribui\u00e7\u00f5es individuais das BMPs, durante a forma\u00e7\u00e3o \u00f3ssea humana (Lavery \n\net al 2009). \n\n \n\n1.1.2 OSTEOCLASTOS \n\n \n\nOs osteoclastos s\u00e3o c\u00e9lulas multinucleadas gigantes, diferenciadas a partir de c\u00e9lulas de \n\nlinhagem hematopoi\u00e9tica da medula \u00f3ssea, os mon\u00f3citos/macr\u00f3fagos (Dougall &amp; Chaisson, \n\n2006), sendo respons\u00e1veis pela reabsor\u00e7\u00e3o \u00f3ssea. Seu citoplasma cont\u00e9m ret\u00edculo \n\nendoplasm\u00e1tico e complexo de Golgi bem desenvolvidos, muitas mitoc\u00f4ndrias e lisossomos. \n\nSintetizam e secretam enzimas proteol\u00edticas, as metaloproteinases (MMP), catepsina K e \n\nfosfatase \u00e1cida, as quais atuam erodindo a matriz prot\u00e9ica (Vaananen, 2005; Zeng et al, 2006). \n\n \n\n \n\n1.2 OSTEOG\u00caNESE \n\nO processo de forma\u00e7\u00e3o \u00f3ssea durante o desenvolvimento do esqueleto envolve uma complexa \n\ncoordena\u00e7\u00e3o de m\u00faltiplos tipos celulares e tecidos. O desenvolvimento \u00f3sseo ocorre atrav\u00e9s de dois \n\npadr\u00f5es de forma\u00e7\u00e3o \u00f3ssea: intramembranosa e endocondral. No entanto, deve se ter em mente a \n\n\n\n17 \n\n \n\ndistin\u00e7\u00e3o em osso como um tecido, contendo c\u00e9lulas \u00f3sseas e matriz mineralizada e osso como um \n\n\u00f3rg\u00e3o, incluindo o tecido \u00f3sseo, cartilaginoso, fibroso, medula e vasos sangu\u00edneos. \n\nNos mam\u00edferos, a forma\u00e7\u00e3o \u00f3ssea \u00e9 um evento tardio no embri\u00e3o e ainda um dos \u00faltimos \n\nest\u00e1gios no desenvolvimento do esqueleto. Em alguns elementos do esqueleto, como parte do cr\u00e2nio e \n\nclav\u00edcula, ocorrem grupos de c\u00e9lulas mesenquimais que se diferenciam diretamente em osteoblastos, \n\nformando o centro de ossifica\u00e7\u00e3o prim\u00e1ria (COP) e iniciando a produ\u00e7\u00e3o de matriz n\u00e3o mineralizada, o \n\noste\u00f3ide. Com a mineraliza\u00e7\u00e3o, os osteoblastos s\u00e3o aprisionados na matriz transformando-se em \n\noste\u00f3citos. Durante o processo de ossifica\u00e7\u00e3o intramembranosa, ocorre \u00e0 forma\u00e7\u00e3o de v\u00e1rios COPs, os \n\nquais crescem radialmente, dando origem aos ossos prim\u00e1rios, os quais s\u00e3o invadidos por vasos \n\nsangu\u00edneos e c\u00e9lulas mesenquimais, formando-se a medula \u00f3ssea (Hall &amp; Miyake 1995; Huang et al, \n\n1997).  \n\nPara o restante do esqueleto, as c\u00e9lulas da condensa\u00e7\u00e3o mesenquimal diferenciam-se em \n\ncondr\u00f3citos formando a cartilagem \u201can\u00e1loga\u201d aos ossos futuros. Na periferia desta cartilagem, c\u00e9lulas do \n\nperic\u00f4ndrio diferenciam-se em osteoblastos, enquanto os condr\u00f3citos tornam-se hipertr\u00f3ficos. \n\nEventualmente, a matriz ao redor destes condr\u00f3citos hipertr\u00f3ficos se calcifica e vasos sang\u00fc\u00edneos \n\npresentes na matriz trazem os osteoblastos (Horton, 1993; Erlebacher et al, 1995).  Uma vez que a matriz \n\n\u00e9 depositada, a medula \u00f3ssea se forma e os primeiros osteoclastos aparecem (Hofstetter et al, 1995). \n\nAssim, os est\u00e1gios seq\u00fcentes de forma\u00e7\u00e3o da cartilagem an\u00e1loga, calcifica\u00e7\u00e3o da cartilagem e forma\u00e7\u00e3o \n\n\u00f3ssea, caracterizam a ossifica\u00e7\u00e3o endocondral. Neste modelo de ossifica\u00e7\u00e3o, os osteoblastos precedem a \n\ndiferencia\u00e7\u00e3o dos osteoblastos (Karsenty, 1999; Deng et al, 2008). \n\nOs primeiros est\u00e1gios do desenvolvimento do esqueleto em vertebrados s\u00e3o dependentes de \n\ngenes que controlam a distribui\u00e7\u00e3o e prolifera\u00e7\u00e3o de c\u00e9lulas da crista neural, escleroma e placa lateral \n\nmesod\u00e9rmica ocorrendo a condensa\u00e7\u00e3o das c\u00e9lulas mesenquimais, pela qual estas de diferenciam em \n\nosteoblastos, no caso do tecido \u00f3sseo (Deng et al, 2008). Esta condensa\u00e7\u00e3o celular \u00e9 o principal est\u00e1gio \n\nno desenvolvimento do esqueleto e outros tecidos mesenquimais. As primeiras observa\u00e7\u00f5es de \n\ncondensa\u00e7\u00e3o celular foram realizadas por Strelzoff em 1873 e van der Stricht em 1890, os quais \n\ndescreveram os processos de osteog\u00eanese e condrog\u00eanese em membros de aves, e Parsons em 1905 \n\npublicou um artigo seguindo os mesmos passos. At\u00e9 aquele momento, raras eram as observa\u00e7\u00e3o de \n\nosteog\u00eanese em mam\u00edferos (Fell 1925; Gould et al, 1992). Segundo Hall &amp; Miyake (1992), as \n\ncondensa\u00e7\u00f5es celulares s\u00e3o iniciadas pelo aumento na atividade mit\u00f3tica ou pela agrega\u00e7\u00e3o de c\u00e9lulas \n\nsimilares ao redor de um centro. Condensa\u00e7\u00e3o \u00e9 definida como a agrega\u00e7\u00e3o de c\u00e9lulas pela qual os \n\n\n\n18 \n\n \n\ntecidos se formam durante o desenvolvimento embrion\u00e1rio e pela qual a condrog\u00eanese e osteog\u00eanese \n\ns\u00e3o iniciadas durante seu reparo e/ou regenera\u00e7\u00e3o (Hall &amp; Miyake 1995).  \n\nRecentemente, Hall &amp; Miyake (2000), descreveram a condensa\u00e7\u00e3o como a terceira entre quatro \n\nfases da esqueletog\u00eanese. A primeira \u00e9 a migra\u00e7\u00e3o das c\u00e9lulas para o local da futura esqueletog\u00eanese; a \n\nsegunda \u00e9 a intera\u00e7\u00e3o tecidual (epitelial-mesenquimal) que resulta na forma\u00e7\u00e3o da condensa\u00e7\u00e3o; e a \n\nquarta \u00e9 diferencia\u00e7\u00e3o em condroblastos ou osteoblastos (Hall &amp; Mayake 2000). Segundo Ede &amp; Agerbak \n\n(1968), o tamanho da condensa\u00e7\u00e3o e a interfer\u00eancia no n\u00famero de c\u00e9lulas, afetam a esqueletog\u00eanese. A \n\ncondensa\u00e7\u00e3o reduzida segue um limiar cr\u00edtico e a esqueletog\u00eanese pode n\u00e3o ser iniciada. Por\u00e9m, um \n\naumento na condensa\u00e7\u00e3o pode resultar num esqueleto muito grande e/ou deformado. Este tamanho \u00e9 \n\nregulado atrav\u00e9s da sinaliza\u00e7\u00e3o envolvendo as BMPs (Hall &amp; Miyake, 1995).  \n\nAmbos os mecanismos, endocondral e intramembranoso, tamb\u00e9m s\u00e3o descritos durante a \n\nregenera\u00e7\u00e3o do tecido, dependendo dos elementos dispon\u00edveis no local onde ocorreu a les\u00e3o (Shapiro, \n\n2008). \n\nDurante a forma\u00e7\u00e3o \u00f3ssea, os osteoblastos sintetizam e depositam col\u00e1geno tipo I/III e com o \n\naux\u00edlio de prote\u00ednas da matriz extracelular, cristais de fosfato de c\u00e1lcio s\u00e3o depositados sobre as fibras \n\ncol\u00e1genas (Shapiro, 2008).  \n\n Significante progresso tem sido realizado nos \u00faltimos anos para a compreeens\u00e3o dessa rede de \n\nmecanismos moleculares que controlam a diferencia\u00e7\u00e3o osteog\u00eanica (Deng et al, 2008). Estimulantes \n\naspectos no desenvolvimento do esqueleto dos vertebrados t\u00eam sido obtidos atrav\u00e9s de estudos \n\ngen\u00e9ticos e moleculares em modelos animais e humanos com desordens inerentes na morfog\u00eanese, \n\norganog\u00eanese e crescimento do esqueleto (Olsen et al, 2000, Harada &amp; Rodan 2003; Ralston &amp; \n\nCrombrugghe, 2006) \n\n Atsawasuwan e colaboradores (2005) estudaram o processo de express\u00e3o das isoformas da \n\nenzima lisil oxidase, a qual inicia a liga\u00e7\u00e3o intermolecular das mol\u00e9culas col\u00e1genas nos res\u00edduos de lisina \n\ne hidroxilisina, em c\u00e9lulas osteobl\u00e1sticas MC3T3-E1 durante o processo de mineraliza\u00e7\u00e3o das fibras, \n\nindicando que sua express\u00e3o \u00e9 altamente regulada durante a diferencia\u00e7\u00e3o dos osteoblastos, a qual \n\nsugere que a enzima tenha papel durante a estabiliza\u00e7\u00e3o das fibras e sua subseq\u00fcente mineraliza\u00e7\u00e3o \n\n(Atsawasuwan et al 2005). Num estudo realizado in vivo, Verdelis e colaboradores (2008) atribu\u00edram, em \n\nparte, a capacidade da dentina sialoprote\u00edna como reguladora da mineraliza\u00e7\u00e3o e remodela\u00e7\u00e3o em \u00f3ssos \n\nde camundongos. Genge e colaboradores (2008), baseados em nucleadores de fosfato de c\u00e1lcio amorfo, \n\nestudaram os efeitos da prote\u00edna anexina-5 (Anx-5), uma prote\u00edna lip\u00eddeo dependente para ligar-se ao \n\n\n\n19 \n\n \n\nc\u00e1lcio. Neste estudo, os autores demonstraram um aumento na nuclea\u00e7\u00e3o e forma\u00e7\u00e3o dos minerais em \n\ncol\u00e1geno tipo II e IX na presen\u00e7a da prote\u00edna. No entanto, o processo de mineraliza\u00e7\u00e3o in vivo continua \n\nn\u00e3o sendo bem compreendido. \n\n \n\n1.3 PROTE\u00cdNAS \u00d3SSEAS \n\n \n\n Diversas prote\u00ednas fazem parte do tecido \u00f3sseo, sendo divididos em prote\u00ednas col\u00e1genas, como o \n\ncol\u00e1geno do tipo I e III, e as prote\u00ednas n\u00e3o col\u00e1genas, como sialoprote\u00edna \u00f3ssea, SPARC, osteocalcina, \n\nosteopontina, a grande fam\u00edlia de prote\u00ednas morfogen\u00e9ticas \u00f3sseas (BMPs), entre outras. No entanto, \n\nser\u00e3o descritas somente as prote\u00ednas em foco no presente estudo. \n\n \n\n1.3.1 COL\u00c1GENO \n\n \n\nO col\u00e1geno \u00e9 o tipo mais abundante de prote\u00edna no organismo, constituindo uma fam\u00edlia de \n\nprote\u00ednas, as quais exercem diferentes fun\u00e7\u00f5es, principalmente estruturais.  Atualmente, s\u00e3o conhecidos \n\n20 tipos de prote\u00ednas col\u00e1genas diferentes, podendo ser classificadas em grupos: formadores de fibras \n\nlongas, como col\u00e1geno tipo I, II, III, V e IX; col\u00e1genos associados a fibrilas, como tipo IX e XII; col\u00e1geno \n\nformador de redes, como tipo IV; col\u00e1geno de ancoragem, como tipo VII (Junqueria &amp; Carneiro 2004).  \n\nO col\u00e1geno do tipo I e III, formadores de fibras longas, s\u00e3o os encontrados nos ossos, sendo mais \n\nbem abordados no estudo. A mol\u00e9cula col\u00e1gena cont\u00e9m 3 cadeias polipept\u00eddicas e cada cadeia possui \n\n1000 amino\u00e1cidos e uma sequ\u00eancia repetida de amino\u00e1cidos Gly-X-Y (na qual, X e Y podem ser qualquer \n\namino\u00e1cido ac\u00eddico, mas geralmente prolina e hidroxiprolina, respectivamente). Essas mol\u00e9culas s\u00e3o \n\nconhecidas como pro-col\u00e1geno, os quais se agregam em subunidades para formar fibrilas, arranjadas em \n\ntr\u00eas cadeias ?-pro, unidas  por pontes de hidrog\u00eanio e intera\u00e7\u00f5es hidrof\u00f3bicas. Esta mol\u00e9cula pr\u00f3-\n\ncol\u00e1gena \u00e9 enviada pela c\u00e9lula para o ambiente extracelular por exocitose, sofrendo a\u00e7\u00e3o da enzima pr\u00f3-\n\ncol\u00e1geno peptidase, a qual cliva os pept\u00eddeos de registro, para que estas mol\u00e9culas, agora conhecidas \n\ncomo tropocol\u00e1geno, a subunidade col\u00e1gena b\u00e1sica, possam se agregar formando fibrilas, finas \n\nestruturas com 10 a 300nm de di\u00e2metro. Um sistema de liga\u00e7\u00f5es covalentes intercadeias estabiliza as \n\nfibras (Patino et al, 2002), esse sistema \u00e9 poss\u00edvel devido ao trabalho das enzimas: N-proteinase, a qual \n\nremovendo a por\u00e7\u00e3o N-propept\u00eddeo; pro-col\u00e1geno C-proteinase, a qual remove por\u00e7\u00e3o C-propept\u00eddeo; e \n\n\n\n20 \n\n \n\nlisil-oxidase, enzima respons\u00e1vel por iniciar a liga\u00e7\u00e3o inter-molecular entre as fibrilas. A bioss\u00edntese do \n\ncol\u00e1geno tipo I \u00e9 o mais estudado at\u00e9 o momento, provavelmente devido a sua alta quantidade no \n\norganismo. \n\nO col\u00e1geno tem uma gama de propriedades biof\u00edsicas e bioqu\u00edmicas, que fazem desta mol\u00e9cula \n\num importante biomaterial. Estas propriedades incluem solubilidade, resist\u00eancia, media\u00e7\u00e3o entre \n\nintera\u00e7\u00f5es intercelulares, estabilidade, biodegradabilidade e baixa imunogenicidade (Patino et al, 2002). \n\nCom o advento da microscopia eletr\u00f4nica de transmiss\u00e3o, importantes caracter\u00edsticas em \n\npequena escala sobre o col\u00e1geno e a estrutura \u00f3ssea foram descobertas. O pioneiro a descrever este \n\nadvento foi Robinson em 1952, observando os componentes inorg\u00e2nicos dos ossos, os cristais de \n\npequenas formas irregulares e sua rela\u00e7\u00e3o com a matriz \u00f3ssea org\u00e2nica. Watson &amp; Robinson (1953), \n\nnotaram a presen\u00e7a de forma\u00e7\u00e3o \u00f3ssea atrav\u00e9s do mesmo modelo de banda observado em col\u00e1geno \n\ntipo I n\u00e3o mineralizado, por\u00e9m corado. A explica\u00e7\u00e3o para esse fen\u00f4meno foi provida por Hodge &amp; \n\nPetruska em 1962, que propuseram o modelo de arranjo em bandas do col\u00e1geno e estrutura \u00f3ssea. \n\nNeste modelo, os minerais se localizam nos espa\u00e7os ente as fibrilas. Hoje se sabe que o col\u00e1geno forma \n\numa rede tri-dimensional na qual os cristais se depositam e crescem (Weiner &amp; Traub, 1989).  \n\n \n\n \n\n2. REGENERA\u00c7\u00c3O \u00d3SSEA \n\n \n\nEmbora os ossos apresentem dureza, est\u00e3o sujeitos a fraturas, de acordo com o esfor\u00e7o aplicado, \n\nsendo estas acompanhadas de hemorragia. As c\u00e9lulas do peri\u00f3steo (tecido conjuntivo que reveste os \n\nossos externamente, excluindo cartilagem articular) e end\u00f3steo (tecido conjuntivo que reveste os \u00f3ssos \n\ninternamente, medula \u00f3ssea e trab\u00e9culas esponjosas) respondem a les\u00e3o, ocorrendo r\u00e1pida prolifera\u00e7\u00e3o \n\nde fibroblastos e c\u00e9lulas mesenquimais, que envolvem a forma\u00e7\u00e3o da cartilagem e fibrocartilagem (calo \n\nfibrocartilaginoso), e preenchem o local do defeito. Na base do calo, osteoblastos iniciam a forma\u00e7\u00e3o da \n\nmatriz \u00f3ssea, resultando em calo \u00f3sseo prim\u00e1rio (osso imaturo). Subsequentemente o osso prim\u00e1rio \u00e9 \n\nremodelado em osso secund\u00e1rio ou lamelar e os vasos sangu\u00edneos do peri\u00f3steo e end\u00f3steo est\u00e3o \n\nenvolvidos na nutri\u00e7\u00e3o \u00f3ssea. \n\n Os ossos t\u00eam a capacidade \u00fanica de se regenerar dependendo do volume danificado, sem o \n\ndesenvolvimento de cicatriz fibrosa, a qual est\u00e1 presente durante cicatriza\u00e7\u00e3o de feridas em tecidos \n\n\n\n21 \n\n \n\nmoles. Isto \u00e9 alcan\u00e7ado atrav\u00e9s dos est\u00e1gios complexos e interdependentes do processo de cicatriza\u00e7\u00e3o, \n\no qual mimetiza o desenvolvimento altamente regulado do esqueleto (Kanczler and Oreffo, 2008; El-\n\nTamer &amp; Reis, 2009). \n\n A remodela\u00e7\u00e3o e reorganiza\u00e7\u00e3o do tecido \u00f3sseo \u00e9 resultado de muitos fatores incluindo est\u00edmulo \n\nmec\u00e2nico, causas metab\u00f3licas (como dieta de c\u00e1lcio, doen\u00e7as, idade), altera\u00e7\u00f5es hormonais e efeito de \n\ndrogas.  \n\nO tipo de regenera\u00e7\u00e3o \u00f3ssea pode ocorrer por diferentes mecanismos e embora a s\u00edntese \u00f3ssea \n\nseja sempre mediada por c\u00e9lulas mesenquimais ou osteoblastos de superf\u00edcie, tamb\u00e9m ir\u00e1 depender do \n\nambiente biof\u00edsico, podendo ser: reparo endocondral; reparo \u00f3sseo prim\u00e1rio, sem a presen\u00e7a de uma \n\nfase cartilaginosa, mediado exclusivamente por osteoblastos provenientes do sistema de Havers \n\nintra\u00f3sseo e osteoclastos; reparo \u00f3sseo direto, ocorrendo tamb\u00e9m sem fase cartilaginosa, no entanto, as \n\nc\u00e9lulas derivam da medula \u00f3ssea; e por distra\u00e7\u00e3o osteog\u00eanica, processo biol\u00f3gico de neoforma\u00e7\u00e3o \u00f3ssea \n\nentre segmentos \u00f3sseos que s\u00e3o gradualmente separados por tra\u00e7\u00e3o controlada. Deve-se ainda \n\nconsiderar o local do defeito, uma vez que o ambiente ir\u00e1 prover os recursos celulares, como agente \n\nprim\u00e1rio para o reparo (Shapiro, 2008). \n\nNo caso de reparo \u00f3sseo endocondral, ap\u00f3s a fratura, forma-se hematoma contendo rede de \n\nfibrina e co\u00e1gulo, os quais servem de arcabou\u00e7o para o crescimento celular. Esta primeira etapa \u00e9 \n\ncaracterizada por uma fase inflamat\u00f3ria e juntamente com o co\u00e1gulo sangu\u00edneo s\u00e3o essenciais para o \n\nreparo. C\u00e9lulas mesenquimais provenientes do peri\u00f3steo proliferam e outras linhagens \n\nosteoprogenitoras se diferenciam e o reparo \u00f3sseo tem in\u00edcio a partir da periferia do c\u00f3rtex \u00f3sseo. \n\nPr\u00f3ximo a fratura, ocorre hipoxia devido ao dano no suprimento sangu\u00edneo, permitindo que c\u00e9lulas \n\nmesenquimais se diferenciem em condroblastos, dando origem a matriz cartilaginosa. Estas massas \n\ncartilaginosas e fibrosas formam o calo \u00f3sseo, o qual ir\u00e1 estabilizar o local da fratura, sendo \n\nposteriormente invadido por vasos sangu\u00edneos e tornando-se mineralizado, formando tecido \u00f3sseo. Para \n\no caso de fratruras que exigem fixa\u00e7\u00e3o, n\u00e3o ocorre \u00e0 forma\u00e7\u00e3o de calo e o reparo \u00f3sseo ocorre sem a \n\npresen\u00e7a de fase cartilagonosa. O tecido \u00f3sseo pode ser depositado no c\u00f3rtex e tamb\u00e9m na cavidade da \n\nmedula, a partir da diferencia\u00e7\u00e3o de c\u00e9lulas mesenquimais, diretamente em osteoblasto (Shapiro, 2008). \n\nOs defeitos \u00f3sseos de grande extens\u00e3o s\u00e3o um desafio para a cirurgia reconstrutiva. O \n\ntratamento mais apropriado \u00e9 o enxerto aut\u00f3logo de osso. Por\u00e9m a quantidade de osso apropriada \u00e9 \n\nlimitada e sua retirada \u00e9 dolorosa, com risco de infec\u00e7\u00e3o, hemorragia, inaptid\u00e3o cosm\u00e9tica, danos \n\nnervosos e a perda de fun\u00e7\u00e3o (Damien &amp; Parsons 1991). Uma alternativa para os cirurgi\u00f5es superarem \n\n\n\n22 \n\n \n\neste problema \u00e9 a utiliza\u00e7\u00e3o de biomateriais de origem sint\u00e9tica ou natural, que permite a migra\u00e7\u00e3o e a \n\nprolifera\u00e7\u00e3o das c\u00e9lulas \u00f3sseas (Langer &amp; Vacanti 1993). Entretanto, o sucesso destes materiais no \n\nreparo de defeitos \u00f3sseos de grande porte \u00e9 limitado. Muitas vezes, estes n\u00e3o possuem as caracter\u00edsticas \n\ne propriedades osteog\u00eanicas e osteoindutiva dos enxertos \u00f3sseos.  \n\nBoa regenera\u00e7\u00e3o \u00f3ssea foi obtida por arcabou\u00e7os reabsorv\u00edveis suplementados com c\u00e9lulas \n\ncompetentes, como por exemplo, c\u00e9lulas tronco mesenquimais (MSC), \u201crecriando um ambiente \n\nembrion\u00e1rio\u201d no tecido adulto danificado, melhorando os resultados cl\u00ednicos (Petite et al, 2000). \n\n \n\n \n\n3. ENGENHARIA DE TECIDO \u00d3SSEO \n\n \n\nA Engenharia de Tecidos emergiu como uma promissora alternativa buscando solu\u00e7\u00f5es para as \n\nlimita\u00e7\u00f5es existentes como os enxertos aut\u00f3logos e/ou heter\u00f3logos para o tratamento de mau \n\nfuncionamento ou reparo de partes danificadas dos tecidos ou \u00f3rg\u00e3os. A Engenharia de tecidos combina \n\nc\u00e9lulas precurssoras provenientes do paciente, matrizes suportes e mol\u00e9culas bioativas (Langer &amp; \n\nVacanti, 1993), que no tecido \u00f3sseo devem induzir a osteog\u00eanese. Aplica os princ\u00edpios e m\u00e9todos da \n\nengenharia e ci\u00eancias da vida dirigindo a compreens\u00e3o fundamental da rela\u00e7\u00e3o estrutura-fun\u00e7\u00e3o nos \n\ntecidos normais ou patol\u00f3gicos de mam\u00edferos e no desenvolvimento de substitutos biol\u00f3gicos que \n\nrestaurem, mantenham ou melhorem as fun\u00e7\u00f5es teciduais (Nerem, 1992; Langer &amp; Vacanti 1993).  \n\nDesde o advento da engenharia de tecido, o tecido \u00f3sseo tem despertado particular interesse, \n\numa vez que possui grande capacidade regenerativa (Bessa et al, 2008, part II). \n\nO biomaterial utilizado para regenera\u00e7\u00e3o \u00f3ssea deve possuir um gama de caracter\u00edsticas \n\nsemelhantes ao osso como, preencher ou servir de suporte para o tecido danificado, ser osteoindutor, \n\nosteocondutor, biodegrad\u00e1vel, permitindo boa osteointegra\u00e7\u00e3o (Albrektsson &amp; Johansson, 2001; \n\nShishatskaya et al, 2006). Segundo Verti (1992) biodegrada\u00e7\u00e3o refere-se a um agente biol\u00f3gico (enzima, \n\nmicroorganismo ou c\u00e9lula) respons\u00e1veis pela degrada\u00e7\u00e3o e dispers\u00e3o in vivo. A biocompatibilidade pode \n\nser definida como a capacidade do material ter uma resposta apropriada numa aplica\u00e7\u00e3o espec\u00edfica, com \n\no m\u00ednimo de rea\u00e7\u00f5es al\u00e9rgicas, inflamat\u00f3rias ou t\u00f3xicas, quando em contacto com os tecidos vivos ou \n\nfluidos org\u00e2nicos, compreendendo as intera\u00e7\u00f5es dos tecidos e fluidos, incluindo sangue, com um \n\nmaterial (Williams, 2003).  \n\n\n\n23 \n\n \n\nOsteointegra\u00e7\u00e3o \u00e9 um termo definido como o contato direto (em n\u00edvel microsc\u00f3pico) entre o \n\ntecido \u00f3sseo vivo e o implante, sem o desenvolvimento de tecido fibroso entre eles. Deve-se ter em \n\nmente importantes termos citados em literatura como a osteoindu\u00e7\u00e3o e osteocondu\u00e7\u00e3o. Osteoindu\u00e7\u00e3o \u00e9 \n\no termo utilizado quando c\u00e9lulas osteoprogenitoras s\u00e3o estimuladas a se diferenciar, induzindo \n\nosteog\u00eanese (Wilson-Hench, 1987). Osteocondu\u00e7\u00e3o \u00e9 o termo utilizado quando uma determinada \n\nsuperf\u00edcie tem um ambiente adequado para o crescimento \u00f3sseo (Br\u00e5nemark et al, 1977; Albrektsson, et \n\nal, 1981).   \n\nOs arcabou\u00e7os utilizados na engenharia de tecidos buscam mimetizar as fun\u00e7\u00f5es da matriz \n\nextracelular natural. O primeiro papel dos arcabou\u00e7os \u00e9 servir de suporte para ades\u00e3o celular, facilitando \n\na localiza\u00e7\u00e3o e libera\u00e7\u00e3o de c\u00e9lulas quando estas s\u00e3o implantadas, consequentemente, propiciando um \n\nsuporte mec\u00e2nico adequado para o crescimento do novo tecido com  suas fun\u00e7\u00f5es apropriadas (Kim et \n\nal., 2001; Lanza et al, 2000).  \n\n Os requerimentos estruturais e mec\u00e2nicos dos suportes para a engenharia de tecidos e os pr\u00e9-\n\nrequisitos para a fabrica\u00e7\u00e3o dos suportes t\u00eam sido avaliados. \u00canfase especial \u00e9 dada ao grupo de t\u00e9cnicas \n\ncom controle computadorizado, fabrica\u00e7\u00e3o s\u00f3lida com forma livre (SFF), tamb\u00e9m conhecida como \n\nprototipagem r\u00e1pida (RP), t\u00e9cnicas que t\u00eam significante vantagem sobre as convencionais, baseadas em \n\nm\u00e9todos de fabrica\u00e7\u00e3o manual (Leong, 2003). \n\nPara o sucesso do suportes, estes devem apresentar as seguintes caracter\u00edstica:  uma apropriada \n\nmacroestrutura para promover a prolifera\u00e7\u00e3o celular e a produ\u00e7\u00e3o de matriz espec\u00edfica ao tecido; uma \n\nalta porosidade na superf\u00edcie, com tamanho de poro adequado para permitir o crescimento e \n\nregenera\u00e7\u00e3o tecidual  evitando a oclus\u00e3o do poro; apropriada morfologia de superf\u00edcie e propriedades \n\nf\u00edsico-qu\u00edmicas para permitir sinaliza\u00e7\u00e3o intracelular e o recrutamento de c\u00e9lulas; o material ainda deve \n\napresentar apropriada taxa e degrada\u00e7\u00e3o, com produtos at\u00f3xicos para c\u00e9lulas (Leong, 2003;  Yeong et al, \n\n2004). \n\n A sinteriza\u00e7\u00e3o seletiva a laser (SLS) \u00e9 um tipo de prototipagem r\u00e1pida com emprego de laser de \n\ng\u00e1s carb\u00f4nico (CO2) para sinteriza\u00e7\u00e3o seletiva do p\u00f3 de pol\u00edmero ou comp\u00f3sito (pol\u00edmero/cer\u00e2mico, \n\nmetal multif\u00e1sico) para formar camadas de material. O feixe de laser \u00e9 direcionado diretamente na \n\ncamada de p\u00f3 atrav\u00e9s de um sistema de esquadrinhamento preciso a laser. As fus\u00f5es de camadas do \n\nmaterial s\u00e3o fixadas umas sobre as outras criando o objeto tridimensional. Durante a fabrica\u00e7\u00e3o, o \n\nobjeto \u00e9 suportado e encaixado pelo p\u00f3 circunvizinho n\u00e3o processado e precisa ser extra\u00eddo das camadas \n\nde p\u00f3 ap\u00f3s a fabrica\u00e7\u00e3o. Devido ao p\u00f3 ser sujeito a uma baixa for\u00e7a de compacta\u00e7\u00e3o durante a sua \n\n\n\n24 \n\n \n\ndeposi\u00e7\u00e3o para formar novas camadas, os objetos fabricados via SLS s\u00e3o usualmente porosos. A \n\nporosidade dos dispositivos fabricados via SLS pode ser controlada atrav\u00e9s do ajuste dos par\u00e2metros do \n\nprocesso SLS (Leong, 2003; Williams, 2005), granulometria do material e projeto mec\u00e2nico dos poros em \n\ntr\u00eas dimens\u00f5es com uma concep\u00e7\u00e3o biomim\u00e9tica (Das, 2003; Williams, 2005). \n\n Matrizes colag\u00eanicas tri-dimensionais t\u00eam sido outra op\u00e7\u00e3o para Engenharia de Tecidos. A partir \n\nde uma solu\u00e7\u00e3o contendo col\u00e1geno, aplica-se a t\u00e9cnica de freeze-dryer, obtendo-se uma matriz \n\ncolag\u00eanica tri-dimensional, poros interconectados e de tamanho controlado (O\u2019Brien et al,  2004). As \n\npropriedades dessas matrizes colag\u00eanicas podem ser melhoradas adicionando-se compostos de fosfato \n\nde c\u00e1lcio, como a hidroxiapatita (HA),  ambos apresentando capacidade osteocondutivas (Al-Munajjed et \n\nal, 2009). \n\nUma variedade de biomateriais tem sido utilizados como suportes osteocondutivos em cirurgias \n\nortop\u00e9dicas, entre eles, destacam-se os suportes inorg\u00e2nicos como hidroxiapatita (Kong et al, 2007), e os \n\npol\u00edmeros (Sun et al, 2004; Shi et al, 2007), sendo estes naturais como col\u00e1geno ou sint\u00e9ticos como PHB, \n\nPCL e PLGA entre outros (Lucchesi et al, 2009; Qian et al, 2009). Para melhorar a qualidade de resposta \n\ntecidual e celular, uma s\u00e9rie de fatores de crescimento, prote\u00ednas osteoindutivas e at\u00e9 mesmo DNA, t\u00eam \n\nsido utilizados, gerando os comp\u00f3sitos.  \n\n \n\n3.1 POL\u00cdMEROS  \n\nNos \u00faltimos 20 anos, a pesquisa no campo dos pol\u00edmeros, tem buscado o desenvolvimento  de \n\nnovos m\u00e9todos para se obterem materiais de origem biol\u00f3gica ou sint\u00e9ticas, altamente compat\u00edveis, \n\ncapazes de melhorar a intera\u00e7\u00e3o com os tecidos (Selfton, 2002; Netti et al, 2002). Junto \u00e0 \n\nbiocompatibilidade, um material utilizado como pr\u00f3tese, dispositivo biom\u00e9dico ou suporte para \n\nengenharia de tecidos deve possuir um complexo arranjo biof\u00edsico, estrutural e propriedades biol\u00f3gicas \n\ncompat\u00edveis com os tecidos. Al\u00e9m disto, um biomaterial ideal para substituir defeitos no tecido, deve ser \n\ncapaz de reproduzir suas fun\u00e7\u00f5es biof\u00edsicas e biol\u00f3gicas (Netti et al, 2002). \n\n\u00c9 fundamental que o biomaterial mantenha suas propriedades mec\u00e2nicas, enquanto o novo \n\ntecido se regenera, suportando-o de modo adequado. Se por um lado, o material for pouco resistente, \n\npode se obter substitutos inadequados. Por outro lado, se o material tiver resist\u00eancia muito superior ao \n\ndo tecido, pode-se causar tens\u00e3o nas bordas do implante podendo resultar em fragilidade do osso. \n\n\n\n25 \n\n \n\nConsequentemente, o biomaterial deve resistir aos procedimentos de esteriliza\u00e7\u00e3o e deve ter uma vida \n\n\u00fatil longa (Seal et al, 2001). \n\nA biointegra\u00e7\u00e3o ideal tem sido esperada em implantes artificiais. Isto implica no fen\u00f4meno que \n\nocorre na interface entre o implante e o novo tecido, n\u00e3o induzindo nenhum efeito delet\u00e9rio como \n\nresposta inflamat\u00f3ria intensa ou forma\u00e7\u00e3o de tecido fibroso. Conseq\u00fcentemente, boas propriedades \n\npara intera\u00e7\u00e3o celular na superf\u00edcie do biomaterial s\u00e3o de grande import\u00e2ncia para serem utilizados \n\ncomo implantes. \n\nIsto significa que estes materiais devem possuir propriedades e fun\u00e7\u00f5es semelhantes as do \n\ntecido local (Sodhi, 1996). Como todos os materiais implantados no organismo, os pol\u00edmeros destinados \n\npara a regenera\u00e7\u00e3o \u00f3ssea devem ser biocompat\u00edveis, mold\u00e1veis ou polimerizados in situ para assegurar \n\num bom ajuste na regi\u00e3o do defeito. Como caracter\u00edsticas essenciais, devem suportar a ades\u00e3o, \n\ncrescimento e diferencia\u00e7\u00e3o celular, promover a r\u00e1pida difus\u00e3o de metab\u00f3litos, catab\u00f3litos e os res\u00edduos \n\ngerados (Peter et al, 1998). \n\nPol\u00edmeros biorreabsorv\u00edveis t\u00eam sido amplamente utilizados como suportes em engenharia de \n\ntecidos para direcionar o crescimento e diferencia\u00e7\u00e3o de c\u00e9lulas espec\u00edficas (Patrick et al., 1998). O uso \n\nde materiais polim\u00e9ricos em aplica\u00e7\u00f5es na \u00e1rea biom\u00e9dica \u00e9 um campo de pesquisa relativamente novo, \n\nem cont\u00ednuo crescimento e para qual os profissionais de diversas \u00e1reas de conhecimento unem seus \n\nesfor\u00e7os para encontrar solu\u00e7\u00f5es de problemas previamente sem resposta (Williams, 1987; Hench, \n\n1998). \n\nNo Brasil t\u00eam-se verificado um crescimento constante no n\u00famero de trabalhos envolvendo \n\npol\u00edmeros com aplica\u00e7\u00f5es biom\u00e9dicas. V\u00e1rios pesquisadores v\u00eam estudando os pol\u00edmeros \n\nbiorreasorv\u00edveis in vitro e sua intera\u00e7\u00e3o in vivo (Lucchesi et al, 2009; Messias et al, 2009; Lucchesi et al, \n\n2007; Silva et al, 2006; Pereira et al, 2006; Rezende et al, 2005; Barbanti et al, 2004; Marreco et al, 2004; \n\nScapin et al, 2003; Luciano et al, 2002; Zoppi, et al, 2001; Ferreira et al, 2001; Duek et al, 1999), al\u00e9m dos \n\npol\u00edmeros de origem natural como as matrizes colag\u00eanicas (Goissis et al, 2003;  Sena et al, 2004), \n\nquitosana, etc. \n\n \n3.1.1 POL\u00cdMEROS SINT\u00c9TICOS: PHB, PCL e PLGA. \n\nOs ensaios com emprego de pol\u00edmeros in vitro s\u00e3o estrat\u00e9gias fundamentais para o \n\ndesenvolvimento no campo da engenharia de tecidos (Tormala et al, 1993). Dois campos em particular \n\nt\u00eam prosperado: a associa\u00e7\u00e3o de fatores osteo-condutivos com o material implantado e a intera\u00e7\u00e3o de \n\n\n\n26 \n\n \n\nc\u00e9lulas tronco osteog\u00eanicas com estes materiais. Em ambos os campos, um entendimento dos \n\nfen\u00f4menos de ades\u00e3o celular e em particular, das express\u00f5es de prote\u00ednas envolvidas na ades\u00e3o de \n\nosteoblastos com os biomateriais \u00e9 de crucial import\u00e2ncia na manuten\u00e7\u00e3o da estrutura tecidual, \n\ncicatriza\u00e7\u00e3o, resposta imune, e tamb\u00e9m na intera\u00e7\u00e3o do tecido com os biomateriais (Anselme, 2002). \n\nDentre os pol\u00edmeros sint\u00e9ticos, o poli(\u00e1cido l\u00e1tico-co-\u00e1cido glic\u00f3lico) (PLGA) est\u00e1 entre alguns dos \n\naprovados para o uso cl\u00ednico em seres humanos pelo Food and Drugs Admnistration (FDA). Estes \n\npol\u00edmeros podem ser facilmente processados dentro da configura\u00e7\u00e3o desejada e suas propriedades \n\nf\u00edsicas, qu\u00edmicas, mec\u00e2nicas e sua degradabilidade, podem ser manipuladas para atender uma \n\nnecessidade em particular.  \n\nO PLGA \u00e9 conhecido por ser um pol\u00edmero biocompat\u00edvel e biorreabsorv\u00edvel se degradando \n\natrav\u00e9s de uma simples hidr\u00f3lise em \u00e1cido l\u00e1ctico e \u00e1cido glic\u00f3lico, sendo estes produtos eliminados do \n\ncorpo atrav\u00e9s de processos metab\u00f3licos normais (G\u00f6pferich, 1996). Sua taxa de degrada\u00e7\u00e3o pode variar \n\ndesde algumas semanas at\u00e9 anos, simplesmente variando o percentual de copol\u00edmeros de \u00e1cido l\u00e1tico \n\npara glic\u00f3lico (Mikos et al, 1993), uma vez que estudos demonstraram que o poli(\u00e1cido l\u00e1tico) puro \n\napresenta um longo tempo de degrada\u00e7\u00e3o in vitro (Duek et al, 1999). A biocompatibilidade do PLGA \n\ntamb\u00e9m tem sido demonstrada em v\u00e1rios tecidos biol\u00f3gicos (Rezende et al, 2005). Por\u00e9m, apesar de \n\npinos do copol\u00edmero poli(\u00e1cido l\u00e1tico-co-\u00e1cido glic\u00f3lico) ter mostrado bons resultados, nas intera\u00e7\u00f5es \n\nc\u00e9lulas/tecido, estes materiais, n\u00e3o possuem as mesmas propriedades mec\u00e2nicas que o osso e n\u00e3o \n\npodem ser implantados por per\u00edodo de tempo prolongado (Seal et al, 2001).  \n\nOutro pol\u00edmero que v\u00eam sendo amplamente usado nos \u00faltimos 30 anos para a produ\u00e7\u00e3o de fios \n\nde sutura, sistemas de libera\u00e7\u00e3o controlada de f\u00e1rmacos e atualmente est\u00e1 sendo explorado para \n\nsubstitui\u00e7\u00e3o de enxerto de osso, \u00e9 a Poli(caprolactona) (PCL) (Heath et al, 2002). Este pol\u00edmero chamou a \n\naten\u00e7\u00e3o devido a sua alta biodegradabilidade, biocompatibilidade e boas propriedades mec\u00e2nicas (Cretu \n\net al, 2003). As blendas polim\u00e9ricas de PCL, assim denominadas por serem obtidas da mistura f\u00edsica de \n\ndois ou mais tipos de pol\u00edmeros, vem sendo investigadas, pois podem melhorar as propriedades f\u00edsicas e \n\nmec\u00e2nicas quando comparadas aos pol\u00edmeros puros (Park et al, 1992).  \n\nAlgumas blendas, incluindo pol\u00edmero sint\u00e9tico e/ou pol\u00edmero biol\u00f3gico (por exemplo, col\u00e1geno), \n\nt\u00eam sido preparadas com a finalidade de melhorar a biocompatibilidade do primeiro (Giusti et al, 1994). \n\nEm geral, a prepara\u00e7\u00e3o de blendas tem sido realizada com o objetivo principal de controlar a velocidade \n\nde degrada\u00e7\u00e3o de pol\u00edmeros biodegrad\u00e1veis. O tempo de degrada\u00e7\u00e3o de um pol\u00edmero biodegrad\u00e1vel \n\npara aplica\u00e7\u00f5es biom\u00e9dicas pode variar de meses a anos, dependendo dos balan\u00e7os \n\n\n\n27 \n\n \n\nhidrof\u00edlico/hidrof\u00f3bico e amorfo/cristalino. Estes balan\u00e7os podem ser controlados em fun\u00e7\u00e3o da \n\nquantidade e do tipo de constituintes usados na prepara\u00e7\u00e3o de uma blenda (Park et al, 1992). \n\n Dentre as vantagens dos pol\u00edmeros biorreabsorv\u00edveis, dependendo dos seus componentes, \n\npodem-se obter moldes com rigidez suficiente, oferecendo suporte mec\u00e2nico por um per\u00edodo de tempo \n\nadequado e permitindo a consolida\u00e7\u00e3o \u00f3ssea, at\u00e9 que se inicie o processo de degrada\u00e7\u00e3o do molde. \n\nDentre os pol\u00edmeros que apresentam vantagens, como termoplasticidade, biocompatibilidade e \n\nbiodegradabilidade, destaca-se o poli (3-hidroxibutirato) (PHB) e seus copol\u00edmeros, poli(hidroxibutirato-\n\nco-hidroxivalerato) (PHBV) (Ferreira, 2001). O PHB e seus copol\u00edmeros rand\u00f4micos contendo unidades do \n\n3-hidroxibutirato e 3-hidroxivalerato (FIG.1) t\u00eam sido produzidos a partir de bact\u00e9rias Alcaligenes \n\neutrophus  [Hankermeyer &amp; Tjeerdema, 1999]. \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \nFigura 1 \u2013 Na presen\u00e7a de \u00e1gua, as liga\u00e7\u00f5es \u00e9steres presentes nestes pol\u00edmeros, s\u00e3o rompidas, \n\nocasionando a quebra da quebra da cadeia, gerando em uma das por\u00e7\u00f5es carb\u00f3xi terminal e hidr\u00f3xi \n\nterminal. \n\n \n\nO PHB \u00e9 um pol\u00edmero altamente cristalino, tendo boa biocompatibilidade, porque seus derivados \n\ns\u00e3o produtos do metabolismo celular, estando presentes no sangue e tecidos. Entretanto, devido ao fato \n\nde ser quebradi\u00e7o e ter baixa resist\u00eancia mec\u00e2nica, sua aplica\u00e7\u00e3o \u00e9 limitada. Embora exista uma \n\ndiversidade de pol\u00edmeros conhecidos, poucos t\u00eam sido investigados como o copol\u00edmero \n\npolihidroxibutirato-co-hidroxivalerato (PHBV) (Volova et al, 2003).  \n\nNo entanto os poli\u00e9steres biorreabsorv\u00edveis como o PHB e seus derivados, s\u00e3o pobres no que diz \n\nrespeito \u00e0 intera\u00e7\u00e3o c\u00e9lula-matriz. Os PHBs s\u00e3o biomateriais hidrof\u00f3bicos (Ferreira et al, 2002; Hasirci et \n\n\n\n28 \n\n \n\nal,2003)  apresentando \u00e2ngulo de contato por volta de 80\no\n , por\u00e9m a maior parte das c\u00e9lulas exibem boa \n\nades\u00e3o celular sobre superf\u00edcie com \u00e2ngulo de contato abaixo de 60\no\n (Yamaguchi et al, 2004). Ferreira et \n\nal. (2002), relatam que o PHBV \u00e9 pol\u00edmero com caracter\u00edsticas hidrof\u00f3bicas, apresentando lenta ades\u00e3o \n\ncelular. A ades\u00e3o celular \u00e9 quesito essencial para tal finalidade e muitas s\u00e3o as op\u00e7\u00f5es dispon\u00edveis na \n\nengenharia de materiais para incrementar a ades\u00e3o tais como o recobrimento com pol\u00edmeros da matriz, \n\nenxertos na superf\u00edcie e o tratamento por plasma (van Kooten, 2004). \n\n \n3.2 TRATAMENTO DE SUPERF\u00cdCIES \n\n \n\nTem-se demonstrado que modifica\u00e7\u00f5es qu\u00edmicas na superf\u00edcie dos materiais t\u00eam um importante \n\npapel na ades\u00e3o e crescimento, prolifera\u00e7\u00e3o e diferencia\u00e7\u00e3o celular al\u00e9m de propiciar que c\u00e9lulas \n\ndiferenciadas possam depositar e remodelar a matriz extracelular depositada (Dalby et al, 2002). Isto \n\nindica que se deve dar aten\u00e7\u00e3o tanto \u00e0 estrutura 3D polim\u00e9rica e tamb\u00e9m ao tratamento de suas \n\nsuperf\u00edcies e/ou incorporar elementos bioativos capazes de influenciar o comportamento celular (Seal et \n\nal, 2001). \n\n Dentre os tratamentos de superf\u00edcie, aquele realizado com plasma \u00e9 particularmente vers\u00e1til \n\npois a modifica\u00e7\u00e3o \u00e9 restrita ao topo da superf\u00edcie, sem comprometer as propriedades do material como \n\num todo (Chan, 1993). O tratamento por plasma pode ser usado para modificar a superf\u00edcie do pol\u00edmero \n\nde maneira n\u00e3o espec\u00edfica por mudan\u00e7as na molhabilidade ou mais especificamente, introduzindo-se \n\numa variedade de grupos funcionais dependendo do tipo de g\u00e1s utilizado (Keen et al, 2006). Al\u00e9m disso, \n\no tratamento por plasma torna a superf\u00edcie est\u00e9ril, podendo ser aplicado em dispositivos biom\u00e9dicos, \n\ninstrumentos cir\u00fargicos, engenharia de tecidos e aplica\u00e7\u00f5es cl\u00ednicas. Estudos mostram que o tratamento \n\npor plasma pode destruir microorganismos, matando bact\u00e9rias e v\u00edrus, esterilizando o material, \n\nrepresentando mais uma vantagem (Chu et al, 2002). \n\n Um grande n\u00famero de pesquisadores tem investigado o tratamento por plasma para a \n\nmodifica\u00e7\u00e3o da superf\u00edcie de pol\u00edmeros como o PHBV.  Kose e colaboradores (2003) modificaram as \n\ncaracter\u00edsticas qu\u00edmicas e f\u00edsicas da superf\u00edcie por plasma de oxig\u00eanio e verificaram que esse tratamento  \n\naumentou a afinidade das c\u00e9lulas, as quais cresceram sobre o material, proliferaram e se diferenciaram, \n\ndando in\u00edcio a produ\u00e7\u00e3o de uma matriz.  Langowski &amp; Uhrich, (2005), estudaram a modifica\u00e7\u00e3o do PHBV \n\npor plasma de oxig\u00eanio, resultando num aumento da hidrofilicidade do material.  Wan et al, (2005), \n\nmelhoraram a hidrofilicidade da superf\u00edcie do PHBV atrav\u00e9s da modifica\u00e7\u00e3o por plasma de oxig\u00eanio, \n\n\n\n29 \n\n \n\nmostrando que o crescimento das c\u00e9lulas mesenquimais foi melhor na superf\u00edcie tratada. Keen et al, \n\n2006, utilizaram plasma de am\u00f4nia e amin\u00f3lise etilenodianima, observando que o tratamento por \n\nplasma acrescentou uma quantidade maior de grupos amina. Lucchesi et al (2008) trataram a superf\u00edcie \n\nde membranas de PHBV com plasma dos gases oxig\u00eanio e nitrog\u00eanio, demonstrando uma altera\u00e7\u00e3o no \n\ncomportamento de ades\u00e3o de c\u00e9lulas Vero.  \n\n \n\n\n\n30 \n\n \n\nII. OBJETIVOS \n\n \n\n \n\n1) Avaliar o comportamento de osteoblasto-like proveniente de calota craniana de ratos Wistar sobre \n\nsuportes de PCL/PLGA. \n\n \n\n2) Avaliar o comportamento in vitro de osteoblastos-like provenientes de calota craniana de coelhos \n\nNew Zealand sobre arcabou\u00e7os de PHB tri-dimensionais obtidos por prototipagem r\u00e1pida e \n\nmodificados por plasma de nitrog\u00eanio e oxigenio. \n\n \n\n3) Avaliar a intera\u00e7\u00e3o pol\u00edmero/c\u00e9lula/tecido in vivo ap\u00f3s implante de arcabou\u00e7os de PHB tri-\n\ndimensionais obtidos por prototipagem r\u00e1pida e modificados por plasma de nitrog\u00eanio e oxigenio, \n\ncom o cultivo pr\u00e9vio de osteoblasto-like provenientes de calota craniana de coelhos New Zealand. \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n\n\n31 \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nCAP\u00cdTULO 2 \n\n  \n\n\n\n32 \n\n \n\n \n\n\n\n33 \n\n \n\n\n\n34 \n\n \n\n\n\n35 \n\n \n\n\n\n36 \n\n \n\n\n\n37 \n\n \n\n\n\n38 \n\n \n\n\n\n39 \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nCAP\u00cdTULO 3 \n\n\n\n40 \n\n \n\nRAPID PROTOTYPING OF POLY(HYDROXYBUTYRATE) SCAFFOLDS TREATED BY \n\nPLASMA TO SUPPORT OSTEOBLASTIC CELLS FROM RABBIT CALVARIA.  \n\n \n\nCarolina Lucchesi\n1,2\n\n, Ricardo Z Lorenzon\n1\n, Betina M P Ferreira\n\n1\n, Marcelo F Oliveira\n\n3\n, Izaque A Maia\n\n3\n, \n\nJorge VL da Silva\n3\n,Eliana A R Duek\n\n1\n, Paulo P Joazeiro\n\n2*\n. \n\n \n\n1. Laboratory of Biomaterials, Center of Medical Science and Health, Pontifical \n\nCatholic University of Sao Paulo, PUC/SP, SP, Brazil. \n\n2. Department of Histology and Embryology, Institute of Biology, State University of \n\nCampinas (UNICAMP), Campinas, SP, Brazil. \n\n3. Center of Information TechnologyRenato Archer, CTI, Campinas, SP, Brazil. \n\n*\npjoaz@unicamp.br \n\n \n\nABSTRACT \n\n \n\nThe complexity of bone into three dimensional (3D) in vitro models remains one of the most \n\nimportant challenges in the field of the tissue engineering. The models should faithfully mimic these \n\ntissues, resembling their organization, their mechanical properties and their physiological response to \n\ndifferent stimuli. Indeed, the development and the optimization of novel culture systems may be necessary \n\nto face the next questions of bone physiology. For the new therapeutic strategy, it is indispensable to \n\nprovide cells with a local environment that enhances and regulates their proliferation and differentiation \n\nfor cell-based tissue regeneration. Biomaterial technology plays an important role in the creation of this \n\ncell environment. In this work three dimensional PHB scaffolds were obtained by rapid prototyping. Cells \n\nobtained from rabbit calvaria were culture on the scaffold 3D PHB scaffolds. The cells response were \n\nevaluated by MTT test, Sirius Red and SEM. The PHB showed good cells viability with no cytotoxic \n\neffects with or without treatment. The physical-chemical modifications on the samples caused by nitrogen \n\nplasma treatment improve cell attachment. The samples allowed improve the synthesis of type I collagen \n\nas one of the characteristics of osteoblast cell. The polymer PHB meets the requirements to act as scaffold \n\nfor Tissue Engineering by being biocompatible, support growth and cell organization and by having its \n\ndegradation products non-toxics to the cells.  The selective laser sintering has been a good technical to \n\nobtain 3D scaffolds for Tissue Engineering. \n\n \n\nKey-words: Poly(hydroxybutyrate) (PHB), Tissue engineering, Osteoblast.  \n\nmailto:pjoaz@unicamp.br\n\n\n41 \n\n \n\nINTRODUCTION \n\n \n\nBone fracture treatment is a widespread clinical practice and about 50% of these treatments need \n\nsurgical intervention (PRAEMER, 1992). Along with the surgery, problems for the restoration of the \n\nmechanical integrity of the tissue and the establishment of the continuity of skeleton may appear (MA, \n\n2001). Tissue engineering, however, appears as the most viable alternative for the restoration of the \n\nskeleton continuity and the bone fixation (FLEMING, 2000). \n\n The concept of Tissue Engineering is based on a cell/polymer system in which a bioresorbable \n\npolymer acts, for a period of time, as a substrate or scaffold to promote tissue formation (PETER, 1998). \n\nMost of bioresorbable implants are of the class of aliphatic polyesters derived from the ?-hydroxy acids \n\nfamily (NEBE, 2001). Other family that is widely studied is that of polyhidroxyalkanoates, which are \n\npolyesters accumulated by bacteria as a store of carbon and energy (REDDY, 2003).  \n\n Poly(3-polyhidrxybutyrate), PHB, is an example of polyhydroxyalkanoates polyesters family, \n\nbeing produced by bacterial fermentation. When deposited in the environment this biomaterial suffers the \n\naction of aerobic microorganisms, being completely degraded into CO2 and H2O. PHB is a bioresorbable \n\npolymer, therefore it is degraded by hydrolyses, generating products that are absorbed by the organism \n\n(KOSE et al., 2003). It was first discovered in Bacillus megaterium, in 1925, by Lemoigne at the Institute \n\nPasteur of Paris. Since then, investigations have revealed its occurrence in a large number of bacteria and \n\nalgae (BARHAM, 1990). \n\n Due the properties as biodegradability, biocompatibility, optical activity, piezoelectricity and non-\n\ntoxicity, PHB has been studied for a variety of medical applications such as controlled drug-release \n\nsystem (POUTON &amp; AKHTAR, 1996), surgical sutures, wound healing, in orthopedics (HOCKING, \n\n1994) and as pericardium substitute (LANGER &amp; VACANTI, 1995). \n\nIn last years it has been studied in Tissue Engineering in the form of porous substrate (DOYLE et \n\nal., 1996; HAZARI et al., 1999). The polymer PHB meets the requirements to act as scaffold for Tissue \n\nEngineering by being biocompatible, support growth and cell organization and by having its degradation \n\nproducts non-toxics to the cells (ZHIJIANG, 2006).   \n\n There is an advantage to use this polymer, it is coming from the Brazilian industry, PHB \n\nIndustrial, which produces the polymer to about U$ 5.00/Kg in installation of 50t/year. That cost is \n\nsignificantly lower than the cost of the material from the international competitor, because there is \n\ntechnology in the production of derived substances from sugar-cane, raw material abundant in Brazil. \n\nMoreover, the cost of the polymer is also lower when compared to other bioresorbable polymers with \n\n\n\n42 \n\n \n\napplications in the biomedical field, such as poly(L-lactic acid), poly(glycolic acid) and poly(p-\n\ndioxanone). \n\n Shishatskaya and Volova (2004) studied the cytotoxics effects of PHB and PHBV films in vitro. \n\nThe authors showed that the materials studied have no cytotoxic effects on fibroblastic NIH 3T3 cells. The \n\npolymer was also studied in vivo. Other similar work developed by the group, surgical sutures made of \n\nPHB and PHBV were implanted in the muscles of Wistar rats, obtaining inflammatory responses similar \n\nto the one obtained with silk yarn and lower than the response obtained with catgut suture \n\n(SHISHATSKAYA et al., 2004). Malm et al. (1992) used PHB to correct defects of the atrial septum in \n\ncalf. Twelve months after the implant, no polymer material was identified, but by polarized light \n\nmicroscopy, small particles of the polymer with a persistent foreign body reaction could be observed. \n\n Most studies involving the PHAs as biomedical devices give attention to the copolymer PHBV. \n\nDue to PHB high level of cristalinity, there are difficulties in the process of obtaining devices with this \n\npolymer. However, by the technique employed in this work, the rapid prototyping by Selecting Laser \n\nSintering (SLS) showed better results with PHB than with its copolymer poly(hydroxybutyrate-co-\n\nhydroxyvalerate) (PHBV), which led us to use the PHB in our studies. \n\n The characteristics of Tissue Engineering scaffolds are major concerns in the quest to fabricate \n\nideal scaffolds. The solid freeform (SFF), also known as rapid prototyping, technologies which are fast \n\nbecoming the techniques of choice for scaffold fabrication with the potential to overcome the limitations \n\nof conventional manual-based fabrication techniques. SFF-fabricated scaffolds have been found to be able \n\nto address most, if not all the macro- and microarchitectural requirements for TE applications as pore size, \n\nporosity and pore interconnectivity (Leong et al., 2003). \n\nAnother issue is to establish of a stable interface between a biomaterial and the host environment \n\nis governed by both the material surface properties and the type and state of the biological tissue. The \n\nsurface properties can be altered to suit a specific biomedical application, once the most of the polymers \n\nhave hydrophobic surfaces, and most of the cells prefer to attach on hydrophilic surfaces (Yamaguchi et \n\nal, 2004). \n\nPlasma treatment can be used to modify a polymer surface in a nonspecific manner by changing \n\nthe wettability or in a more specific manner by introducing a variety of functional groups depending on \n\nthe type of gas used.  \n\nIn the present study, we treated tridimensional PHB scaffolds, obtaining by rapid prototyping, by \n\noxygen and nitrogen plasma with the aim to evaluate the behavior of cell adhesion, proliferation and \n\ndifferentiation of osteoblasts cells from rabbit calvaria. \n\n  \n\n\n\n43 \n\n \n\nMATERIAL AND METHODS \n\n \n\nScaffolds Preparation  \n\n \n\nThree-dimensional PHB (Biocycle\n\u00ae\n, PHB Industrial S/A, Brazil) scaffolds were designed using a \n\n3-D solid modeling software, exported to a Sinterstation 2000TM machine (3D Systems, Valencia, CA), \n\nand constructed by Selective Laser Sintering processing (SLS). This PHB has a particle size distribution in \n\nthe 10-100 ?m range. The circular scaffolds were produced with 6mm of diameter, 2mm of thickness and \n\n200-500 \u00b5m porous size. The samples were storage under vacuum until plasma treatment. \n\n \n\nPlasma treatment \n\n \n\nThe plasma treatment was performed using a radio frequency Anatech LTD Ashing plasma \n\napparatus. The plasma conditions employed in the treatment was PHB untreated; PHB treated by N2, 50W, \n\n150mTorr and 600s; PHB treated by O2, 100W, 300mTorr and 600s. The values of power, pressure, and \n\ntime were chosen based on preliminary studies with PHBV (Lucchesi et al., 2008).  \n\n \n\nCell isolation, seeding and culture \n\n \n\n Osteoblastic cells were obtained from 10 calvaria of young male adult (15 days old, 100\u2013150 g) \n\nNew Zealand rabbits, from university?s central animal house (PUC/SP-CCMB, Centro de Ci\u00eancias \n\nM\u00e9dicas e Biol\u00f3gicas, Sorocaba, SP, Brazil). Following euthanasia by cervical displacement, the calvaria \n\nwere aseptically excised, cleaned with a soft tissue, and washed in Dulbecco?s modified Eagle?s  medium \n\n(DMEM) (Nutricell - Nutrientes Celulares, Campinas, SP, Brazil) containing 125 \u00b5g/mL gentamicin \n\nsulfate and amphotericin B (Sigma). This concentration of antibiotics was 5 times the normal amount used \n\nin cell culture and was used as a precautionary measure to avoid contamination during harvest. In sterile \n\natmosphere, the calvaria were fragmented and submitted to enzymatic digestion for cellular isolation with \n\n1 mg/mL collagenase type 1A in DMEM (Sigma Chemical, St. Louis, MO) during 2 hours at 37\u00b0C. After \n\nthis procedure, it was submitted to a three-stage centrifugation for 10 minutes at 1200 rpm (200 xg), and \n\nsubsequently resuspended in DMEM containing 10% of fetal bovine serum (FBS) and antibiotic. After \n\ncentrifugation, the pellet was resuspended in DMEM and cellular viability was quantified by staining with \n\nTripan Blue vital stain (Sigma) in a Neubauer camera. Osteoblasts were seeded at a density of \n\napproximately 10\n5\n cells/mL in culture flasks (TPP \u2013 Techno Plastic Products, Trasadigen, Switzerland) \n\n\n\n44 \n\n \n\ncontaining DMEM, supplemented with 10% SFB (both Nutricell), 25 \u00b5g/mL gentamicin, 2.5 \u00b5g/mL \n\namphotericin B, 10 mM ?-glycerol phosphate, 50 mg/mL L-ascorbic acid (Sigma) and 10 nM \n\ndexamethasone (all Sigma) to promote cells with osteoblastic phenotype, which were used in experiments \n\nafter the third subculture. The flasks were incubated in a humidified incubator at 37\u00b0C (5% CO2/95% \n\nbalanced air). When cells reached 80% of confluence, cell cultures were considered to have reached full \n\ngrowth and the cells were enzymatically lifted from the flask by using a 0.25% trypisin/EDTA solution \n\nand monitored daily with an inverted microscope, Eclipses TS 100 (Nikon, Tokyo, Japan). The culture \n\nmedium was replaced tree times for week. \n\n \n\nCell Adhesion and Viability Assays \n\n \n\nIdentification of cell adhesion and viability on blends were carried out by performing the MTT \n\nassay, a modification of Mosmann?s (Mosmann, 1993)\n \n method, which was used for both cell adhesion \n\nand direct cell cytotoxicity assays (Santos Jr et al,  2001) Previously, the sterilized scaffolds were placed \n\nin a 96-well plate (Corning) with 100 \u00b5L of culture medium and incubated at 37\u00b0C for 24 h, according to \n\nSantos Jr., et al. (2005). After incubation, 2x10\n5\n cells/mL in 100 \u00b5L DMEM supplemented with 10% FBS \n\nwere added to the wells containing the membranes. The cells were cultured for 2 h and 24 h to allow cell \n\nadhesion and to conduct cell viability assays, respectively. After the cells were washed twice with 0.1 M \n\nphosphate-buffered saline (PBS), pH 7.4, at 37\u00baC and incubated with 100 \u00b5L DMEM, an MTT assay \n\nmixture [10 \u00b5L per well, containing 5mg/mL of 3-(4,5-dimethylthiazol-2-yl)- 2,5-diphenyl-tetrazolium \n\nbromide - MTT, Sigma] was added to each well and incubated for 4 h at 37\u00baC. After 4h, 100 ?L of \n\nDimethyl Sulphoxide (DMSO, Sigma) and 25 \u00b5L of Glycine/Sorensen buffered solution replaced the \n\nassay mixture in each well to dissolve the formazan crystals. Absorbance was quantified by a \n\nspectrophotometer at 570 nm, using a Elx-800-UV, Bio-Tek Instruments, USA. MTT is a colorless \n\ntetrazolium salt that forms a dark compound when oxidized by mitochondria, which is detected by \n\nspectrophotometer. For the viability assay, latex membranes embed in 1% phenol were used as positive \n\ncontrol, and the culture plate (polystyrene) was used as negative control. For cell adhesion evaluation, \n\nTeflon dishes were used as negative control and the culture plate itself was used as positive control. The \n\nmembranes were sterilized by UV irradiation for 30 min. Absorbance of all experimental conditions was \n\nalso read. Comparison of continuous variables for all groups was done with ANOVA. When a significant \n\ndifference was found (p &lt;0.05), the groups were compared using Tukey?s test.  \n\n \n\n \n\n\n\n45 \n\n \n\nColorimetric assay by Sirius Red \n\n \n\nPreviously, the sterilized scaffolds were placed in a 96-well plate (Corning) with 100 \u00b5L of \n\nculture medium and incubated at 37\u00b0C for 7, 14 and 28 days. Sirius Red was purchased from Sigma \n\n(Sigma Chemical, St Louis, MO, US). The dye was dissolved in saturated aqueous picric acid at a \n\nconcentration of 1 mg/mL. Bouin?s fluid were used to fix the samples and it was prepared by mixing 15 \n\nmL saturated aqueous picric acid with 5 ml 35% formaldehyde and 1 mL glacial acetic acid. Although \n\nboth reagents are stable for months, but we used freshly prepared dye reagent for each experiment and all \n\nchemicals were of analytical grade. Staining of extracellular matric (ECM) standards and cell layers, and \n\nquantification of the dye reaction. Solutions of the different ECM materials were dissolved in PBS at 0.1% \n\n(1 mg/mL), pipetted into 24-well plates, and air dried overnight in a sterile bench before fixation with 1 \n\nmL/well Bouin?s fluid. The cells layers were extensively washed with PBS prior and after fixation. Then, \n\nthe cells were stained by Sirius Red for 1 h under mild shaking on a microplate shaker. Thereafter, the dye \n\nsolution was removed by suction and the stained cell layers washed with 0.01 N hydrochloric acid to \n\nremove all non-bound dye. The stained material was dissolved in 0.1 N sodium hydroxide using a \n\nmicroplate shaker for 30 min at room temperature. The dye solution was transferred to the plate reader and \n\nthe optical density (OD) measured with a Biorad microplate reader 355 at 550 nm and the 0.1 N sodium \n\nhydroxide  was used as a blank (Tullberg &amp; Jundt, 1999).  \n\n \n\nScanning Electron Microscopy (SEM)  \n\n \n\nThe scaffolds were sterilized by UV irradiation for 30 min and placed in 96-well plates. \n\nApproximately 2x10\n5\n cells/mL osteoblastic cells in DMEM supplemented with 10% FBS were seeded in \n\neach well containing the membranes and cultured at 37\no\n C. After 6h, 1d, 2d, 7d, 14d and 21 days, the \n\nsamples were fixed in a fixative solution prepared by dissolving 2.5% paraformaldehyde, 2.5% \n\nglutaraldehyde, 0.03% picric acid, 1% tannic acid in 0.1M cacodylate buffer and the same volume of \n\nDMEM for 1h at room temperature (RT), washed in 0.1M cacodylate buffer, post-fixed in 1% osmium \n\ntetroxide in water for 1h at RT in the dark, washed in water, dehydrated with ethanol, critical point dried \n\n[Balzers CDT 030] and coated with gold in a sputter coater [Balzers CDT 050]. The coated specimens \n\nwere observed with a JEOL 5800 scanning electron microscope. \n\n \n\n\n\n46 \n\n \n\nRESULTS AND DISCUSSION  \n\n \n\nIn this study we used osteoblastic cells from the calvaria of New Zealand rabbits, 15 days old, to \n\nevaluate the biocompatibility of the 3D PHB scaffolds, and to examine the possibility of its use in bone \n\nfractures recuperation processes.  \n\n \n\nCell Viability Assay \n\n \n\n The statistical analyze of the viability assay showed difference among the samples and the \n\ncontrols, in which the positive control (phenol) presented a lower absorbance than the negative control \n\n(polystyrene) and all the samples in study presented a higher level of absorbance than the controls, \n\npositive and/or negative (p &lt;0.05). There was no significant difference among the plasma treated and \n\nuntreated samples (p > 0.05) (Figure1). \n\n \n\n \n\n \n\n \n\nFigure 1 \u2013 Evaluation of cellular viability on three-dimensional devices of PHB. Quantification by MTT. \n\n \n\n The PHB scaffolds, treated or not, showed to be less cytotoxic to the cells. There was no \n\nsignificant difference among the samples (p>0.05). Since the polystyrene has good biocompatibility, our \n\nresults indicate the good cytocompatibility of the material. \n\n\n\n47 \n\n \n\n A variety of polyesters has been used as biomedical device, with excellent results as its \n\nbiocompatibility (SHIVE, 1997). PHB is among those polyesters with good results in vivo \n\n(SHISHATSKAYA et al., 2004) and in vitro (SHISHATSKAYA &amp;VOLOVA, 2004). \n\n Shamsuria et al. (2004) studied the cytotoxicity effects of hydroxyapatite (HA), of natural coral \n\n(NC) and of polyhidroxybutarate (PHB) with human osteoblastic cells CRL-1543. After 72h hours of \n\nincubation, PHB samples obtained the higher percentage of viable cells. Suwantong et al. (2007) studied \n\nthe biocompatibility of mouse fibroblasts (L929) and Schwann cells (RT4-D6P2T) seeded on fiber mats of \n\nPHB and PHBV, not observing any negative response about the cytotoxicity of the materials. Our results \n\nare found in agreement with the literature, where PHB does not present any rate of toxicity. The plasma \n\ntreatment in this study, independently of the gas used, did not alter the cytocompatibility of the material.   \n\n The cytocompatibility of the material is not the only requisite to consider it biocompatible, but it?s \n\nan important characteristic. MTT is reagent metabolized in the mitochondria, which allows us to say, that \n\nin the intracellular levels, the cells presented viables (MARQUES et al., 2005), which is also an important \n\nfactor of the biocompatibility of the material. \n\n  \n\nCell adhesion \n\n \n\nIn this study the statistical analyze of cell adhesion after 2 hours of incubation showed  significant \n\ndifferences among the positive (polystyrene plates) and negative controls (Teflon) and the samples, where \n\nthe positive control (+) showed superior absorbance over the negative control (-)  and all the samples in \n\nstudy presented higher rates of absorbance than both controls (p &lt;0.05). The untreated PHB scaffolds \n\npresented significant difference compared to the nitrogen plasma treated PHB, which presented the \n\nhighest absorbance rate (p &lt;0.05) (Figure 2).    \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n\n\n48 \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nFigure 2 \u2013 Evaluation of cellular adhesion on three-dimensional devices of PHB. Quantification by MTT \n\n \n\n The three-dimensional PHB scaffolds, treated or not, showed to allow the cell adhesion of \n\nosteoblasts even higher than the positive control. When we compare our samples, we observe that the \n\nnitrogen plasma treated samples presented better results and it was efficient to improve the cell adhesion \n\nof the material.  \n\n The cell adhesion phenomenon is of extreme importance to the biomaterials science. Once \n\nadhered on the material the cells can migrate and/or proliferate and exercise its physiological activities, \n\nsuch as the production of extracellular matrix. The adhesion is a consequence of the interaction of the \n\nproteins adsorbed on the substrate. These interactions involve electric charge, bridges of hydrogen and \n\nelectrostatic forces. Other factors that modulate cell adhesion are the functional chemical groups present \n\non the polymer surface, which is related to the hydrophilicity/hydrophibicity of the material surface (CHU \n\net al., 2002). Surface rugosity is other important factor that can affect cell adhesion.  \n\nCell adhesion to polymeric substrates is one of the main points of tissue engineering, because the \n\nadhesive interactions control the cell physiology and also determines cell morphology (NEBE, 2001).   \n\nAccording to some authors the hydrophilicity is a factor very important to the biomaterial \n\ncytocompatibility studies. Cell adhesion and growth on biomaterials surfaces are strongly influenced by \n\nthe hydrophilicity/hydrophobicity balance, or wettability (TEZCANER et al, 2003; MA et al, 2003). \n\nThe literature has also reported that there is no obvious correlation between hydrophilicity and cell \n\nbehavior, as cell attachment; others demonstrated that the cells prefer to anchor on hydrophilic surfaces \n\n\n\n49 \n\n \n\n(WAN et al, 2003). Another studies showed that the cells adhere, spread and grow more easily on \n\nmoderate hydrophilic substrate than on hydrophobic or very hydrophilic substrate (TEZCANER et al, \n\n2003; MA et al, 2003; WAN et al, 2003). \n\nAlthough no topographical analyze of the materials used in this study was made, its widely \n\ndescribed in the literature that the plasma treatment modifies physico-chemically the materials surface. \n\nWan and collaborators could observe that the PLLA, when treated by ammonia plasma, had its \n\nhydrophilicity and energy surface level was improved . And such improvement provided a better quality \n\nof cell adhesion (WAN et al., 2003). Wang et al. (2005) cultivate osteoblasts (from bone marrow of \n\nrabbits and fibroblasts (L929) on PHB and PLA, having better results of cell adhesion for PHB. Lucchesi \n\nand collaborators (2007) studied Vero cells on PHBV samples treated by N2 and O2 plasma and showed \n\nthat the plasma treated improved the cell attachment on the scaffolds. \n\n \n\nCollagen quantification assay by Sirius Red \n\n \n\nThe biochemistry analyze of the quantification of collagen after 7 days of culture revealed that \n\nthere was significant difference between the control (polystyrene plate),  the untreated samples and the \n\nsamples treated by nitrogen plasma (p<0.05). There was no statistically difference between untreated PHB \n\nand PHB treated by nitrogen. The PHB treated by oxygen showed similar absorbance compare to control \n\n(p>0.05). After 14 days of culture the analyses revealed that there was significant difference among the \n\ncontrol and scaffolds (p<0.05). But, there was no difference between the PHB treated or untreated \n\nsamples. After 28 days there was no significant difference among the samples (p>0.05) (Figure 3).  \n\nBesides the samples with cells, we also dyed samples of PHB without cell, treated and untreated, \n\nand we discount the value of their absorbance in the value of the other samples (with cells). It was made \n\nbecause of the possibility of the dye react with the biomaterial. \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n\n\n50 \n\n \n\n \n\nFigure 3: Quantification of collagen on three-dimensional devices of PHB after 7, 14 and 28 days of cell \n\nculture through the absorbance of Sirius red. \n\n \n\nAs we could see by the graphics, the PHB scaffolds treated by plasma of O2 and N2, obtained a \n\nvalue of absorbance below the value obtained by the untreated PHB after the first 7 days of culture. With \n\n14 days of culture, the treated samples showed a significant improvement in the amount of collagen \n\nproduced, obtaining values of absorbance closer to the ones obtained by the untreated PHB. \n\nAmong the advantages of the method of coloring by Sirius red stands out the fact that the dye is \n\nhighly specific for collagen proteins type I and III, in this case. The method is based on the selective \n\nconnection of the Sirius red (acid dye) with collagen proteins (basic amino acids) and it has been applied \n\nto quantify collagen, not reacting with other components of the extracellular matrix, like fibronectin for \n\nexample. This is important because fibronectin can be expressed in large quantities by pre-osteoblastic cell \n\nwith poor differentiation and fast proliferation (TULLBERG-REITEN &amp; JUNDT, 1999). \n\nMineralization substances such as dexametasone, ascorbic acid and ?-glicerophosphate, present in \n\nthe culture medium used in this study, can alter collagen synthesis after prolonged periods. Tullberg-\n\nReiten &amp; Jundt  (1999) verified that the combination of ascorbic acid and ?-glicerophosphate stimulate the \n\nsynthesis of collagen, and that dexametasone reduce the synthesis after 14 days of culture. The author also \n\nconfirms that the ascorbic acid is considered an important inductor of synthesis of collagen, and that the \n\nascorbic acid well as the ?-glicerophosphate is essential to the maturation of the bone mineralization.  \n\n\n\n51 \n\n \n\nIn the present study the control samples received the same mineralization medium that the PHB \n\nsamples received, however, the higher rate of absorbance obtained by the PHB samples demonstrated that \n\nthe polymer not only allowed the osteoblasts to synthesize collagen type I and III, but also stimulate its \n\nsynthesis. It was not possible to do an evaluation about the influence of each mineralization substance in \n\nthe synthesis of collagen in our study, once the culture medium used had three substances together. Such \n\nfact, however, do not affect our work, once the amount of collagen produced by the cells cultured on PHB \n\nwas superior than the amount produced by the ones cultured on the polystyrene plate as control.   \n\nCollagen is the major component of the extracellular matrix and it represents about 90% of the \n\norganic substances present in the bone tissue. According to Tullberg-Reiten &amp; Jundt (1999), places with \n\nlarge collagen deposition can represent places of synthesis of mature matrix before mineralization begins. \n\nDue to the material be three-dimensional and opaque, the visualization of these deposits was not possible \n\nby optical microscopy, but the quantitative analyze shows us evidence of its presence as both of its \n\nsynthesis.  \n\nYet, collagen type I is the major extracellular component of the osteoblasts phenotype \n\ncharacterization (TULLBERG-REINERT &amp; JUNDT, 1999). The high absorbance of the Sirius red \n\nevidences the phenotype of the osteoblastic cells in this study. The use of this method for the \n\ncharacterization of the cell phenotype has been described in the literature (SARUWATARI et al., 2005).  \n\nFor the statistical analyses we applied variance analyze (ANOVA) and Tukey?s test when the \n\ndifference was significant (p &lt;0.05) to compare the different treatment. \n\n \n\nUltrastructural study  \n\n \n\n Through the scanning electron microscopy we could observe the PHB scaffold with cells and its \n\ndifferent treatments, which allowed cell growth on all samples (Fig. 4-9). The scaffolds showed to be \n\nunstable during the analyses, which made the image obtaining harder. According to previous results \n\nobtained by the group, the PHB scaffolds showed rough structure suggesting higher porosity and low \n\nmechanical properties (Oliveira et al, 2007).  \n\n After 6 hours of culture, the cells adhered on PHB scaffolds treated and untreated by plasma, \n\napparently similarly, with rounded morphology and not differing in quantity (Fig. 4). These aspects did \n\nnot differ from the ones obtained after 24 hours of cell culture, although a huge amount of fibrilar material \n\nwas observed on cells surface, that could suggested some matrix synthesis (Fig. 5). We could observe that \n\nafter 48 hours of culture the presence of vesicles on cell surfaces was more frequent (Fig. 6). From day 7, \n\nthere are evidences that the cells recover the entire scaffold, presenting structures similar to \n\n\n\n52 \n\n \n\nmicrovilosities, being possibly, secretion of extracellular matrix (Fig. 7), specially at the treated samples \n\nby plasma (Fig. 7B-7C).  The samples after 14 days of culture, presented a high quantity of fibril material, \n\nseeing cell emitting cytoplasmatic projections. The fibril material on cell surfaces presented itself in \n\nfibrous form (Fig. 8).  After 21 days of culture, cells recovered the polymeric devices, presenting \n\nthemselves close to one another and emitting cytoplasmatic projections to cellular groups more distant and \n\ngranules that could suggesting minerals depositions since we used osteogenic medium (Fig. 9). \n\n In general, the cells presented a rounded morphology, elongated or polygonal, with cytoplasmatic \n\nprojections and particulate material on cell surface. The samples, independently of the treatment \n\nemployed, presented themselves extremely irregular, which made the comparisons very difficult. \n\nHowever, it?s widely described in the literature that the plasma treatment, modify the surface properties of \n\nthe material (KEEN et al., 2006) and that these surface properties influence the events of cell/substrate \n\ninteraction. This is clear in many studies that show that these properties determine the type of biological \n\nmolecule adsorbed (BOYAN et al., 1996). Other factors that influence in the material biocompatibility are \n\nsurface rugosity, surface chemical groups and surface hydrophilicity. Lucchesi et al. (2008) observed that \n\nVero cells, when cultured on PHBV membranes treated by oxygen or nitrogen plasma presented different \n\nbehavior. Besides that, we should take into consideration the fact that different cellular types respond in \n\ndifferent ways to different surfaces (COCHRAN et al., 1994). According to Bowers et al. (1992), cells \n\nsimilar to osteoblast, \u201costeoblast-like\u201d, present a higher percentage of cell adhesion on substrates with \n\nrough surface, while fibroblasts adhere much better on flat surfaces. However, the PHB samples behaved \n\nthemselves unstably to the electron beam, impairing not only the images analyses, but also its obtaining. \n\nBy this technique, it was not possible to compare the plasma treated and untreated scaffolds.  \n\n The selective laser sintering has been a good technical to obtain 3D scaffolds for Tissue \n\nEngineering. For biomedical field it might be a great tool with high precision to mimetize bone \n\narchitecture besides of the micro-fabrication. \n\n \n\nCONCLUSION \n\n \n\nThe PHB showed good cells viability with no cytotoxic effects with or without treatment. The \n\nphysical-chemical modifications on the samples caused by nitrogen plasma treatment improve cell \n\nattachment. The samples allowed improve the synthesis of type I collagen as one of the characteristics of \n\nosteoblast cell. The selective laser sintering has been a good technical to obtain 3D scaffolds for Tissue \n\nEngineering. \n\n \n\nACKNOWLEDGEMENTS  \n\n\n\n53 \n\n \n\n \n\nThe authors thank FAPESP process # (proc. 06/07147-3), Laborat\u00f3rio nacional de Luz Sincrotron (LNLS) \n\nand Centro de Tecnologia da Informa\u00e7\u00e3o Renato Archer (CTI). \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n\n\n54 \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nFigure 4: Scanning Electron Microscopy of PHB scaffold after 6 hours of cell culture. A) PHB; B) PHB \n\nO2; C) PHB N2.  \n\n\n\n55 \n\n \n\n  \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nFigure 5: Scanning Electron Microscopy of PHB scaffold after 24 hours of cell culture. A) PHB; B) PHB \n\nO2; C) PHB N2.  \n\n\n\n56 \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nFigure 6: Scanning Electron Microscopy of PHB scaffold after 48 hours of cell culture. A) PHB; B) PHB \n\nO2; C) PHB N2.  \n\n\n\n57 \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nFigure 7: Scanning Electron Microscopy of PHB scaffold after 7days of cell culture. A) PHB; B) PHB \n\nO2; C) PHB N2.  \n\n\n\n58 \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nFigure 8: Scanning Electron Microscopy of PHB scaffold after 14 days of cell culture. A) PHB; B) PHB \n\nO2; C) PHB N2.  \n\n\n\n59 \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nFigure 9: Scanning Electron Microscopy of PHB scaffold after 21 days of cell culture. A) PHB; B) PHB \n\nO2; C) PHB N2.  \n\nA \n\nB \n\nC \n\n\n\n60 \n\n \n\nREFERENCES \n\n \n \n\nBARHAM, P. J. Physical properties of poly(hydroxybutyrate) and poly(hydroxybutyrate-hydroxyvalerate). DAWES, \n\nE.A. (ed). Novel Biodegradable Microbial Polyesters. Kluwer (1990) 694-697. \n\n \n\nBOWERS, K.T.; KELLER, J.C.; RANDOLPH, B.A.; WICK, D.G.; MICHAELS, C.M. Optimization of surface \n\nmicromorphology for enhanced osteoblast responses in vitro. Int J Oral Maxillofac Implants, v.7, n.3, p. 302-10, \n\n1992. \n\n \n\nBOYAN, B.D.; HUMMERT, T.W.; DEAN, D.D.; SCHWARTZ, Z. Role of material surfaces in regulating bone and \n\ncartilage cell response. Biomaterials, v.17, p. 137-146, 1996. \n\n \n\nCHU, P.K.; CHEN, J.Y.; WANG, L.P.; HUANG, N.  Plasma-surface modification of biomaterials.  Mater Sci Eng \n\nVer. v.36, p.143-206, 2002. \n\n \n\nCOCHRAN, D.; SIMPSON, J.; WEBER, H.; BUSER, D. Attachment and growth of periodontal cells on smooth and \n\nrough titanium. Int J Oral Max Implant, v. 9, n. 3, p.  289-297, 1994. \n\n \n\nDOYLE, V.; PEARSON, R.; LEE, D.J. An investigation of the growth of human dermal fibroblasts on poly-L-lactic \n\nacid in vitro. J Mater Sci Mater Med, v. 7, pp. 381, 1996. \n\n \n\nFLEMING, J. E.; CORNELL, C. N.; MUSCHLER, G. F. Bone cells and matrices in orthopedic tissue engineering. \n\nOrthop. Clin. North. Am. v.31, p.357\u201374, 2000. \n\n \n\nHAZARI, A.; WIBERG, M.; JOHANSSON-RUDEN, G.; et al. A resorbable nerve conduit as an alternative to nerve \n\nautograft in nerve gap repair. British Journal of Pastic Surgery, v. 52, pp. 653-657, 1999. \n\n \n\nHOCKING, P.J.; ZIEGLER, J.B. Chemistry and Technology of Biodegradable Polymers. G. GRIFFIN, J.L. (editor). \n\nLondon: Chapman and Hall. p.48. 1994. \n\n \n\nKEEN, I.; BROOTA, O.; RINTOUL, L.; FREDERICKS, P.; TRAU, M.; GRONDAHL, L. Introducinh amine \n\nfunctionalities on a poly(3-hydroxybutirate-co-3-hydroxivalerate) surface: compring the use og ammonia plasma \n\ntreatment and ethylenediamine aminolysis. Biomacromolecules, v.7, p.427,  2006. \n\n \n\nKOSE, G.T.; BER, S.; KORKUSUZ, F.; HASIRCI, V. Poly(3-hydroxybutyric acid-co-3-hydroxyvaleric acid)  based \n\ntissue engineering matrices. J Mater Sci Mater Med, v.14 p.121-126, 2003. \n\n \n\nLANGER, R.; VACANTI, J.P. Artificial organs. Sci Am. v.273, n.3, p.130-133, 1995.  \n\n \n\nLEONG, K.F. et al. Solid freeform fabrication of tree-dimensional scaffolds for engineering replacement tissue and \n\norgans. Biomaterials, v.24, p.2363-2378, 2003. \n\n \n\nLUCCHESI. C.; FERREIRA, B.M.; DUEK, E.A.; SANTOS JR, A.R.; JOAZEIRO, P.P. Increased response of Vero \n\ncells to PHBV matrices treated by plasma. J Mater Sci Mater Med, v.19, n.2, p.3725-3730, 2008. \n\n \n\nMA, Z.; GAO, C.; GONG, Y. &amp; SHEN, J. Chondrocyte behaviors on poly-L-lactic acid (PLLA) membranes \n\ncontaining hydroxyl, amide or carboxyl groups. Biomaterials, v.24, n.21, p.3725-3730, 2003. \n\n \n\nMALM, T.; BOWALD, S.; KARACAGIL, A.; BYLOCK, S. A.; BUSCH, C. A new biodegradable patch for closure \n\nof atrial septal defect. An experimental study. Scand. J. Thoracic Cardiovasc. Surg., v.1, p. 9\u201314, 1992. \n\n \n\n\n\n61 \n\n \n\nMARQUES, A. P.; CRUZ, H.R.; COUTINHO, O.P.; REIS, R.L. Effect of starch-based biomaterials on the in vitro \n\nproliferation and viability of osteoblast-like cells. J Mater Sci Mate. Med, v.16, p.  833-842, 2005. \n\n \n\nMOSMANN, T. A rapid colorimetric assay of cellular growth and survival: Aplication to proliferation and \n\ncytotoxicity assays.  J. Immunol. Methods, v.65, p.55-63, 1983. \n\n \n\nNEBE, B. et al. Structural alterations os adhesion mediating components in cells cultured on poly-?-hydroxy butyric \n\nacid. Biomaterials. 22 (2001) 2425-2434. \n\n \n\nOLIVEIRA, M., MAIA, I.A., NORITOMI, P.Y., NARGI, G.C., SILVA, J.V.L., FERREIRA, B.M.P., DUEK, E.R. \n\nConstru\u00e7\u00e3o de Scaffolds para engenharia tecidual utilizando prototipagem r\u00e1pida Revista Mat\u00e9ria, v.12, n.2, p.373 \u2013 \n\n382, 2007. \n\n \n\nPRAEMER, A.; FURNER, S.; RICE, S. P. Musculoskeletal conditions in the United States. IL, USA: American \n\nAcademy of Orthopaedic Surgeons. (1992). \n\n \n\nPETER, S.J., MILLER, M.J., YASKI, A.W. et al., Polymer concepts in tissue engineering. Journal of Biomedical \n\nMaterials Research, v. 43, pp. 422-427, 1998. \n\n \n\n \n\nPOUTON, C.W.; AKHTAR, S. Biosynthetic polyhydroxyalknoates and their potencial in drug delivery. Adv Drug \n\nDel Rev,  v.18, p.133-162,  1996. \n\n \n\nREDDY, C.S., GHAI, R., RASHIMI et al., Polyhydroxyalkanoates: an overview. Bioresource Technology, v. 87, pp. \n\n137-146, 2003. \n\n \n\nSANTOS Jr., A. R.; BARBANTI, S.H.; DUEK, E.A.R.; DOLDER, M.A.H.;  WADA, R.S.; WADA, M.L. Vero cell \n\ngrowth and differentiation on poly(L-lactic acid) membranes of different pore diameters.  Artif. Organs, v.25, p.7, \n\n2001. \n\n \n\nSANTOS JR, A.R.; FERREIRA, B.M.P.; DUEK, E.A.R.; DOLDER M.A.H.; WADA, M.L.F. Use of blends of \n\nbioabsorbable poly(L-lactic acid)/poly(hydroxybutyrate-co-hydroxyvalerate) as surface for Vero cells culture. Braz J \n\nMed Biol Res, v.38, p.1623-32, 2005. \n\n \n\nSARUWATARI , L.;  AITA,  H.;  BUTZ, F.; NAKAMURA, H.K.; OUYANG, J.; YANG, Y.; CHIOU, W.A.; \n\nOGAWA, T. Osteoblasts generate harder, stiffer, and more delamination-resistant mineralized tissue on titanium \n\nthan on polystyrene, associated with distinct tissue micro- and ultrastructure. J Bone Miner Res., v.20, n.11, p.2002-\n\n2016, 2005.  \n\n \n\nSHAMSURIA, O.; FADILAH, A.S.; ASIAH, A.B.; RODIAH, M.R.; SUZINA, A.H.; SAMSUDIN, A.R. In vitro \n\ncytotoxicity evaluation of biomaterials on human osteoblast cells CRL-1543; hydroxyapatite, natural coral and \n\npolyhydroxybutarate. Med J Malaysi, v. 59, suppl B. p.174-175, 2004. \n\n \n\nSHISHATSKAYA, E.I.; VOLOVA, T.G. A comparative investigation of biodegradable polyhydroxyalkanoates \n\nfilms as matrices for in vitro cell culture. J Mater Sci Mater Med, v.15, p. 915-923, 2004. \n\n \n\nSHISHATSKAYA, E.I.; VOLOVA, T.G.; PUZYR, A.P.; MOGYLNAYA, O.A.; EFREMOV, S.N. Tissue response \n\nto the implantation of biodegradable polyhydroxyalkanoate suture. J Mater Sci Mater Med, v.15, p. 719-728, 2004. \n\n \n\nSHIVE, M.S.; ANDERSON, J.M. Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv Drug \n\nDeliv Rev, v.28, p.5-24, 1997. \n\n \n\nSUWANTONG, O.; WALEETORNCHEEPSAWAT, S.; SANCHAVANAKIT, N.; PAVASANT, P.; \n\nCHEEPSUNTHORN, P.; BUNAPRASERT, T.; SUPAPHOL, P. In vitro biocompatibility of electrospun poly(3-\n\n\n\n62 \n\n \n\nhydroxybutyrate) and poly(3-hydroxybutyrate-co-3-hydroxyvalerate) fiber mats. Int J Biol Macromol, v.40 p. 217\u2013\n\n223, 2007.   \n\n \n\nTEZCANER, A.; BUGRA, K.; HASIRCI, V. Retinal pigment epithelium cell culture on surface modified poly \n\n(hydroxybutyrate \u2013 co \u2013 hydroxyvalerate) thin films. Biomaterials, 24, p.4573-4583, 2003. \n\n \n\nTULLBERG-REINERT, H. &amp; JUNDT, G. In situ measurement of collagen synthesis by human bone cells with a \n\nSirius Red-based colorimetric microassay: effects of transforming growth factor b2 and ascorbic acid 2-phosphate. \n\nHistochem Cell Biol, v.112, p.271\u2013276, 1999. \n\n \n\nVOLOVA, T.; SHISHATSKAYA, E.; SABASTIANOV, V.; EFREMOV, S.; MOGILNAYA, O. Results of \n\nbiomedical investigations of PHB and PHB/PHV fibers. Biochemical Eng J v.16, p.125, 2003. \n\n \n\nWAN Y, YANG J, YANG J, BEI J, WANG S. Cell adhesion on gaseous plasma modified poly-(L-lactide) surface \n\nunder shear stress field. Biomaterials., v.24, n.21, p.3757-64, 2003. \n\n \n\nWANG, W.; YANG, F.; WU, O.; CHENG, Y. Effect of composition of poly(3-hydroxybutyrate-co-3-\n\nhydroxyhexanoate) on growth of fibroblast and osteoblast.  Biomaterials, v.26, p. 755\u2013761, 2005. \n\n \n\nYAMAGUCHI, M. et al. M. Surface modification of poly(L-lactic acid) affects initial cell attachment, cell \n\nmorphology, and cell growth. J Artif Organs, v.7, p.187-193, 2004. \n\n \n\nZHIJIANG, C. Biocompatibility and biodegradation of novel PHB porous substrates with controlled multi-pore size \n\nby emulsion templates method. J. Mater. Sci.: Mater. Med., v.17, p.1297-1303, 2006. \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n\n\n63 \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nCAP\u00cdTULO 4 \n\n \n\n\n\n64 \n\n \n\n \n\nOSTEOBLAST CELLS ON 3D PHB OBTAINED BY RAPID PROTYPING: IN \n\nVIVO STUDY \n\nCarolina Lucchesi\n1,2\n\n, C\u00edntia Cristina Santos\n1\n, Betina M P Ferreira\n\n1\n, Marcelo F Oliveira\n\n3\n, Izaque A Maia\n\n3\n, \n\nJorge VL da Silva\n3\n,Eliana A R Duek\n\n1\n, Paulo P Joazeiro\n\n2*\n. \n\n1. Laboratory of Biomaterials, Center of Biomedical and Biological Sciences, Pontifical \n\nCatholic University of Sao Paulo, PUC/SP, SP, Brazil. \n\n2. Department of Histology and Embryology, Institute of Biology, State University of \n\nCampinas (UNICAMP), Campinas, SP, Brazil. \n\n3. Center of Research Renato Archer, CenPRA, Campinas, SP, Brazil. \n\n*pjoaz@unicamp.br  \n\n \n\n \n\nABSTRACT   \n\nControlling the differentiation of bone mesenchymal cells and providing tissue functions in \n\nengineered constructs before implantation are major challenges. Poly(hydroxybutyrate) (PHB) has good \n\nproperties as biodegradability, biocompatibility, optical activity, piezoelectricity, non-toxicity and also it \n\nhas been studied for a variety of medical applications. Here we evaluate the tissue interaction of 3D PHB \n\nscaffolds implant in rabbit calvaria. The scaffolds were obtained by rapid prototyping and some of the \n\nscaffolds were treated by nitrogen plasma. The PHB scaffolds had osteoblast cells culture prior implant in \n\nrabbit calvaria model at 7, 15, 30, 60 and 90days. Histological evaluation were used to investigated the \n\nresponse of the tissue to the three-dimensional environment provided by polymer and cells. The PHB \n\nporous scaffolds had higher amount of new bone area compared to scaffolds without cell culture and \n\ndefect control area, suggesting that scaffold material and design combinations could be tailored to \n\nfacilitate filling of bony defects.  \n\nKey-words: Poly(hydroxybutyrate) (PHB); Bone; Calvaria; In vivo; Rapid Prototyping. \n\n \n\nINTRODUCTION  \n\nThe reconstruction of calvarial and maxillofacial bone defects caused by trauma, diseases, or \n\ncongenital anomalies needs reliable reconstruction tools. The repair of three dimensional structurally \n\ncomplicated bone defects poses a challenge to implant design and manufacturing. The combination of \n\ncomputer tomography and rapid prototyping technology has offered solutions to this challenge (Chiarini et \n\nal, 2004; Choi &amp; Cheung, 2005; Tuusa et al, 2008). \n\nThe development and modification of orthopedic implants has taken place for many years in an \n\neffort to create an optimal interaction between the body and the implanted material. The goal of achieving \n\nan optimal bone-implant interface has been approached by the alteration of implant surface topography, \n\nmailto:pjoaz@unicamp.br\n\n\n65 \n\n \n\nchemistry, energy and charge as well as bulk material composition. Schmidt et al. (2001) defines an ideal \n\nbone implant material as having a biocompatible chemical composition to avoid adverse tissue reaction, \n\nexcellent corrosion resistance in the physiologic milieu, acceptable strength, a high resistance to wear and \n\na modulus of elasticity similar to that of bone to minimise bone resorption around the implant (Pearce et \n\nal, 2007).  \n\nIn order to determine whether a new material conforms to the requirements of biocompatibility \n\nand mechanical stability prior to clinical use, it must undergo rigorous testing under both initial in vitro \n\nand then in vivo conditions. However, in vitro characterization is not able to demonstrate the tissue \n\nresponse to materials, instead being confined to the response of individual cell lines or primary cells taken \n\nfrom animals. No in vitro cell culture system is able to produce loading that simulates the in vivo situation \n\nand currently very few ex vivo systems are able to approach such physiological loading (and usually only \n\nwith small tissue samples (Davies et al., 2006). For these reasons animal models are essential for \n\nevaluating biocompatibility, tissue response and mechanical function of an orthopaedic  material prior to \n\nclinical use in the human (Pearce et al, 2007).  \n\nPoly(hydroxybutyrate) (PHB) is known as a very rigid, highly crystalline, and hence slow \n\ndegrading, but thermoplastic polymer (Gogolewski et al, 1993). It is thought to be useful for bone tissue-\n\nengineering approaches due to the negligible acidification of surrounding tissue during degradation \n\ncompared to other polyesters (Chen &amp; Wang, 2002).  Porous scaffolds of PHB and co-polymers have \n\nmainly been revealed with good biocompatibility and they have been used for many medical applications \n\n(Zheng et al, 2003). \n\n Another crucial characteristic is the geometry of a scaffold, such as the pore size, porosity, and  \n\npore interconnectivity, which can affect the diffusion of the nutrients, cell attachment, migration, and \n\ntissue ingrowths that are necessary for the bone formation process (Kim et al, 2008a). Others studies aim \n\nto evaluate the effect of implant surface modification on alteration of the bone-implant interaction (Kim et \n\nal, 2008b). In order to draw accurate conclusions regarding the effects of implant modification, we implant \n\n3D PHB scaffolds treated by N2 plasma with osteoblast cells as a purpose to filling out bone defects. \n\n    \n\n \n\nMETHODS \n\nScaffolds Preparation  \n\nThree-dimensional PHB (Biocycle\n\u00ae\n, PHB Industrial S/A, Brazil) scaffolds were designed using a \n\n3-D solid modeling software, exported to a Sinterstation 2000TM machine (3D Systems, Valencia, CA), \n\nand constructed by Selective Laser Sintering processing (SLS). This PHB has a particle size distribution at \n\nthe 10-100 ?m range. The scaffolds were produced with 6mm of diameter, 2mm of thickness and 200-500 \n\n\u00b5m porous size. The samples were storage under vacuum until plasma treatment. \n\nPlasma treatment \n\nThe plasma treatment was performed using a radio frequency Anatech LTD Ashing plasma \n\napparatus. The plasma conditions employed in the treatment was PHB untreated; PHB treated by N2, 50 \n\nW, 150mTorr and 600s; PHB treated by O2, 100 W, 300mTorr and 600 s The values of power, pressure, \n\nand time were chosen based on preliminary studies with PHBV (Lucchesi et al, 2008).  \n\n\n\n66 \n\n \n\nScanning Electron Microscopy (SEM) \n\n \n\nThe blends were sterilized by UV irradiation for 30 min and placed in 96-well plates. \n\nApproximately 2x10\n5\n cells/mL in DMEM medium supplemented with 10% FBS were seeded in each well \n\ncontaining the PHB scaffolds and cultured at 37\no\n C. After 24 hours, the samples were fixed in a fixative \n\nsolution prepared by dissolving 2.5% paraformaldehyde, 2.5% glutaraldehyde, 0.03% picric acid, 1% \n\ntannic acid in 0.1M cacodylate buffer and the same volume of DMEN medium for 1h at room temperature \n\n(RT), washed in 0.1M cacodylate buffer, post-fixed in 1% osmium tetroxide in water for 1h at RT in the \n\ndark, washed in water, dehydrated with ethanol, critical point dried (Balzers CDT 030, Balzers Inc., Elgin, \n\nIL, USA) and coated with gold in a sputter coater (Balzers CDT 050, Balzers Inc., Elgin, IL, USA). The \n\ncoated specimens were observed with a JEOL 5800 scanning electron microscope. \n\n \n\nCell isolation, culture and seeding \n\n \n\nOsteoblastic cells were obtained from 10 calvaria of young male adult (15 days old, 230\u2013280 g) \n\nNew Zealand rabbits, from university?s central animal house (PUC/SP-CCMB, Centro de Ci\u00eancias \n\nM\u00e9dicas e Biol\u00f3gicas, Sorocaba, SP, Brazil). Following euthanasia by cervical displacement, the calvaria \n\nwere aseptically excised, cleaned with a soft tissue, and washed in Dulbecco?s modified eagle?s medium \n\n(DMEM) (Nutricell - Nutrientes Celulares, Campinas, SP, Brazil) containing 150 ?g/ml gentamicin \n\nsulfate (Sigma Chemical, St. Louis, MO) and 15\u00b5g/ml Amphotericin B (Sigma). This concentration of \n\nantibiotic was 3 times the normal amount used in cell culture and was used to prevent contamination \n\nduring harvest. In sterile atmosphere, the calvaria were fragmented and submitted to enzymatic digestion \n\nfor cellular isolation in DMEM medium and 1mg/mL of collagenase type II (GIBCO, Invitrogen \n\nCorporation, Carlsbad, CA) during 2 hours at 37\u00b0C. After this procedure, it was submitted to a three-stage \n\ncentrifugation for 10 minutes at 240 g force, and subsequently resuspended in DMEM medium containing \n\n10% of fetal bovine serum (FBS) and antibiotic. After centrifugation, the pellet was resuspended in \n\nDMEM medium and cellular viability was quantified by staining with Tripan Blue vital stain (Sigma) in a \n\nNeubauer camera. Osteoblasts were seeded at a density of approximately 10\n5\n cells/ml in culture flasks \n\n(TPP-Techno Plastic Products, Trasadigen, Switzerland) containing DMEM medium, supplemented with \n\n10% FBS and 50 ?g/mL gentamicin, 10 mM ?-glycerol phosphate (Sigma), and 50 \u00b5g/mL L-ascorbic acid \n\n(Sigma) containing 100 nM dexamethasone (Sigma) to promote cells with osteoblastic phenotype, which \n\nwere used in experiments at the third subculture. The flasks were incubated in a humidified incubator at \n\n37\u00b0C (5% CO2/balanced air). When cells reached 80% of confluence, cell cultures were considered to \n\nhave reached full growth and the cells were enzymatically lifted from the flask by using a 625 mg/mL \n\ntrypsin/EDTA (Nutricell) solution and monitored daily with an inverted microscope, Eclipse TS 100 \n\n(Nikon, Tokyo, Japan). At the third subcultive 2x10\n5\ncells/ml were seemed in the PHB scaffold treated and \n\nuntreated by plasma and it was kept for 24 hours at the same conditions for the implant procedures. \n\nAnimal model  \n\n \n\nThe animal model used in this study was New Zealand rabbit (3 months age) with 2.5-3.0 Kg. The \n\nanimals were obtained from University?s Central Animal House at Pontif\u00edcia Universidade Cat\u00f3lica de \n\n\n\n67 \n\n \n\nS\u00e3o Paulo, in Centro de Ci\u00eancias M\u00e9dicas e Biol\u00f3gicas de Sorocaba (PUC-SP/CCMB). The animals were \n\nkept in cages separately and received commercial food and water \u201cad libitum\u201d. Rabbits are the most \n\ncommonly used animals for medical research, being used in approximately 35% of musculoskeletal \n\nresearch studies (Neyt et al., 1998). International standards established regarding the species suitable for \n\ntesting implantation of materials in bone, state that dogs, sheep, goats, pigs or rabbits are suitable. \n\nAlthough rabbit have a different microstructure from humans histologically (Wang et al., 1998), there are \n\nethical implications of using companion animals for medical research. Rabbits are commonly used for \n\nscreening implant materials prior to testing in a larger animal model (Pearce et al, 2007).  \n\n  The experimental protocol used in this work is in agreement with both the standards of The \n\nAmerican Society for Testing and Materials (ASTM F-981-93) and the Ethical Principles for Animal \n\nExperimentation adopted by the Brazilian Animal Experimentation Board (COBEA). It was also approved \n\nby the Research in Ethics Commission  from Vale do Para\u00edba University according to Ethics and \n\nPrinciples from  National and International Guidelines of research involving animals under protocol \n\nnumber A38/CEP/2008.  \n\n \n\nSurgical procedure \n\n \n\nThe rabbits were acclimated for 1 week before operation and monitored for general appearance, \n\nactivity, excretion, and weight. Fifteen rabbits were used and were randomly shared in 5 groups, \n\nequivalent at the different times of implant of the scaffold (7, 15, 30, 60 and 90 days), and 3 rabbits were \n\nused for each time. They were implanted PHB scaffolds with different treatments in the same animal: \n\nPHB with cells, PHB without cells and PHB with cells and treated by Nitrogen plasma. Cylindrical \n\nimplants are not recommended to be larger than 2mm in diameter and 6mm in length for rabbits \n\n(International Standard ISO 10993-6, 1994; Pearce 2007). \n\n The animals were anesthetized with ketamine (50 mg/kg IM) and xylasine (5 mg/kg IM). After \n\nshaved and disinfecting the operative site, the periosteum was resected, and 4 defects site with 6 mm \n\ndiameter each were provoked carefully by dental bar cooled (Beltec) with sterile saline solution. The \n\ncraniotomy segment was removed and the damage to the underlying dura and superior sagittal sinus vein \n\nwere avoided. The defect was rinsed with sterile saline thoroughly and bone fragments were washed out. \n\nThree defects were filling out with the scaffolds and one of them was kept without scaffold as a \n\ndefect control. The design of the scaffolds implants follow above: Group 1 \u2013 Defect control, it was not \n\nfilling out (G1); Group 2 \u2013 Defect filling out by PHB without cells (G2); Group 3 \u2013 Defect filling out by \n\nPHB with cells (G3). Group 4 - Defect filling out by PHB treated by nitrogen plasma with cells (G4). \n\n(Fig.1).  \n\nThe calvaria segments were removed carefully without disturbing the underlying dura-mater. The \n\nanimals were harvested under pre-anesthesia by administration of Ketamine (50 mg/kg IM) and Xylazine \n\n(5 mg/kg IM), and euthanized with Sodium Pentobarbital (200mg/Kg IP). After that, the soft tissues were \n\nremoved, and the skull was resected. The samples were kept in 4% formaldeide solution for histological \n\nprocedures. \n\n \n\n \n\n \n\n\n\n68 \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nFigure 1: Design of the surgery at the rabbits. 1 - Control defect site; 2 - PHB implanted without cells; 3 - \n\nPHB implanted with cells; 4 - PHB treated by nitrogen plasma with cells. \n\n \n\nHistology \n\nThe calvaria segments for histological examination were fixed in 4% buffered formalin (pH 7.4). \n\nThe samples were decalcified in 10% EDTA solution and then they were dehydrated in a graded series of \n\nethanol, and half of the samples were embedded in resin methylmethacrylate (Kit #14702231731, \n\nHistoresin, Leica) and another half in paraffin (Histoseck, Merck). After polymerization, 3 ?m and 5 ?m \n\nsections respectively, they were cut from the center of the implants using a microtome RM2245 (Leica \n\nReichert Jung, Nu\u00dfloch, Germany). Light microscopic sections were stained with Toluidine Blue and \n\nHematoxilin-Eosin, respectively. The samples were observed and evaluated by optical light microscope \n\n(Nikon, Eclipse E800, Tokyo, Japan). \n\n  \n\n \n\nRESULTS \n\n \n\nGross Analyses \n\n \n\nAll 15 rabbits tolerated the anesthesia and the surgical procedures well and experienced no \n\ncomplications during the experimental period. Upon sacrifice, gross examination of the dissected \n\nspecimens of the calvaria showed no difference between the PHB groups and the control group defects in \n\nterms of signs of inflammation and integrity of the healing wound. \n\n \n\nUltrastructural analyses  \n\n \n\nThrough the scanning electron microscopy it was possible visualize the ustrastructural \n\nmorphology of PHB scaffolds (Figure 2) and with cells attached after 24h (Figure 3).  We can observe \n\nhttp://www.leica-microsystems.com/Configurator/LMSSHOP.nsf/PC?openagent&amp;product=Leica%20CONSUMABLES&amp;sheet=HBUCONS&amp;config=%202&amp;optionset=o14\n\n\n69 \n\n \n\nclusters of cells attached in the PHB treated and untreated by plasma after 24 hours of culture in \n\nosteogenic medium. The cells adhered to the scaffolds and interact themselves showing cells agglomerate \n\n(Figure 3A-B). We could note some products on cells and scaffolds surface.  \n\n \n\nHistological Analyses \n\n \n\nThe healing of the defects in the control group was mainly by scar formation. There were a few \n\nbony islands scattered along the defect margins, which might have resulted from bone debris produced by \n\ndrilling through bone. The healing of the PHB group produced a tissue regenerate with many blood \n\nvessels and cellular marrow spaces.  \n\nAt 7 days post-surgery all the PHB samples with and without cells showed fibrin network, \n\nmesenchymal cells, blood vessels (Figure 4), edema, cell proliferation with no significant inflammatory \n\nreaction, and at PHB N2 some cells showed osteoblast?s phenotype (Figure 4D). The defect control was \n\nnoted large hemorrhage area, bone fragments, and some bone formation close to the edge of the defect \n\n(Figure 4E). \n\n At 15 days post-surgery it was observed at all the samples with PHB, fibrous connective tissue, \n\nfibroblasts, blood vessels, and mesenchymal cells (Figure 5). At the defect control, it was observed fibrous \n\nconnective tissue without bone formation (Figure 5A). At the PHB treated by N2, it was noted osteoblasts \n\ncells secreting bone matrix, collagen fibers and a slight inflammatory process (Figure 5D).  \n\n At 30 days post-surgery, it was observed fibrous connective tissue around all of the samples with \n\nPHB as fibroblasts, blood vessels and mesenchymal cells. It was presented osteoblasts around of the \n\npolymer and of the edges of the defect. Large amount of new bone formation almost cover the defect \n\n(Figure 6). The PHB without cells, it was showed osteoids and osteoblasts around of the polymer (Figure \n\n6C). PHB treated by N2, there was new bone tissue growing up from the edges of the defect toward to the \n\npolymer with the fibrous connective tissue, osteoids and osteoblasts (Figure 6D). The control defect area \n\nthere was growth bone tissue near of the edges, and a thick layer of fibrous connective tissue, with no \n\nsignificant new bone formation (Figure 6A). \n\n After 60 days post-surgery, the connective tissue around all of the PHB samples was slight. Blood \n\nvessels and mesenchymal cells condensed were presented with bone tissue growing up from the edges and \n\nabsent inflammatory process. The mainly difference between the samples were that PHB with cells \n\nshowed more of osteoids and osteoblast around the polymer than the other samples with new bone \n\nformation (Figure 7). The defect control area has shown bone tissue growing up from the edges, some \n\nosteoids and larger amount of connective tissue than PHB samples (Figure 7A-D).  \n\nThe 90 days PHB samples with cells tended to have more mature, trabecular bone whereas the \n\nPHB without cells samples had more bone tissue and less trabeculated chunks of bone. Although, statistics \n\nanalyses were not made it to quantified. It was observed connective tissue, blood vessels, mesenchymal \n\ncells aggregated, osteoblasts-like and growth of bone tissue from the edges of the defect in all of the \n\npolymers. PHB treated by N2 and PHB with cells, we could observe osteocytes in the bone matrix and \n\nosteoblasts between bone fragments. The bone matrix showed some organizations and large amount of \n\nosteoblasts were observed (Figure 8B and 8C). The defect control was almost filling out by immature \n\nbone tissue (Figure 8A). \n\n \n\n\n\n70 \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nFigure 2: Scanning electron microscopy of PHB scaffolds without cell culture. A) PHB without \n\ntreatment; B) PHB treated by nitrogen plasma. \n\nA \n\nB \n\n\n\n71 \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nFigure 3: Scanning electron microscopy of PHB scaffolds. A) PHB without treatment; B) PHB treated by \n\nnitrogen plasma. \n\nA \n\nB \n\n\n\n72 \n\n \n\n \n\n \n\n \n \n\n \n\nFigure 4: Sections after 7 days of implant. All the PHB samples (P) showed mesenchymal cells (C), blood \n\nvessels (arrow), fibrin network (F) and edema. A) Control defect showing with hemorrhage area (H); B) \n\nPHB without cells; C) PHB with cells; D) PHB N2 with cells. Bar = 50\u00b5m. \n\n\n\n73 \n\n \n\n \n \n\n \n\nFigure 5: Sections after 15 days of implant. The PHB samples with cells culture prior implant showed \n\ncells (C) in differentiation process around the polymer (P), blood vessels (arrow). A) Control defect \n\nshowing with hemorrhage area (H) and edema; B) PHB without cells showed more cells of inflammatory \n\nprocess than the samples with cells culture prior implant; C) PHB with cells; D) PHB N2 with cells. Bar = \n\n50\u00b5m. \n\n\n\n74 \n\n \n\n \n \n\nFigure 6: Sections after 30 days of implant. All of the samples with PHB (P) showed fibroblasts, blood \n\nvessels (arrow), fibrous tissue and cells (C). A) Control defect; B) PHB without cells showed a larger \n\namount of connective tissue (T) than the other PHB samples; C) PHB with cells; D) PHB N2 with cells. \n\nBar = 50\u00b5m. \n\n\n\n75 \n\n \n\n \n \n\nFigure 7: Sections after 60 days of implant. The connective tissue around all of the PHB samples was \n\nslight. Blood vessels (arrow) and mesenchymal cells condensed (C) were presented with some osteoids \n\n(O), mainly in the samples with cell cultures prior implant. A) Control defect; B) PHB without cells; C) \n\nPHB with cells; D) PHB N2 with cells. Bar = 50\u00b5m. \n\n\n\n76 \n\n \n\n \n\n \n\nFigure 8: Sections after 90 days of implant. A) Control defect with bone repair from the edges (E); B) \n\nPHB without cells; C) PHB with cells; D) PHB N2 with cells. Note the samples with cell culture prior \n\nimplant there were more osteoids (O) than PHB without cells or the defect control area. All the samples \n\n(P) showed blood vessels (arrow), mesenchymal cells, osteoblast cells and connective tissue. Bar = 50\u00b5m. \n\n\n\n77 \n\n \n\n \n\n \n\nDISCUSSION \n\nBone defects are a significant clinical problem. These defects can be caused by inflammation, \n\ntrauma, congenital malformation, diseases or oncological surgery (Mai et al, 2006). The available \n\nliterature data suggest that both nonresorbable and resorbable polymers can be used for the preparation of \n\nthe scaffolds for the treatment of bone defects (Hoffman et al, 2009; Jiya et al, 2009). \n\nThe bioresorbable polymers should satisfied several biological requirements as the polymer do not \n\ninduce foreign body reaction, was not be carcinogenic, mutagenesis or teratogenesis, did not cause \n\nallergies, hipersensibility ou toxicicity, even stimulate the complement system, it is a relevant importance \n\n(Orefice et al, 2006). However, is has been described in literature that ever material introduce in the body \n\nit will have some kind of reaction, in a large or smaller proportion. At this point all of the PHB samples \n\nused in this research were appropriated according to biological and technical requirements, which are in \n\nagreement with Gogolewski et al., 2004. The scanning electron microscopy (SEM) analyses showed that \n\neven with 24 hours the cells were capable to produce some extracellular matrix protein, because it was \n\npossible to observe some molecule on the cells and scaffolds surfaces. \n\nAfter implantation at the rabbit calvarial defects, all the scaffold groups were observed to be \n\ncompatible with the soft and hard tissues, without showing any significant adverse reactions. No \n\ninflammatory cells were found in any of the specimens. Compared to the control group, wherein new bone \n\nformation most of the time it was limited only to the defect margin (Figure 6A), all of the scaffold groups \n\nshowed a large amount of new bone formation, with the ingrowth of bony tissues into the pore channels \n\n(Figure 5 and 6). The same process was noted in our samples and defect control.  \n\nShort time post-implantation, there was some edema, which it has been related as a normal \n\nphysiological process of bone repair (K\u00f6se et al., 2004). In the implants or control defect, it was noted \n\nhemorrhage, as blood vessels, matrix destruction and probably death of bone cells around. During the \n\nhealing, it is normal that the clot, wastes cells, and matrix are removed by macrophages, and the \n\nperiosteum and endosteum near of the implant site response with an intense cell proliferation (Davies, \n\n2000). \n\nAfter one or two months the PHB samples shown more osteoids and new bone formation than the \n\ndefect control, mainly the samples with cells (Figure 4 and 5). It was observed lots of agglomerated cells \n\n(Figure 5B-D). These are a common phenomenon described of cell condensations by large number of \n\nauthors (Fell, 1925; Hall &amp; Miyake 1992; Olsen et al, 2000; Shapiro 2008) that should happen before cell \n\ndifferentiation. It was unclear in this research those agglomerated cells are cells from the body and those \n\ncells migrated for the local lesion or if those cells were in the scaffold. We believe that both hypotheses \n\ncould happen because even the PHB without cells it was observed some cells condensation, in a smaller \n\nproportion though. \n\nFor long term post-implantation, we believed that the retard in the bone growth, in the group with \n\nPHB compared to the defect control should be due to the slow degradation of the polymer, which acts as a \n\nphysical barrier avoiding the bone growth. On the other hand, for human being could be really useful if we \n\nconsider the fact that human bone take at least 4 months to regenerate (Davies, 2005). And we should \n\nconsider that apparently the same amount of bone was observed at the control defect. One of the major \n\nproblems encountered by surgeons who deal with large bone defects is the difficulty of maintaining \n\n\n\n78 \n\n \n\nviability within bone-grafted tissue in order to ensure graft survival and eventual restoration of the defect \n\n(Jan et al, 2006). In this study, the PHB had being shown suitable as a long term implant, and besides, the \n\nfirst step is designated a good material that it will be able to be use as bone in the future. \n\nIt is known bone tissue has a great regenerative potential with the capacity to restore its structure \n\nand originals functions. There are situations when the bone defect is not to be able to regenerate by itself. \n\nIn that case, could be necessary a bone graft to suitable treatment and good prognostic (Nair et al, 2007).  \n\nA critical-sized defect is by definition the smallest full thickness osseous wound that will not heal \n\nspontaneously during the lifetime of an animal (Schmitz JP &amp; Hollinger, 1986; Jan et al, 2006; Prado et \n\nal, 2006). According to Hollinger 1990, it was found experimentally that the CSD size for rabbits is 15 \n\nmm or more. Although there are some authors using different sizes as a defect control. Kim et al. (2008b) \n\ninvestigate the in vivo performance of the engineered bioceramic scaffolds using a 10mm rabbit calvarial \n\ndefect model. Hokugo et al. (2007) investigated the enhancement of biological function of platelet growth \n\nfactors after integration of PRP into biomaterials, using a 5mm defect as a control in rabbit calvaria.  \n\n The rabbit calvarial defect model is analogous in many ways to clinical maxillofacial \n\nreconstruction. There is an osseous defect with a periosteal blood supply and there is a membranous \n\npattern of bone repair and healing. One difference, however, is the presence of a pulsatile dural layer in \n\nthe base of the rabbit calvarial model, which is not present in extracranial maxillofacial wounds (Ahmed et \n\nal, 2006). However, at the present study the animal model was suitable for our purpose. \n\n A great number of biomaterials have been tested in the last decades for bone tissue engineering, \n\nbut few have been demonstrated good results. Among the polymers, the PHB have been used as medical \n\ndevice and it has been shown good results in vivo and in vitro (Shishatskaya et al, 2004; Shishatskaya &amp; \n\nVolova, 2004). A large amount of requirements are needed for a suitable material, and some of those are \n\ntheirs architecture, and surface properties.  With the aim to improve these property of the materials for \n\ntissue engineering, scaffolds has been developing and the rapid prototyping appear as a great tool. \n\nTherefore, exploiting a scaffold with high porosity and interconnectivity in conjunction with high \n\nmechanical strength has been one of the important issues in the production of artificial bone grafts (Kim et \n\nal, 2008b). \n\nIn this study, we used a specially designed three-dimensional PHB as scaffold to the osteoblast for \n\nfilling out bone defects and improve bone augmentation. Bone is a complex and structured three-\n\ndimensional tissue.  PHB scaffold developed with macrochanneled pores (200-500\u00b5m) shows ongoing \n\nincreases in the cell proliferation. Although there are few in vivo studies reporting the effect of porosity \n\nusing the PHB scaffolds, some limited number of works has been carried out using other types of \n\nmaterials. Roy et al. (2003) reported improved tissue ingrowth and new bone formation on the composite \n\nscaffolds (PLGA/tricalcium phosphate) by increasing the porosity, demonstrating that channel size, \n\nporosity, and pore size can be controlled and used to influence new bone formation and calvarial defect \n\nhealing.  Hu et al 2009, suggested that the NF scaffolds resembling a native collagen fibrillar matrix, with \n\nappropriate pore sizes, and a high-porosity, effectively support osteogenesis of hMSCs showing \n\nmineralized bone formation. Tian et al, 2009 investigate in vivo biocompatibility and osteogenesis as well \n\nas degradability of the porous strontium-doped calcium polyphosphate (SCPP) scaffolds enhanced \n\nosteogenesis and degradability. According to Karageorgiou &amp; Kaplan (2005), the porosity and pore size of \n\nbiomaterial scaffolds play a critical role in bone formation. In vivo, higher porosity and pore size result in \n\ngreater bone ingrowth. \n\n\n\n79 \n\n \n\nTo regenerate new bone tissues, the appropriate biological properties are required for cell \n\nscaffolds including good cell attachment/proliferation, differentiation function, and support of bone \n\nformation in three dimensions prior to vast degradation of the scaffold (Tanaka et al, 2008). Concerning \n\nthe degradation, as seen in Figure 5B-D, the scaffolds implanted between calvaria bone and periosteum \n\nhad maintained their three-dimensional structures at least 2 months. Importantly, new bone was found in \n\nthe PHB scaffold. \n\n According to our results all PHB scaffolds did not showed severe inflammatory response and \n\nallowed bone regeneration compare to defect control. PHB obtained by rapid prototyping, treatment by \n\nplasma and seeded cells onto scaffolds prior implant have been shown good techniques to obtain \n\nbiocompatible, 3D scaffolds which it will improve bone regeneration, being promises to Tissue \n\nEngineering.  \n\n \n\n \n\nCONCLUSION  \n\n \n\nWe conclude that the PHB scaffold with osteogenic cells could be useful as graft on flat bone \n\ntissue for the purpose of bone thickness augmentation improving regeneration. \n\n \n\nACKNOWLEDGEMENTS  \n\n \n\nThe authors thank FAPESP (proc. 06/07147-3), Centro de Tecnologia da Informa\u00e7\u00e3o Renato \n\nArcher (CTI), Laborat\u00f3rio Nacional de Luz Sincrotron (LNLS). \n\n \n\nREFERENCES  \n\n \n\nASTM F-981-93, (2004) Standard Practice for Assessment of Compatibility of Biomaterials for Surgical Implants \n\nwith Respect to Effect of Materials on Muscle and Bone. Annual Book of American Society for Testing and Materials \n\nStandards. \n\nCHEN, L.J.; WANG, M. Production and evaluation of biodegradable composites based on PHB-PHV copolymer. \n\nBiomaterials, v.23, p.2631, 2002. \n\n \n\nCHIARINI, L.; FIGURELLI, S.; POLLASTRI, G.; TORCIA, E.; FERRARI, F.; ALBANESE, M.; NOCINI, P.F. \n\nCranioplasty using acrylic material: A new technical procedure. J Craniomaxillofac Surg, v.32, p.5\u20139, 2004. \n\n \n\nCHOI, S.H.; CHEUNG, H.H. A multi-material virtual prototyping system. Comput Aided Des, v.37, p.123\u2013136, \n\n2005. \n\n \n\nDAVIES, J.E. Bone Engineering. Hong Kong: Rainnbow graphic and Printing, 2000. \n\n  \n\nDAVIES, C.M.; JONES, D.B.; STODDART, M.J.; KOLLER, K.; SMITH, E.; ARCHER, C.W.; RICHARDS, R.G. \n\nMechanically loaded ex vivo bone culture system \u201eZetos?: systems and culture preparation. Eur Cell Mater, v.11, \n\np.57-75, 2006. \n\n \n\nFELL, H.B. The histogenesis of cartilage and bone in the long bones of the embryonic fowl. J Morph Physiol, v.40, \n\nn.3, p.417-459, 1925. \n\n \n\n\n\n80 \n\n \n\nGOGOLEWSKI, S.; JOVANOVIC, M.; PERREN, S.M.; DILLON, J.G.; HUGHES, M.K. Tissue response and in \n\nvivo degradation of selected polyhydroxyacids: polylactides (PLA), poly(3-hydroxybutyrate) (PHB), and poly(3-\n\nhydroxybutyrate-co-3-hydroxyvalerate) (PHB/VA). J. Biomed. Mater. Res. v.27, p.1135, 1993. \n\n \n\nGOGOLEWSKI, S. Bioresorbable Polymers in Repair, Replacement and Regeneration of Tissues and Organs. \n\nEuropean Cells and Materials, v.7, S.1, p.32, 2004. \n\n  \n\nHALL, B.K.; MIYAKE, T. The membranous skeleton: the role of cell condensations in vertebrate skeletogenesis. \n\nAnat Embryol, v.186, p.107-124, 1992. \n\n \n\nHOFMANN, M.P.; MOHAMMED, A.R.; PERRIE, Y.; GBURECK, U.; BARRALET, J.E. High-strength resorbable \n\nbrushite bone cement with controlled drug-releasing capabilities. Acta Biomater. v.5. n.1, p.43-9, 2009. \n\n \n\nHOKUGO, A.; SAWADA, Y.; HOKUGO, R.; IWAMURA, H.; KOBUCHI, M.; KAMBARA, T.; MORITA, S.; \n\nTABATA, Y.. Controlled release of platelet growth factors enhances bone regeneration at rabbit calvaria. Oral Surg \n\nOral Med Oral Pathol Oral Radiol Endod, v.104, n.1, p.44-8, 2007. \n\n \n\nHOLLINGER, J.O.; KLEINSCHMIDT, J.C. The critical size defect as an experimental model to test bone repair \n\nmaterials. J Craniofac Surg, v.1, p.60\u201368, 1990. \n\n \n\nHU, J.; FENG, K.; LIU, X.; MA, P.X. Chondrogenic and osteogenic differentiations of human bone marrow-derived \n\nmesenchymal stem cells on a nanofibrous scaffold with designed pore network. Biomaterials, v.30, n.28, p.5061-\n\n5067, 2009. \n\n \n\nInternational Standard ISO 10993-6 (1994) Biological evaluation of medical devices - Part 6. 1-11. Jee, WS, Bartley, \n\nMJ, Cooper, R, Dockum. \n\n \n\nJAN, A.M.A.; S\u00c1NDOR, J.K.B.; IERA, D.; MHAWI, A.; PEEL, S.; EVANS, A.W.; CLOKIE, C.M.L. Hyperbaric \n\noxygen results in an increase in rabbit calvarial critical sized defects. Oral Surg Oral Med Oral Pathol Oral Radiol \n\nEndod, v.101, p.144-149, 2006. \n\n \n\nJIYA, T.; SMIT, T.; DEDDENS, J.; MULLENDER, M. Posterior lumbar interbody fusion using nonresorbable poly-\n\nether-ether-ketone versus resorbable poly-L-lactide-co-D,L-lactide fusion devices: a prospective, randomized study \n\nto assess fusion and clinical outcome. Spine (Phila Pa 1976), v.34, n.3, p.233-7, 2009.  \n\n \n\nKARAGEORGIOU, V.; KAPLAN, D. Porosity of 3D biomaterial scaffolds and osteogenesis. Biomaterials, v.26, \n\nn.27, p.5474-91, 2005. \n\n \n\naKIM, S.S.; GWAK, S.J.; KIM, B.S. Orthotopic bone formation by implantation of apatite-coated poly(lactide-co-\n\nglycolide)/hydroxyapatite composite particulates and bone morphogenetic protein-2. J Biomed Mater Res A, v.87, \n\nn.1, p.245-53, 2008. \n\n \n\nbKIM, H.W.; SHIN, S.Y.; KIM, H.E.; LEE, Y.M.; CHUNG, C.P.; LEE, H.H.; RHYU, I.C. Bone formation on the \n\napatite-coated zirconia porous scaffolds within a rabbit calvarial defect. J Biomater Appl., v.22, n.6, p.485-504, 2008.  \n\n \n\nK\u00d6SE, G.T.; KORKUSUZ, F.; KORKUSUZ, P.; HASIRCI, V. In vivo tissue engineering of bone using poly(3-\n\nhydroxybutyric acid-co-3-hydroxyvaleric acid) and collagen scaffolds. Tissue Eng., v.10, n.7-8, p.1234-50, 2004. \n\n \n\nLUCCHESI. C.; FERREIRA, B.M.; DUEK, E.A.; SANTOS JR, A.R.; JOAZEIRO, P.P. Increased response of Vero \n\ncells to PHBV matrices treated by plasma. J Mater Sci Mater Med, v.19, n.2, p.635-43, 2008.  \n\n \n\nMAI, R.; HAGEDORN, M.G.; GELINSKY, M.; WERNER, C.; TURHANI, D.; SP\u00c4TH, H.; GEDRANGE, T.; \n\nLAUER. G. Ectopic bone formation in nude rats using human osteoblasts seeded poly(3)hydroxybutyrate \n\nhttp://www.sciencedirect.com/science?_ob=ArticleURL&amp;_udi=B6WP1-4J4WCGF-B&amp;_user=10&amp;_coverDate=02%2F28%2F2006&amp;_rdoc=10&amp;_fmt=high&amp;_orig=browse&amp;_srch=doc-info(%23toc%236977%232006%23998989997%23615799%23FLA%23display%23Volume)&amp;_cdi=6977&amp;_sort=d&amp;_docanchor=&amp;_ct=33&amp;_acct=C000050221&amp;_version=1&amp;_urlVersion=0&amp;_userid=10&amp;md5=03c4c890119f2e7bf2edff27cfb67043\nhttp://www.sciencedirect.com/science?_ob=ArticleURL&amp;_udi=B6WP1-4J4WCGF-B&amp;_user=10&amp;_coverDate=02%2F28%2F2006&amp;_rdoc=10&amp;_fmt=high&amp;_orig=browse&amp;_srch=doc-info(%23toc%236977%232006%23998989997%23615799%23FLA%23display%23Volume)&amp;_cdi=6977&amp;_sort=d&amp;_docanchor=&amp;_ct=33&amp;_acct=C000050221&amp;_version=1&amp;_urlVersion=0&amp;_userid=10&amp;md5=03c4c890119f2e7bf2edff27cfb67043\n\n\n81 \n\n \n\nembroidery and hydroxyapatite-collagen tapes constructs. Journal of Cranio-Maxillofacial Surgery, v.34, S2, p.101\u2013\n\n109, 2006. \n\n \n\nNAIR, M.; NAIR, U.; SEYEDAIN, A.; GASSNER, R.; PIESCO, N.; MOONEY, M.; GANTA, S.; AGARWAL, S. \n\nCorrelation of tuned aperture computed tomography with conventional computed tomography for evaluation of \n\nosseous healing in calvarial defects. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and \n\nEndodontology. v.103, n.2, p.267-273, 2007. \n\n \n\nNEYT, J.G.; BUCKWALTER, J.A.; CARROLL, N.C. Use of animal models in musculoskeletal research. Iowa \n\nOrthop J, v.18, p.118-123, 1998.  \n\n \n\nOLSEN, B.R.; REGINATO, A.M.; WANG, W. Bone development. Annu Rev Cell Dev Biol, v.16, p.191-220, 2000. \n\n \n\nOR\u00c9FICE R.L.; PEREIRA, M.M.; MANSUR, H.S. Biomateriais: fundamentos e aplica\u00e7\u00f5es. Rio de Janeiro: Cultura \n\nM\u00e9dica, 2006. \n\n \n\nPEARCE, A.I.; RICHARDS, R.G.; MILZ, S.; SCHNEIDER, E.; PEARCE. S.G. Animal models for implant \n\nbiomaterial research in bone: a review. Eur Cell Mater, v.2, n.13, p.1-10, 2007. \n\n \n\nPRADO, A.F.; ANBINDER, A.L.; JAIME A.P.G.; LIMA A.P.; BALDUCCI I.; ROCHA R.F. Defeitos \u00f3sseos em \n\nt\u00edbias de ratos: padroniza\u00e7\u00e3o do modelo experimental. Revista de Odontologia da Universidade Cidade de S\u00e3o \n\nPaulo, v.18, n.1, p.7-13, 2006. \n\n \n\nROY, T.D.; SIMON, J.L.; RICCI, J.L.; REKOW, E.D.; THOMPSON, V.P.; PARSONS, J.R. Performance of \n\ndegradable composite bone repair products made via three-dimensional fabrication techniques. J Biomed Mater Res \n\nA, v.66, n.2, p.283-91, 2003. \n\n \n\nSCHMIDT, C.; IGNATIUS, A.A.; CLAES, L.E. Proliferation and differentiation parameters of human osteoblasts \n\non titanium and steel surfaces. J Biomed Mater Res, v.54, p.209-215, 2001. \n\n \n\nSHAPIRO, F. Bone development and its relation to fracture repair. The role of mesenchymal osteoblasts and surface \n\nosteoblasts. European Cells and Materials, v.15, p.53-76, 2008.  \n\n \n\nSHISHATSKAYA, E.I.; VOLOVA, T.G. A comparative investigation of biodegradable polyhydroxyalkanoates \n\nfilms as matrices for in vitro cell culture. J Mater Sci Mater Med, v.15, p. 915-923, 2004. \n\n \n\nSHISHATSKAYA, E.I.; VOLOVA, T.G.; PUZYR, A.P.; MOGYLNAYA, O.A.; EFREMOV, S.N. Tissue response \n\nto the implantation of biodegradable polyhydroxyalkanoate suture. J Mater Sci Mater Med, v.15, p. 719-728, 2004. \n\n \n\nTANAKA, T.; HIROSE, M.; KOTOBUKI, N.; TADOKORO, M.; OHGUSHI, H.; FUKUCHI, H.; SATO, J.; SETO, \n\nK. Bone augmentation by bone marrow mesenchymal stem cells culture in three-dimension biodegradable polymer \n\nscaffolds. J Biom Res A, 2008. Epub ahead. \n\n \n\nTIAN, M.; CHEN, F.; SONG, W.; SONG, Y.; CHEN, Y.; WAN, C.; YU, X.; ZHANG. X. In vivo study of porous \n\nstrontium-doped calcium polyphosphate scaffolds for bone substitute applications. J Mater Sci Mater Med, v.20, n.7, \n\np.1505-1512, 2009. \n\n \n\nTUUSA, S.M.; PELTOLA, M.J.; TIRRI, T.; PUSKA, M.A.; R\u00d6YTT\u00c4, M.; AHO, H.; SANDHOLM, J.; LASSILA, \n\nL.V.; VALLITTU, P.K. Reconstruction of critical size calvarial bone defects in rabbits with glass-fiber-reinforced \n\ncomposite with bioactive glass granule coating. J Biomed Mater Res B Appl Biomater, v.84, n.2, p.510-519, 2008. \n\n \n\nWANG, X.; MABREY, J.D.; AGRAWAL, C.M. An interspecies comparison of bone fracture properties. Biomed \n\nMater Eng, v.8, p.1-9, 1998. \n\n \n\n\n\n82 \n\n \n\nWANG, J.S.; DIAZ, J.; SABOKBAR, A.; ATHANASOU, N.; KJELLSON, F.; TANNER, K.E.; MCCARTHY, I.D.; \n\nLIDGREN, L. In vitro and in vivo biological responses to a novel radiopacifying agent for bone cement. J R Soc \n\nInterface, v.22, n.2, p.71-78, 2005. \n\n \n\nZHENG, Z.; DENG, Y.; LIN, X.S.; ZHANG, L.X.; CHEN, G.Q. Induced production of rabbit articular cartilage-\n\nderived chondrocyte collagen II on polyhydroxyalkanoate blends. J. Biomater. Sci.-Polym. Ed., v.14, p.615, 2003. \n\n\n\n83 \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nCAP\u00cdTULO 5 \n\n\n\n84 \n\n \n\n \n\nCONCLUS\u00d5ES \n\n \nAs blendas de PCL/PLGA paresentaram caracter\u00edsticas desej\u00e1veis como dispositivos para \n\naplica\u00e7\u00f5es em Engenharia de Tecido \u00d3sseo, como ades\u00e3o, prolifera\u00e7\u00e3o celular e aus\u00eancia de efeitos \n\ncitot\u00f3xicos. \n\nOs arcabou\u00e7os de PHB apresentaram boa viabilidade celular, n\u00e3o apresentam qualquer efeito \n\ncitot\u00f3xico nos arcabou\u00e7os independentes do tratamento por plasma. As modifica\u00e7\u00f5es f\u00edsico-qu\u00edmicas nos \n\narcabou\u00e7os por plasma de nitrog\u00eanio melhoraram a ades\u00e3o celular. Os arcabou\u00e7os permitiram a s\u00edntese de \n\ncol\u00e1geno tipo I, sendo esta uma importante caracter\u00edstica de c\u00e9lulas osteobl\u00e1sticas. O processo de \n\nobten\u00e7\u00e3o dos arcabou\u00e7os de PHB por prototipagem r\u00e1pida apresentou-se uma \u00f3tima t\u00e9cnica para o \n\ndesenvolvimento de dispositivos tri-dimensionais aplicado a Engenhria de Tecidos.  \n\nA intera\u00e7\u00e3o c\u00e9lula/PHB/tecido mostrou-se promissora como suporte para o prop\u00f3sito de acelerar o \n\nreparo \u00f3sseo. Os arcabou\u00e7os de PHB com c\u00e9lulas previamente cultivadas apresentaram maior forma\u00e7\u00e3o \n\n\u00f3ssea, sugerindo que a combina\u00e7\u00e3o do arcabou\u00e7o e pr\u00e9-cultivo celular facilitam a regenera\u00e7\u00e3o \u00f3ssea, \n\npodendo ser utilizados para o preenchimento de defeitos \u00f3sseos. \n\nOs pol\u00edmeros PCL, PLGA e PHB apresentaram boa intera\u00e7\u00e3o com c\u00e9lulas osteobl\u00e1sticas \n\npossibilitando a continuidade de seus estudos com aplica\u00e7\u00e3o \u00e0 Engenharia de Tecidos \u00d3sseos. \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n\n\n85 \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nCAP\u00cdTULO 6 \n\n \n\n\n\n86 \n\n \n\nREFER\u00caNCIAS BIBLIOGR\u00c1FICAS \n\n \nACKERMAN, L.V.; SPJUT, H.J.; ABELL, M.R. Bones and Joints. Baltimore: Williams and Wilkins. 1976. \n \nALBERTS, B.; JOHNSON, A.; LEWIS, J.; et al. 5\n\nth \ned. Molecular Biology of the Cell. New York: Garland \n\nScience, 2005. \n \nAL-MUNAJJED, A.A.; PLUNKETT, N.A.; GLEESON, J.P.; WEBER, T.; JUNGREUTHMAYER, C.; \nLEVINGSTONE, T.; HAMMER. J.; O'BRIEN, F.J. Development of a biomimetic collagen-hydroxyapatite \nscaffold for bone tissue engineering using a SBF immersion technique. J Biomed Mater Res B Appl \nBiomater, v.90, n.2, p.584-591, 2009. \n \nALBREKTSSON, T.; JOHANSSON, C. Osteoinduction, osteoconductionmand osseointegration. Eur Spine \nJ, v.10, S.96\u2013S101, 2001. \n \nALBREKTSSON, T.; BR\u00c5NEMARK, P.I.; HANSSON, H.A.; LINDSTR\u00d6M, J. Osseointegrated titanium \nimplants. Requirements for ensuring a long-lasting, direct bone anchorage in man. Acta Orthop Scand, \nv.52, p.155\u2013170, 1981. \n \nANSELME K. Osteoblast adhesion on biomaterials. Biomaterials, v.21, p.667\u2013681, 2000. \n \nATSAWASUWAN, P.; MOCHIDA, Y.; PARISUTHIMAN, D.; YAMAUCHI, M. Expression of lysyl oxidase \nisoforms in MC3T3-E1 osteoblastic cells. Biochemical and Biophysical Research Communications, v.327, \np.1042\u20131046, 2005. \n \nBARBANI, N.; GIUSTI, P.; LAZZERI, L.; POLACCO, G.; PIZZIRANI, G. Bioartificial materials based on \ncollagen: Collagen cross-linking with gaseous glutaraldehyde. J. Biomater. Sci. Polym. Ed., v.7, p.461\u2013\n469, 1995. \n \nBARBANTI, S.H.; SANTOS JR.; A.R., ZAVAGLIA, C.A.C.; DUEK, E.A.R. Porous and dense poly(L-lactic \nacid) and poly(D,L-lactic acid-co-glycolic acid) scaffolds: in vitro degradation in culture medium and \nosteoblasts culture. Journal of Materials Science: Materials in Medicine, v.15, p.1315-1321, 2004. \n \nBENIASH, E.; TRAUB, W.; VEIS, A.; WEINER, S. A transmission electron microscope study using vitrified \nice sections of predentin: structural changes in the dentin collagenous matrix prior to mineralization. J. \nStruct. Biol v.132, n.3, p.212\u2013225, 2000. \n \nBESSA, P.C.; CASAL, M.; REIS, R.L. Bone proteins in tissue engineering: the road from laboratory to \nclinic, part II. J Tissue Eng Regen Med, v.2, p.81-96, 2008. \n \nBORNSTEIN, P. Diversity of function is inherent in matricellular proteins: an appraisal of thrombospondin \n1. J. Cell Biol., v.130, p.503-506, 1995. \n \nBOSKEY, A.L. Matrix Proteins and Mineralization: An Overview. Connective Tissue Res, v.35, n.1 -4, \np.357-363, 1996. \n \nBRADLEY, W.G.; WILKES, G.L. Some mechanical property considerations of reconstituted collagen for \ndrug release supports. Biomater. Med. Dev. Artif. Organs, v.5, p.159\u2013175, 1977. \n \nBRADSHAW, A.D.; SAGE, E.H. SPARC, a matricellular protein that functions in cellular differentiation and \ntissue response to injury. J Clin Invest, v.107, p.1049-1054, 2001. \n \n\n\n\n87 \n\n \n\nBR\u00c5NEMARK, P.I.; HANSSON, B.O.; ADELL, R.; BREINE, U.; LINDSTR\u00d6M, J.; HALL\u00c9N, O.; \u00d6HMAN, \nA. Osseointegrated titanium implants in the treatment of the edentulous jaw. Scand J Plast Reconstr Surg, \nv.11, S.16, p:1\u2013175, 1977. \n \nBREKKEN, R.A.; SAGE, E.H. SPARC, a matricellular protein: at the crossroads of cell-matrix \ncommunication. Matrix Biol, v.19, p.:816\u2013827, 2001. \n \nRUDER, S.P.; CAPLAN, A.I. Bone regeneration through cellular engineering. LANZA, R.; LANGER, R.; \nVACANTI, J.  Principles in Tissue Engineering. San Diego: Academic Press, 2000, p.683-696. \n \nBUCKWALTER, J.A.; GLIMCHER, M.J.; COOPER, R.R.; RECKER, R. Bone biology. II: Formation, form, \nmodeling, remodeling, and regulation of cell function. Instr Course Lect, v.45, p.387\u201399, 1996. \n \nBUCKWALTER, J.A.; GLIMCHER, M.J.; COOPER, R.R.; RECKER, R. Bone biology. I: Structure, blood \nsupply, cells, matrix, and mineralization. Instr Course Lect., v.45, p.371\u201386, 1996. \n \nCHAN, C.-M. Polymer surface modification and characterisation. Hanser: Munich, 1993. \n \nCHU, P.K. et al  Plasma-surface modification of biomaterials.  Mater Sci Eng Ver, v.36, p.143-206, 2002. \n \nCHVAPIL, M.; SPEER, D.P.; HOLUBEC, H.; CHVAPIL, T.A.; KING, D.H. Collagen fibers as a temporary \nscaffold for \nreplacement of ACL in goats. J. Biomed. Mater. Res., v.27, n.3, p.313\u2013325, 1993. \n \nCLARKE, K.I.; GRAVES, S.E.; WONG, A.T.C.; TRIFFITT, J.T.; FRANCIS, M.J.O.; CZERNUSZKA, J.T. \nInvestigation into the Formation and Mechanical-Properties of a Bioactive Material Based on Collagen and \nCalcium-Phosphate. J Mater Sci Mater Med, v.4, p.107-110, 1993. \n \nCRETU, A.; GATTIN, R.; BRACHAIS, L.; BARBIER-BAUDRY, D. Synthesis and degradation of poly (2-\nhydroxyethyl methacrylate)-graft-poly (-caprolactone) copolymers. Polymer Degration and Stability. v.83, \nn.3, p.309-404, 2004.  \n \nDALBY, M.J. et al.  Increasing fibroblast response to materials  using nanotopograhy: morphological and \ngenetic measurements of cell response to 13 nm high polymer demixed island. Experimental Cell \nResearch, v.276, p.1-9, 2002.  \n \nDAMIEN, C.; PARSONS, R. Bone graft and bone graft substitutes: a review of current technology and \napplications. J. Appl. Biomat. v.2, p.187\u2013208, 1991. \n \nDAS, S. et al Freeform fabrication of Nylon-6 tissue engineering scaffolds. Rapid Prototyping J, v.9, n.1, p. \n43\u201349, 2003. \n \nDATTA, H.K.; NG, N.F.; WALKER, J.A.; TUCK, S.P.; VARANASI, S.S. The cell biology of bone \nmetabolism. J. Clin. Pathol. v.61, p.577-587, 2008. \n \nDENG, Z.-L.; SHARFF, K.A.;  TANG, N.; et al. Regulation of osteogenic differentiation during skeletal \ndevelopment. Frontiers in Bioscience, v.13, p.2001-2021, 2008. \n \nDESHPANDE, A.S.; BENIASH, E. Bio-inspired Synthesis of Mineralized Collagen Fibrils. Cryst Growth \nDes. v.8, n.8, p.3084-3090, 2008. \n \nDOUGALL, W.C.; CHAISSON, M. The RANK/RANKL/OPG triad in cancer-induced bone diseases. \nCancer Metastasis Rev v.25, p.541-549, 2006. \n \n\n\n\n88 \n\n \n\nDUCY, P.; SCHINKE, T.; KARSENTY, G. The osteoblast: a sophisticated fibroblast under central \nsurveillance. Science, v.289, p.1501\u20134, 2000.  \n \nDUEK, E.A.R.; ZAVAGLIA, C.A.C.; BELANGERO, W.D. In vitro study of poly(lactic acid) pin degradation. \nPolymer, v.40, p.6465-6473, 1999. \n \nEDE, D.A.;. AGERBAK, G.S. Cell adhesion and movement in relation to the developing limb pattern in \nnormal and talpid3 mutant chick embryos. J. Embryol. exp. Morph. v.20,n.1, p.81-100, 1968. \n \nEL-TAMER, M.K.; REIS, R.L. Progenitor and stem cells for bone and cartilage regeneration. J Tissue Eng \nRegen Med., v.3, n.5, p.327-37, 2009. \n \nERLEBACHER, A.; FILVAROFF, E.H.; GITELMAN, S.E.; DERYNCK, R. Toward a molecular \nunderstanding of skeletal development. Cell, v.80, p.371\u2013378, 1995. \n \nFELL, H.B. The histogenesis of cartilage and bone in the long bones of the embryonic fowl. J Morph \nPhysiol, v.40, n.3, p.417-459, 1925. \n \nFERREIRA, B.M.P.; ZAVAGLIA, C.A.C.; DUEK, E.A.R. Films of Poly(L-lactic acid)/Poly(hydroxybutyrate-\nco-hydroxyvalerate) Blends: In Vitro Degradation. Materials Research, v.4, n.1, p.34-42, 2001. \n \nFERREIRA, B.M.P. et al. Films of PLLA/PHBV blends: Thermal, Morphological and Mechanical \nCharacterization. J Applied Polym Sci, v.86, p. 2898-2906, 2002. \n \nFONSECA, M.J.; ALSINA, M.A.; REIG, F. Coating liposomes with collagen (Mr 50000) increases uptake \ninto liver. Biochim. Biophys. Acta, v.1279, n.2, p.259\u2013265, 1996. \n \nFUNK, S.E.; SAGE, E.H. The Ca2(+)-binding glycoprotein SPARC modulates cell cycle progression in \nbovine aortic endothelial cells. Proc Natl Acad Sci USA, v.88, p.2648-2652, 1991. \n \nGENGE, B.R.; WU, N.N.Y.; WUTHIER, R.E. Mineralization of Annexin-5-containing Lipid-Calcium-\nPhosphate Complexes. The Journal Biological Chemistry, v.283, n.15, p.9737\u20139748, 2008. \n \nGIUSTI, P.; LAZZERI, L.; DE PETRIS, S.; PALLA, M.; CASCONE, M.G. Collagen-based new bioartificial \npolymeric materials. Biomaterials, v.15, n.15, p.1229-1233, 1994.  \n \nGOISSIS, G.; MARGINADOR, S.V.S.; MARTINS, V.C.A. Biomimetic mineralization of charged collagen \nmatrices: in vitro and in vivo study. Artif Organs, v.27, p.437-443, 2003. \n \nG\u00d6PFERICH, A. Mechanisms of polymer degradation and erosion. Biomaterials, v.17, p.103-114, 1996. \n \nGOULD, S.E.; UPHOLT, W.B.; KOSHER, R.A. Syndecan 3: a member of the syndecan family of \nmembrane-intercalated proteoglycans that is expressed in high amounts at the onset of chicken limb \ncartilage differentiation. Proc. Natl, Acad. Sci. USA, v.89, p.3271-3275, 1992. \n \nHALL, B.K.; MIYAKE, T. The membranous skeleton: the role of cell condensations in vertebrate \nskeletogenesis. Anat Embryol, v.186, p.107-124, 1992. \n \nHALL, B.K.; MIYAKE, T. Divide, accumulate, differentiate: cell condensation skeletal development \nrevisited. Int. J. Dev. Biol., v.39, p.881-893, 1995. \n \nHALL, B.K.; MIYAKE, T. All for one and one for all: condensations and the initiation of skeletal \ndevelopment. Bio Essays ,v.22, p.138\u2013147, 2000. \n \n\nhttp://www.ncbi.nlm.nih.gov/pubmed/19418440?itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum&amp;ordinalpos=4\n\n\n89 \n\n \n\nHARADA, S.; RODAN, G.A. Control of osteoblast function and regulation of bone mass. Nature, v.423, \np.349-355, 2003. \n \nHASIRCI, V. et al. Macroporous poly(3-hydroxybutyrate-co-3-hydroxyvalerate) matrices for bone tissue \nengineering. J Appl Polym Sci, v.87, 1949-1958, 2003. \n \nHEATH, D.; CRISTHIAN, P.; GRIFFIN, M. Involvement of tissue transglutinase in the stabilisation of \nbiomaterials/tissue interfaces. Biomaterial, v.23, p.1519-1526, 2002. \n \nHENCH, L.L. Biomaterials: a forecast for the future.  Biomaterials, v.19, p.1419-1423, 1998. \n \nHODGE, A.J.; PETRUSKA, J.A. Electron Microscopy, Fifth International Congress for Electron \nMicroscopy, Philadelphia, 1962, ed. BREESE JR, S.S. v.1. New York: Academic Press, 1962. vol. 1. \n \nHOFSTETTER, W.; WETTERWALD, A.; CECCHINI, M.G.; MUELLER, C.; FELIX, R. Detection of \ntranscripts and binding sites for colony-stimulating factor-1 during bone development. Bone, v.17, p.145\u2013\n151, 1995. \n \nHOHENESTER, E.; MAURER, P.; TIMPL, R. Crystal structure of a pair of follistatin-like and EF-hand \ncalcium-binding domains in BM-40. EMBO J, v.16, p.3778-3786, 1997. \n \nHOLLAND, P.W.; HARPER, S.J.; MCVEY, J.H.; HOGAN, B.L. In vivo expression of mRNA for the Ca\n\n++\n-\n\nbinding protein SPARC (osteonectin) revealed by in situ hybridization. J Cell Biol, v.105, p.473\u2013 482, \n1987.  \n \nHOKUGO, A.; SAWADA, Y.; HOKUGO, R.; IWAMURA, H.; KOBUCHI, M.; KAMBARA, T.; MORITA, S.; \nTABATA, Y. Controlled release of platelet growth factors enhances bone regeneration at rabbit calvaria. \nOral Surg Oral Med Oral Pathol Oral Radiol Endod. v.104, n.1, p.44-8, 2007 \n \nHOLLINGER, J,O.; KLEINSCHMIDT, J.C. The critical size defect as an experimental model to test bone \nrepair materials. J Craniofac Surg, v.1, p.60\u201368, 1990. \n \nHORTON, W.A. Morphology of connective tissue: Cartilage. In Connective tissue and its heritable \ndisorders. New York: Wiley-Liss, 1993, p.73\u201384. \n \nHOWE, A.K.; APLIN, A.E.; JULIANO, R.L. Anchorage-dependent ERK signaling\u2013mechanisms and \nconsequences. Curr Opin Genet Dev, v.12, p.30\u201335, 2002. \n \nHUANG, L.F.; FUKAI, N.; SELBY, P.B.; OLSEN, B.R.; MUNDLOS, S. Mouse clavicular development: \nanalysis of wild-type and cleidocranial dysplasia mutant mice. Dev. Dyn,. v.210, p.33\u201340, 1997. \n \nISHAUG, S.L.; CRANE, G.M.; MILLER, M.J.; YASKO, A.W.; YASZEMSKI, M.J.; MIKOS, A.G. Bone \nformation by three-dimensional stromal osteoblast culture in biodegradable polymer scaffolds. J Biomed \nMater Res, v.36, p.17\u201328, 1997. \n \nJAN, A.M.A.; S\u00c1NDOR, J.K.B.; IERA, D.; MHAWI, A.; PEEL, S.; EVANS, A.W.; CLOKIE, C.M.L. \nHyperbaric oxygen results in an increase in rabbit calvarial critical sized defects. Oral Surg Oral Med Oral \nPathol Oral Radiol Endod, v.101, p.144-149, 2006. \n \nJUNQUEIRA, L.C.; CARNEIRO, J. 11\u00aaed. Histologia B\u00e1sica. Rio de janeiro: Ed Guanabara Koogan, Rio \nde Janeiro, 2004. \n \nKANCZLER, J.M.; OREFFO, R.O.C. Osteogenesis and angiogenesis: the potential for engineering bone. \nEuropean Cells and Materials, v.15, p.100-114, 2008. \n\nhttp://www.ncbi.nlm.nih.gov.ezp-prod1.hul.harvard.edu/pubmed?term=%22Hokugo%20A%22%5BAuthor%5D&amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstract\nhttp://www.ncbi.nlm.nih.gov.ezp-prod1.hul.harvard.edu/pubmed?term=%22Sawada%20Y%22%5BAuthor%5D&amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstract\nhttp://www.ncbi.nlm.nih.gov.ezp-prod1.hul.harvard.edu/pubmed?term=%22Hokugo%20R%22%5BAuthor%5D&amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstract\nhttp://www.ncbi.nlm.nih.gov.ezp-prod1.hul.harvard.edu/pubmed?term=%22Iwamura%20H%22%5BAuthor%5D&amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstract\nhttp://www.ncbi.nlm.nih.gov.ezp-prod1.hul.harvard.edu/pubmed?term=%22Kobuchi%20M%22%5BAuthor%5D&amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstract\nhttp://www.ncbi.nlm.nih.gov.ezp-prod1.hul.harvard.edu/pubmed?term=%22Kambara%20T%22%5BAuthor%5D&amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstract\nhttp://www.ncbi.nlm.nih.gov.ezp-prod1.hul.harvard.edu/pubmed?term=%22Morita%20S%22%5BAuthor%5D&amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstract\nhttp://www.ncbi.nlm.nih.gov.ezp-prod1.hul.harvard.edu/pubmed?term=%22Tabata%20Y%22%5BAuthor%5D&amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstract\njavascript:AL_get(this,%20'jour',%20'Oral%20Surg%20Oral%20Med%20Oral%20Pathol%20Oral%20Radiol%20Endod.');\nhttp://www.sciencedirect.com/science?_ob=ArticleURL&amp;_udi=B6WP1-4J4WCGF-B&amp;_user=10&amp;_coverDate=02%2F28%2F2006&amp;_rdoc=10&amp;_fmt=high&amp;_orig=browse&amp;_srch=doc-info(%23toc%236977%232006%23998989997%23615799%23FLA%23display%23Volume)&amp;_cdi=6977&amp;_sort=d&amp;_docanchor=&amp;_ct=33&amp;_acct=C000050221&amp;_version=1&amp;_urlVersion=0&amp;_userid=10&amp;md5=03c4c890119f2e7bf2edff27cfb67043\n\n\n90 \n\n \n\n \nKARSENTY, G. The genetic transformation of bone biology. Genes Dev. V.13, p.3037-3051, 1993. \n \nKAUFMANN, B.; MULLER, S.; HANISCH, F.G.; HARTMANN, U.; PAULSSON, M.; MAURER, P. et al. \nStructural variability of BM-40/SPARC/osteonectin glycosylation: implications for collagen affinity. \nGlycobiology v.14, p.609-619, 2004. \n \nKEEN, I. et al. Introducinh amine functionalities on a poly(3-hydroxybutirate-co-3-hydroxivalerate) surface: \ncompring the use of ammonia plasma treatment and ethylenediamine aminolysis. Biomacromolecules, \nv.7, p.427, 2006. \n \nKIKUCHI, M.; MATSUMOTO, H.N.; YAMADA, T.; KOYAMA, Y.; TAKAKUDA, K.; TANAKA, J. \nGlutaraldehyde crosslinked hydroxyapatite/collagen self-organized nanocomposites. Biomaterials, v.25, \np.63-69, 2004. \n \nKIM, B.S. et al.  Development of biocompatible synthetic extracellular matrcies for tissue engineering. \nTrends Biotechnol, v.16, p. 224-230, 2001. \n \nKIM, S.S.; PARK, M.S.; GWAK, S.J.; CHOI, C.Y.; KIM, B.S. Accelerated bonelike apatite growth on \nporous polymer/ceramic composite scaffolds in vitro. Tissue Eng, v.12, p.2997\u20133006, 2006. \n \nKNESER, U.; SCHAEFER, D.J.; POLYKANDRIOTIS, E.; HORCH, R.E. Tissue engineering of bone: the \nreconstructive surgeon's point of view. J. Cell. Mol. Med., v.10, n.1, p.7-19, 2006. \n \nKONG, L.; AO, Q.; WANG, A.; GONG, K.; WANG, X.; LU, G.; GONG, Y.; ZHAO, N.; ZHANG, X. \nPreparation and characterization of a multilayer biomimetic scaffold for bone tissue engineering. J \nBiomater Appl, v.22, p.223\u2013239, 2007. \n  \nK\u00d6SE, G.T. et al. Poly(3-hydroxibutiric acid-co-3-hydroxyvaleric acid) based tissue engineering matrices. \nJ Mater Sci Mater Med,  v.14, p. 121-6, 2003. \n \nLANDIS, J.L.; SILVER, F.H. The structure and function of normally mineralizing avian tendons. Comp \nBiochem Phys, v.133, p.1135\u20131157, 2002. \n \nLANE, T.F.; IRUELA-ARISPE, M.L.; SAGE, E.H. Regulation of gene expression by SPARC during \nangiogenesis in vitro. Changes in fibronectin, thrombospondin-1, and plasminogen activator inhibitor-1. J \nBiol Chem, v.267, p.16736-16745, 1992. \n \nLANE, T.F.; SAGE, E.H. The biology of SPARC, a protein that modulates cell-matrix interactions. FASEB \nJ, v.8, p.163\u2013173, 1994. \n \nLANGER, R.; VACANTI, J.P. Tissue engineering, Sci, v.260, p.920-926, 1993. \n \nLANGOWSKI, B.A.; UHRICH, K.E. Microscale plasma-initiated patterning (muPIP). Langmuir, v.21, \np.10509-14, 2005.  \n \nLANZA R.P. et al.  Principles of tissue engineering. 2.ed. San Diego: Academic Press, p.101-110, 2000. \n \nLAVERY, K.; HAWLEY. S.; SWAIN, P.; ROONEY, R.; FALB, D.; ALAOUI-ISMAILI, M.H. New insights into \nBMP-7 mediated osteoblastic differentiation of primary human mesenchymal stem cells. Bone, v.45, p.27\u2013\n41, 2009. \n \nLEE, C.H.; SINGLA, A.; LEE, Y. Biomedical applications of collagen. Int J Pharmac, v.221, p.1\u201322, 2001. \n \n\n\n\n91 \n\n \n\nLEFEBVRE, F.; PILET, P.; BONZON, N.; DACULSI, G.; RABAUD, M. New preparation and microstructure \nof the Endo-Patch elastin\u2013collagen containing glycosaminoglycans. Biomaterials, v.17, p.1813\u20131818, \n1996. \n \nLEONG, K.F. et al. Solid freeform fabrication of tree-dimensional scaffolds for engineering replacement \ntissue and organs. Biomaterials, v.24, p.2363-2378, 2003. \n \nLI, R.H.; WOZNEY, J.M. Delivering on the promise of bone morphogenetic proteins. Trends Biotechnol, \nv.19, p.255-265, 2001. \n \nLUCCHESI C, FERREIRA BMP, DUEK EAR, SANTOS J\u00daNIOR AR, JOAZEIRO PP. Increased response \nof Vero cells to PHBV matrices treated by plasma. J Mater Sci Mater Med, v.19, n.2, p.635-643, 2008. \n \nLUCCHESI, C.; BARBANTI, S.H.; JOAZEIRO, P.P.; DUEK, E.A.R. Cell culture on PCL/PLGA blends. J \nAppl Polym Sci, v.115, n.5, p. 2609-2615, 2009.  \n \nLUCIANO, R.; ZAVAGLIA, C.A.C.; DUEK, E. A. R, Synthesis And Caracterization of Porous Poly( Lactide \nAcid) Membranes: Study In Vitro And In Vivo. J Mater Science Mater Med, v.14, p. 1-8, 2002. \n \nLUDWIG, S.C.; KOWALSKI, J.M.; BODEN, S.D. Osteoinductive bone graft substitutes. Eur Spine J, v.9, \nS119-S125, 2000. \n \nMCPHERSON, J.M.; SAWAMURA, S.;  AMSTRONG, R. An examination of the biologic response to \ninjectable, glutaraldehyde cross-linked collagen implants. J. Biomed. Mater. Res., V.20, p.93\u2013107, 1986. \n \nMAEDA, M.; TANI, S.; SANO, A.; FUJIOKA, K. Microstructure and release characteristics of the \nminipellet, a collagen based drug delivery system for controlled release of protein drugs. J. Controlled. \nRel., v.62, p.313\u2013324, 1999. \n \nMARIE, P.A. Differenciation, fonction et controle de l\u2019osteoblaste. Med Sci (Paris), v.17, 1252-1259, 2001. \n \nMARIE, PA. Transcription factors controlling osteoblastogenesis. Archives of Biochemistry and \nBiophysics, v.473, p.98\u2013105, 2008. \n \nMARQUIS, M.E.; LORD, E.; BERGERON, E.; DREVELLE, O.; PARK, H.; CABANA, F.; SENTA, H.; \nFAUCHEUX, N. Bone cells-biomaterials interactions. Frontiers in Bioscience, v.14, p.1023-1067, 2009. \n \nMARRECO P.R.; da LUZ, M.P.; GENARI, S.C.; MORAES, A.M. Effects of different sterilizations methods \nof the morphology, mechanical properties, and cytotoxicity of chitosan membranes used has wound \ndressings. J Biomed Mater Res B Applied Biomaterial, v.15, p.868-77, 2004. \n \nMARTINEK, N.; ZOU, R.; BERG, M.; SODEK, J.; RINGUETTE, M. Evolutionary conservation and \nassociation of SPARC with the basal lamina in Drosophila. Dev Genes Evol, v.212, p.124-133, 2002. \n \nMARTINEK, N.; SHAHAB, J.; SODEK, J.; RINGUETTE, M. Is SPARC an Evolutionarily Conserved \nCollagen Chaperone? J Dent Res, v.86, n.4, p.296-305, 2007 \n \nMAURER, P.; HOHENESTER, E. Structural and functional aspects of calcium binding in extracellular \nmatrix proteins. Matrix Biol, v.15, p.569-580, 1997. \n \nMAURER, P.; SASAKI, T.; MANN, K.; GOHRING, W.; SCHWARZBAUER, J.E.; TIMPL, R. Structural and \nfunctional characterization of the extracellular calcium binding protein BM-40/secreted protein, acidic, rich \nin cysteine/osteonectin from the nematode Caenorhabditis elegans. Eur J Biochem, v.248, p.209-216, \n1997. \n\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Lord%20E%22%5BAuthor%5D&amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstract\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Bergeron%20E%22%5BAuthor%5D&amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstract\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Drevelle%20O%22%5BAuthor%5D&amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstract\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Park%20H%22%5BAuthor%5D&amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstract\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Cabana%20F%22%5BAuthor%5D&amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstract\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Senta%20H%22%5BAuthor%5D&amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstract\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Faucheux%20N%22%5BAuthor%5D&amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstract\n\n\n92 \n\n \n\n \nMESSIAS, A.D.; ARAGONES, A.; DUEK, E.A.R. PLGA-Hydroxyapatite Composite Scaffolds for \nOsteoblastic-Like Cells. Key Engineering Materials,  v.396-398, p.461-464, 2009. \n \nMIKOS, A.G.; SARAKINOS, G.; LEITE, S.M.; VACANTI, J.P. LANGER  Laminated three-dimensional \nbiodegradable foams for use in tissue engineering. Biomaterials, v.14, p.323-330, 1993. \n \nMURATA, M.; MAKI, F.; SATO, D.; SHIBATA, T.; ARISUE, M. Bone augmentation by onlay implant using \nrecombinant human BMP-2 and collagen on adult rat skull without periosteum. Clin. Oral Implants Res., \nv.11, n.4, p.289\u2013295, 2000. \n \nNAKAGAWA, T.; TAGAWA, T. Ultrastructural study of direct bone formation induced by BMPs-collagen \ncomplex \nimplanted into an ectopic site. Oral Dis., V.6, n.3, p.172\u2013179, 2000. \n \nNEREM RM. Tissue engineering in the USA. Med Biol Eng Comput., v.30, n.4, CE8-12, 1992. Review. \n \nNETTI, P.A.; AMBROSIO, L.; NICOLAIS, L. Biofunctional materials for tissue reconsruction. In: \nInternational Conference on Advances of Biomaterials for Reconstructive Medicine. Capri, IL17, p.60, \n2002. \n \nNIMNI, M.E.; HARKNESS, R.D. Molecular structures and functions of collagen. In: Nimni, M.E. (Ed.), \nCollagen-Biochemistry, v.I. Boca Raton: CRC Press, p.1\u201379, 1988. \n \nO\u2019BRIEN, F.J.; HARLEY, B.A.; YANNAS, I.V.; GIBSON, L. Influence of freezing rate on pore structure in \nfreeze-dried collagen-GAG scaffolds. Biomaterials, v.25, p.1077-1086, 2004. \n \nOLSEN, B.R.; REGINATO, A.M.; WANG, W. Bone development. Annu Rev Cell Dev Biol, v.16, p.191-\n220, 2000. \n \nPARK, T.G.; COHEN,S.; LANGER, R. Poly(L-lactic acid) Pluronic blends: characterization of phase \nseparation behavior, degradation, and morphology and use as protein-releasing matrices. \nMacromolecules, v.25, p.116-122, 1992. \n \nPATINO, M.G.; NEIDERS, M.E.; ANDREANA, S.; COHEN, R.E. Collagen: an overview. Implant Dent, \nv.11, n.3, p.280-285, 2002. \n \nPATRICK, J.C.W. et al. editors. Frontiers in tissue engineering. New York: Pergamon, 1998. \n \nPEREIRA L.F.R.; CAMARGO M.C.L.; DIAS C.J.JR, BALDUINO A, LORA S, LANGONE F,BOROJEVIC R, \nBLANCO M.AM. Bone marrow stromal cells and resorbable collagen guidance tubes enhance sciatic \nnerve regeneration in mice. Exp Neurol, v.198, p. 457-68, 2006. \n \nPETER, S.J.; MILLER, M.J.; YASKO, A.W.; YASZEMSKI, M.J.; MIKOS AG. Polymer concepts in tissue \nengineering.  J. Biom. Mater. Res., v.43, p.422-427, 1998.  \n \nPETITE, H.; RAULT, I.; HUC, A.; MENASCHE, P.H.; HERBAGE, D. Use of the acyl azide method for \ncrosslinking collagen rich tissues such as pericardium. J. Biomed. Mater. Res., v.24, p.179\u2013187, 1990. \n \nPETITE H, VIATEAU V, BENSA\u00cfD W, MEUNIER A, DE POLLAK C, BOURGUIGNON M, OUDINA K, \nSEDEL L, GUILLEMIN G. Tissue-engineered bone regeneration. Nat Biotechnol., v.18, n.9, p.959-63, \n2000. \n \n\n\n\n93 \n\n \n\nPRADO, A. F.; ANBINDER A.L.; JAIME A.P.G.; LIMA A.P.; BALDUCCI I.; ROCHA R.F. Defeitos \u00f3sseos \nem t\u00edbias de ratos: padroniza\u00e7\u00e3o do modelo experimental. Revista de Odontologia da Universidade \nCidade de S\u00e3o Paulo,  v.18, n.1, p.7-13, 2006. \n \nQIAN, Y.; YAO, G.; LIN, Z.; CHEN, J.; FAN, Y.; DAVEY, T.; XU, J.; ZHENG, M. Natural Bone Collagen \nScaffold Combined with OP-1 for Bone Formation Induction In Vivo. J Biomed Mater Res Part B: Appl \nBiomater, v.90B, p.778\u2013788, 2009. \n \nRALSTON, S. H.; AND, D.E.; CROMBRUGGHE, B. Genetic regulation of bone mass and susceptibility to \nosteoporosis. Genes Dev, v.20, p.2492-2506, 2006. \n \nREZENDE, C.A.; LUCCHESI, C.; PERIS-BARBO, M.L.; DUEK, E.A.R. Membranas de Poli(\u00e1cido l\u00e1tico-\nco-\u00e1cido glic\u00f3lico) como curativos para pele: degrada\u00e7\u00e3o in vitro e in vivo. Pol\u00edmeros, v.15, n.3, 323-238, \n2005. \n \nROBEY, G.P.; FINDLAY, D.M.; YOUNG, M.F.; BERESFORD, J.N.; STUBBS, J.N.; FISHER, L.W.; \nTERMINE, J.D.  J.Bone Min. Res. V.1, p.288, 1986. \n \nROBINSON, R.A. An electron-microscopic study of the crystalline inorganic component of bone and its \nrelationship to the organic matrix. J Bone Joint Surg Am. v.34, p.389-476, 1952. \n \nROMBERG, W. R.; WERNESS, P.G.; RIGGS, B. L.; MANN, K.G. Inhibition of hydroxyapatite crystal \ngrowth by bone specific and other calcium-binding proteins, Biochem., v.25, p.1176-1180, 1986. \n \nRUDERMAN, R.J.; WADE, C.W.R.; SHEPARD, W.D.; LEONARD, F. Prolonged resorption of collagen \nsponges: vaporphase treatment with formaldehyde. J. Biomed. Mater. Res., v.7, p.263\u2013265, 1973. \n \nSCAPIN, S.M.; SILVA, D.R.;JOAZEIRO, P.P.; ALBERTO-RINCON, M.C.; LUCIANO, R.M., DUEK, E.A.R., \nUse of trietilcitrate plasticizer in the production of poly(L-lactic acid) implants with different degradation \ntimes. J Mater Sci Mater Med, v.14, p.635-40, 2003. \n \nSCHMITZ, J.P.; HOLLINGER, J.O. The critical size defect as an experimental model for \ncraniomandibulofacial nonunions. Clin Orthop Res, v.205, p.299-308, 1986. \n \nSEAL, B.L.; OTERO, T.C.; PANITCH, A.  Polymeric biomaterials for tissue and organ regeneration.  \nMater. Sci. Eng. Res., v.34, p.147-230, 2001. \n \nSEFTON, M.V. Tissue engineering vital organs.  In: International Conference on Advances of Biomaterials \nfor Reconstructive Medicine. Capri, v.19, p.62, 2002. \n \nSENA, L.A.; SERRICELLA, P.; BOROJEVIC, R.; ROSSI, A.M.; SOARES, G.A. Synthesis and \ncharacterization of hydroxyapatite on collagen gel. Key Eng Mater, v.254\u2013256, p.493\u2013496, 2004. \n \nSHAPIRO, F. Bone development and its relation to fracture repair. The role of mesenchymal osteoblasts \nand surface osteoblasts. European Cells and Materials, v.15, p.53-76, 2008.  \n \nSHI, X.; SITHARAMAN, B.; PHAM, Q.P.; LIANG, F.; WU, K.; BILLUPS. E.W.; WILSON, L.J.; MIKOS, A.G. \nFabrication of porous ultrashort single-walled carbon nanotube nanocomposite scaffolds for bone tissue \nengineering. Biomaterials, v.28, p.4078\u20134090, 2007. \n \nSHISHATSKAYA, E.I.; KHLUSOV, I,A.; VOLOVA, T.G. A hybrid PHB-hydroxyapatite composite for \nbiomedical application: production, in vitro and in vivo investigation. J Biomater Sci Polym Ed., v,17, n.5, \np.481-98, 2006. \n \n\n\n\n94 \n\n \n\nSILVA D.R. et al. In vivo interaction of cells on poly L-(lactic acid) membranes containing plasticizer. J \nBiomater Sci Polym Ed , v.17 , p.177, 2006. \n \nSODHI, R.N.S. Applications of surface analytical and modification techniques to biomaterials research.  J. \nElectr. Spectrosc. Phenom. v.81, p.269, 1996.  \n \nSTRELZOFF. Zur lehre den Knochentwicklung. Med. Cent, n.18, 1873. \n \nSUN, T.S.; GUAN, K.; SHI, S.S.; ZHU, B.; ZHENG, Y.J.; CUI, F.Z.; ZHANG, W.; LIAO, S,S. Effect of \nnano-hydroxyapatite/collagen composite and bone morphogenetic protein-2 on lumbar intertransverse \nfusion in rabbits. Chin J Traumatol, v.7, p.18\u201324, 2004. \n \nSUZUKI, S.; KAWAI, K.; ASHOORI, F.; MORIMOTO, N.; NISHIMURA, Y.; IKADA, Y. Long-term follow-up \nstudy of artificial dermis composed of outer silicone layer and inner collagen sponge. Br. J. Plast. Surg., \nv.53, n.8, p.659\u2013666, 2000. \n \nSWEETWYNE, M.T.; BREKKEN, R.A.; WORKMAN, G.; BRADSHAW, A.D.; CARBON, J.; SIADAK, A.W.; \nMURRI, C.; SAGE, E.H. Functional Analysis of the Matricellular Protein SPARC with Novel Monoclonal \nAntibodies. Journal of Histochemistry &amp; Cytochemistry, v.52, n.6, p.723\u2013733, 2004. \n \nTERMINE, J.D.; KLEINMAN, H.K.; WHITSON, S.W.; CONN, K.M.; MCGARVEY, M.L.; MARTIN, G.R. \nOsteonectin, a bone-specific protein linking mineral to collagen. Cell v.26, p.99-105, 1981. \n \nTORMALA, P.; DAVIDSON, C.L.; KLOPPER, P.J.; LINCLAU. L.A. Tissue response to a braided poly-L-\nlactide implant in an experimental reconstruction of anterior cruciate ligament. J. Mat. Sci. Mater. Med. \nV.4, p.547, 1993. \n \nTREMBLE, P.M.; LANE, T.F.; SAGE, E.H.; WERB, Z. SPARC, a secreted protein associated with \nmorphogenesis and tissue remodeling, induces expression of metalloproteinases in fibroblasts through a \nnovel extracellular matrix-dependent pathway. J Cell Biol, v.121, p.1433-1444, 1993. \n \nTU, R.; LU, C.L.; THYAGARAJAN, K.; WANG, E.; NGUYENM, H.; SHEN, S.; HATA, C.; QUIJANO, R.C. \nKinetic study of collagen fixation with polyepoxy fixatives. J. Biomed. Mater. Res., v.27, p.3\u20139, 1993. \n \nVAANANEN, K.: Mechanism of osteoclast mediated bone resorption \u2013 rationale for the design of new \ntherapeutics. Adv Drug Deliv Rev v.57, p.959-971, 2005. \n \nvan DER STRICHT, O. recherch\u00e9 sur le cartilage articulaire des oiseaux. Arch de Biol., t.10, p.1, 1890. \n \nvan KOOTEN et al. Plasma-treated polysterene surfaces: model surfaces for studying cell-biomaterial \ninteractions. Biomaterials, v.25, p. 1735-1747, 2004. \n \nVERDELIS, K.; LING, Y.; SREENATH, T.; HARUYAMA, N.; MACDOUGALL, M.; VAN DER MEULEN, \nM.C.H.;  LUKASHOVA, L.; SPEVAK, L.; KULKARNI, A.B.; BOSKEY, A.L. DSPP Effects on in vivo Bone \nMineralization. Bone, v.43, n.6, p.983-990, 2008. \n \nVERT, M.; LI, M. S.; SPENLEHAUER, G. &amp; GUERIN, P. Bioresorbability and biocompatibility of aliphatic \npolyesters. J Mater Sci Mater Med, v.3, p.432, 1992.  \n \nVOLOVA, T. et al. Results of biomedical investigations of PHB and PHB/PHV fibers. Biochemical Eng J, \nv.16, p.125, 2003. \n \nWAHL, D.A.; CZERNUSZKA, J.T. Collagen-hydroxyapatite composites for hard tissue repair. Eur Cell \nMater., v.28, n.11, p.43-56, 2006. \n\n\n\n95 \n\n \n\n \nWAN, Y. et al. Adhesion and proliferation of OCT-1 osteoblast-like cells on micro- and nono-scale \ntopography structured poly (L-lactide). Biomaterials, v.26, p.4453-4456, 2005. \n \nWANG, H.; FERTALA, A.; RATNER, B.D.; SAGE, E.H.; JIANG, S. Identifying the SPARC binding sites on \ncollagen I and procollagen I by atomic force microscopy. Anal Chem, v.77, p.6765-6771, 2005. \n \nWATSON, M.L; ROBINSON, R.A. Collagen-crystal relaships on bone. II. Electron microscopy study of \nbasic calcium phosphate crystals. Am J Anat, v93, p.25, 1953. \n \nWEINER, S.; TRAUB, W. Crystal size and organization in bone. Connect Tissue Res, v.21, p.259\u201365, \n1989.  \n \nWEINER, S.; WAGNER, H.D.  Bone fractures. Bone, v.26, n.6, p.875-876, 2000. \n \nWILLIAMS, D.F. (ed), Definitions in Biomaterials - Progress in Biomedical Engineering, Elsevier, v.4, \nCap.1, 1987. \n \nWILLIAMS, D.F. Revisiting the definitions of biocompatibility. Medical devices techonology, v.14, n.8, \np.10-13, 2003. \n \nWILLIAMS, J. M. et al Bone tissue engineering using Polycaprolactone scaffolds fabricated via selective \nlaser sintering. Biomaterials, v.26, p. 4817-4827, 2005. \n \nWILSON-HENCH, J. Osteoinduction. WILLIAMNS, D.F. (ed) Progress in biomedical engineering, v.4. \nDefinitions in biomaterials. Elsevier, Amsterdam, p.29, 1987. \n \nWOOLEY, D.E. Mammalian collagenases. PIEZ, K.A., REDDI, A.H. (Eds.), Extracellular Matrix \nBiochemistry. New York: Elsevier, p.119\u2013158, 1984. \n \nWorld Health Organization: The burden of musculoskeletal conditions at the start of the new millennium. \nWHO Technical Report Series, 919, 2003. World Health Organization, Geneva (Switzerland), 2003. 228 p. \n \nYAMAGUCHI, M. et al. M. Surface modification of poly(L-lactic acid) affects initial cell attachment, cell \nmorphology, and cell growth. J Artif Organs, v.7, p.187-193, 2004. \n \nYEONG, W.-Y. et al. Rapid prototyping in tissue engineering: challenges and potential. Trends Biotechnol, \nv.22, n.12, 2004. \n \nZENG, G.-Z.; TAN, N.-H.; HAO, X.-J.; MU, Q.-Z.; LIA, R.-T. Natural inhibitors targeting osteoclast-\nmediated bone resorption. Bioorg Med Chem Lett, v.16, p.6178\u20136180, 2006. \n \nZOPPI, R.A.; BARROS, P.P.; CORA\u00c7A, D.C.; DUEK, E.A.R. Preparation and characterization of poly(L-\nlactic acid) and poly(ethylene oxide) blends. Materials Research. v.4, n.2, p.117-125, 2001. \n\n \n\n \n\n \n\njavascript:AL_get(this,%20'jour',%20'Bone.');\n\n\n96 \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nAP\u00caNDICE\n\n\n\n97 \n\n \n\n\n\n98"}]}}}